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ABSTRACT 
 
Pyruvate Dehydrogenase Complex Deficiency (PDCD) is a severe inborn error 
of metabolism that causes cell energy impairment, and predominantly results from 
mutations in PDHA1 gene that encodes the crucial E1α subunit. Albeit, there is a 
second isoform encoded by PDHA2, a testis-specific gene, whose potential activation in 
somatic tissues constitutes a conceptual therapy for PDCD.  
Since the human PDHA2 gene regulation has remained elusive over the time, the 
present work was designed to disclose the regulatory mechanisms involved in this gene 
tissue-specific expression, namely its activation in spermatogenic cells and its silencing 
in somatic ones. 
The first part of this thesis (chapter 1) comprises a general introduction with a 
review of the literature concerning Pyruvate Dehydrogenase Complex (PDC), PDHA2 
gene and transcriptional regulation, later ending with the objectives of the present work. 
Our studies commenced by exploring an interesting case that was found during 
our routine laboratory diagnostics (chapter 2). We reported a family, whose PDC 
molecular analysis revealed the presence in circulating lymphocytes of an incomplete 
PDHA1 transcript together with a normal PDHA2 transcript. Moreover, both transcripts 
were translated into full-length proteins, thus leading to the co-existence of both PDHA 
isoforms in somatic cells. This was the first time that the expression of the PDHA2 gene 
was observed in somatic cells and, accordingly, it represented a unique opportunity to 
study PDHA2 regulatory mechanisms. Our findings led us to speculate that the 
explanation for the somatic activation of PDHA2 gene expression should rely on 
epigenetic mechanisms, namely DNA methylation. 
Before any meaningful attempt to elucidate PDHA2 regulation, it was required 
to fully characterize the expression pattern of this gene. Therefore, in chapter 3 we 
described for the first time the transcriptional and translational patterns of human PDHA 
genes during spermatogenesis. We confirmed the ubiquitous expression of PDHA1 gene 
in all somatic cells, whereas the expression of PDHA2 gene was restricted to germ cells. 
Moreover, we could establish that the switch from the X-linked to the autosomic gene 
expression occurs in spermatocytes, before the first meiotic division of 
spermatogenesis.  
Subsequently, and consistently with the knowledge that DNA methylation is a 
mechanism involved in tissue-specific regulation of PDHA2 gene in mouse, our first 
Abstract 
 
xxii 
approach was to analyze the transcriptional profile and DNA methylation status of 
PDHA2 gene (chapter 4). Indeed, we revealed that PDHA2 methylation status was 
perfectly correlated with transcriptional activity, although, and surprisingly, it was the 
methylation status of the gene-coding region that underlied this correlation.  
In the following studies, we further explored the regulatory mechanisms that 
govern PDHA2 gene expression, including the role of DNA methylation and histone 
modifications (chapter 5). Functional deletion studies revealed that the -122 to -6 
promoter region is indispensable for basal expression of this TATA-less promoter, and 
suggested that an epigenetic program was controlling PDHA2 gene expression. Indeed, 
we found that 5’-aza-2’-deoxycytidine (a hypomethylating agent) induced a relevant 
demethylation of the coding region and the concomitant PDHA2 gene derepression in a 
somatic cell line.  
Taken together, our results proved the involvement of DNA methylation as a 
primary regulatory mechanism of PDHA2 gene expression. Moreover, we disclosed the 
possibility to activate PDHA2 gene expression in somatic cells, which may open new 
therapeutic avenues for PDCD caused by PDHA1 mutations.  
 
Keywords: Pyruvate Dehydrogenase Complex Deficiency; PDHA2 gene; 
spermatogenesis; gene expression and regulation; DNA methylation. 
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RESUMO 
 
O Complexo do Piruvato Desidrogenase (cPDH) desempenha um papel central 
no metabolismo celular por estabelecer a ligação entre a glicólise e o ciclo dos ácidos 
tricarboxílicos, realizando a conversão de piruvato em acetil-CoA, fundamental para a 
obtenção de energia. As deficiências associadas a este complexo constituem uma das 
doenças genéticas mais comuns do metabolismo energético mitocondrial. 
O fenótipo clínico das deficiências do cPDH é caracterizado principalmente por 
grave hiperlactacidémia e neurodegenerescência crónica, sendo no entanto observado 
um largo espectro de características clínicas. Dada esta heterogeneidade, o fenótipo é 
normalmente classificado em três categorias distintas de acordo com a gravidade 
apresentada: neonatal, infantil e benigno. 
As terapias actualmente empregues visam estimular a actividade do complexo e 
melhorar o fenótipo clínico, e consistem, por exemplo, na implementação de uma dieta 
cetogénica, na suplementação com cofactores (tiamina, carnitina e ácido lipóico) e/ou 
na administração de dicloroacetato. Contudo, estas terapias revelam-se claramente 
insuficientes, pois raramente alteram a degenerescência neurológica associada à 
patologia, o que torna deste modo pertinente a procura de novas abordagens 
terapêuticas, nomeadamente ao nível genotípico. 
O cPDH é um sistema multienzimático constituído por múltiplas cópias de 
diferentes componentes: E1 (piruvato desidrogenase), um heterotetrâmero de duas 
subunidades α e duas β; E2 (di-hidrolipoíl-lisina acetiltransferase); E3 (di-hidrolipoíl 
desidrogenase); E3BP (proteína de ligação a E3); PDK (piruvato desidrogenase cinase) 
e PDP (piruvato desidrogenase fosfatase). 
Apesar deste complexo ser codificado por 13 genes diferentes, a maioria dos 
casos reportados de deficiência em cPDH resulta de mutações no gene PDHA1, que 
codifica a subunidade α do primeiro componente catalítico do complexo, E1. Esta 
subunidade apresenta-se sob duas isoformas distintas: uma codificada pelo gene 
PDHA1 e expressa em todos os tecidos somáticos; e uma segunda, codificada pelo gene 
PDHA2 e exclusivamente expressa nas células espermatogénicas. A existência desta 
segunda isoforma, e a sua potencial activação nos tecidos somáticos, foi apontada por 
alguns autores como a terapia ideal para os casos de deficiência em cPDH que resultam 
de mutações no gene PDHA1. No entanto, o conhecimento dos mecanismos de 
regulação da expressão do gene PDHA2 humano é extremamente diminuto e, 
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consequentemente, o principal objectivo do presente trabalho consistiu em investigar os 
mecanismos que modulam a especificidade tecidular deste gene, nomeadamente a sua 
activação nas células espermatogénicas e a sua repressão nos tecidos somáticos. 
O primeiro capítulo da tese apresenta uma revisão geral da literatura sobre o 
cPDH, o gene PDHA2 e a regulação da transcrição génica, terminando com a descrição 
dos objectivos delineados para o presente trabalho. 
O trabalho iniciou-se com um interessante caso clínico que surgiu na nossa 
rotina laboratorial de diagnóstico (capítulo 2), o qual constituiu o ponto de partida para 
os estudos subsequentes. Neste capítulo reportamos o estudo de uma família, cuja 
análise molecular ao nível dos linfócitos revelou a presença simultânea de um transcrito 
PDHA1 incompleto e de um transcrito PDHA2 íntegro. Segundo o nosso conhecimento, 
esta é a primeira vez que a expressão do gene PDHA2 foi observada em células 
somáticas, o que representa uma oportunidade única para estudar os mecanismos de 
regulação deste gene. A análise deste caso permitiu-nos postular que a activação 
somática do gene PDHA2 se encontra, muito provavelmente, relacionada com 
mecanismos epigenéticos de regulação, nomeadamente com o estado de metilação do 
DNA. 
Antes de qualquer tentativa de elucidar os mecanismos envolvidos na regulação 
da expressão do gene PDHA2, revelou-se necessário obter algum conhecimento 
relativamente ao padrão de expressão deste gene em tecidos humanos, dada a ausência 
de dados na literatura. Desse modo, no capítulo subsequente (capítulo 3) descrevemos 
pela primeira vez o padrão de expressão dos genes PDHA1 e PDHA2, ao nível de 
expressão quer das proteínas quer dos transcritos, em diversos tecidos e células, e em 
particular durante a espermatogénese. Os resultados permitiram-nos confirmar a 
expressão somática do gene PDHA1, bem como a expressão exclusiva do gene PDHA2 
em células espermatogénicas. 
Para além disso, a análise do padrão de expressão destes genes durante a 
espermatogénese levou-nos a concluir que a forma somática PDHA1 é substituída pelo 
forma testicular PDHA2 ao nível do espermatócito, antes da primeira divisão meiótica 
das células germinativas. Observámos também que, quer ao nível do homogeneizado 
testicular, quer ao nível do espermatozóide maduro, a proteína PDHA2 é a única 
isoforma encontrada, embora com uma massa molecular inferior à esperada, e 
concluímos que a activação do gene PDHA2 é uma maneira de assegurar a expressão da 
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subunidade E1α durante a espermatogénese e garantir a viabilidade e funcionalidade 
destas células germinativas.  
Numa primeira abordagem para compreender a regulação da expressão do gene 
PDHA2, e de acordo com o conhecimento sobre a metilação do DNA como um 
mecanismo importante na regulação da especificidade tecidular deste gene no 
murganho, começámos por avaliar os seus padrões de metilação e de transcrição em 
tecidos somáticos e testiculares humanos (capítulo 4). A análise da sequência do gene 
PDHA2 revelou a presença de duas ilhas CpG: uma no promotor próximo que se 
apresenta metilada em todos os tipos de tecidos estudados, e outra localizada na região 
codificante que se apresenta metilada nos tecidos somáticos e completamente 
desmetilada nas células espermatogénicas, onde o transcrito PDHA2 é normalmente 
expresso. É importante salientar que este padrão de metilação revelou uma correlação 
perfeita com a actividade transcricional, mas que neste caso particular é a desmetilação 
da ilha localizada na região codificante, e não no promotor do gene, que se correlaciona 
com a sua expressão. 
Nos estudos posteriores, pretendemos estudar os mecanismos de regulação e 
clarificar o papel da metilação na expressão do gene PDHA2 (capítulo 5). Começámos 
por clonar diferentes porções do promotor do gene PDHA2 e procedemos à análise das 
respectivas actividades transcricionais após transfecção em diversas linhas de células 
somáticas: SH-SY5Y (neuroblastoma humano), HeLa (adenocarcinoma cervical 
humano) e Ntera2/Clone D1 (teratocarcinoma humano). Os resultados revelaram que a 
transcrição dirigida pelo promotor ocorre nestas linhas celulares, as quais não 
expressam normalmente o gene PDHA2, e que esta actividade transcricional não 
apresentou diferenças óbvias entre as diversas linhas. Estes resultados sugerem que, 
após introdução transiente em células somáticas de plasmídeos contendo a região 5’ 
adjacente do gene PDHA2, o promotor não responde aos mecanismos de regulação que 
normalmente operam nestas células para inibir a expressão do gene in vivo. Para além 
disso, estes dados sugerem também que a expressão específica de tecido do gene 
PDHA2 não deverá envolver factores de transcrição específicos celulares, quer 
activadores ou repressores, mas possivelmente outro nível de modulação, como por 
exemplo mecanismos epigenéticos de regulação. 
Numa abordagem para avaliar o envolvimento de modificações epigenéticas na 
regulação da expressão deste gene, nomeadamente uma possível interacção entre a 
metilação do DNA e a acetilação das histonas, procedemos ao tratamento de uma linha 
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celular somática (SH-SY5Y) com o fármaco hipometilante 5’-aza-2’-desoxicitidina 
(DAC) e com tricostatina A (TSA) que inibe as desacetilases de histonas. 
Os resultados da avaliação dos níveis de mRNA por qRT-PCR mostraram que o 
DAC induz a activação do gene PDHA2 em linhas celulares somáticas (SH-SY5Y), 
tendo-se observado, após estudos de imunoprecipitação da cromatina, o concomitante 
recrutamento da RNA polimerase II para o promotor próximo. Paralelamente, observou-
se que o DAC induz uma desmetilação relevante da ilha CpG localizada na região 
codificante, o que constitui assim a prova de que a metilação do DNA na região 
codificante desempenha uma função importante na regulação da expressão do gene 
PDHA2. 
Para terminar a presente tese, é apresentada no capítulo 6 uma discussão dos 
resultados obtidos, incluindo uma análise integrada de todo o trabalho e respectivas 
conclusões, bem como algumas perspectivas de trabalho futuro. 
Em suma, este trabalho contribuiu para o esclarecimento dos mecanismos de 
regulação da especificidade tecidular do gene PDHA2, demonstrando o envolvimento 
da metilação do DNA como mecanismo primário de regulação da expressão deste gene. 
Para além disso, demonstrou-se a possibilidade de activação do gene em células 
somáticas, o que constitui um avanço relevante na direcção de novas abordagens 
terapêuticas para as deficiências do cPDH causadas por mutações no gene PDHA1. 
 
Palavras-Chave: Deficiência do Complexo Piruvato Desidrogenase; gene 
PDHA2; espermatogénese; expressão e regulação génicas; metilação do DNA 
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1.1. Pyruvate Dehydrogenase Complex (PDC) 
 
1.1.1. Biological importance 
 
Pyruvate dehydrogenase complex (PDC) is a multienzyme system located in the 
mitochondrial matrix that fulfills a major role in aerobic energy metabolism (Robinson, 
2001). This system represents the critical link between glycolysis and the tricarboxylic 
acid cycle by catalyzing the conversion of pyruvate, mainly derived from dietary 
glucose, to acetyl-CoA, which is then further oxidized for energy production or serves 
as substrate for biosynthetic processes (Patel and Harris, 1995) (Figure 1.1.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Cellular localization of pyruvate dehydrogenase complex (PDC) and its relationships 
with energy metabolism. PDC links glycolysis to tricarboxylic acid (TCA) cycle by converting pyruvate 
derived from carbohydrates (mainly glucose) into acetyl-CoA. Subsequently, acetyl-CoA is metabolized 
in the TCA cycle, which presents a central role in the chemical conversion of carbohydrates, fatty acids 
and amino acids into carbon dioxide, water and usable energy (ATP) by cooperation with the electron 
transport chain  (adapted from Patel and Harris, 1995 and http://www.wiley.com/college/ boyer/ 
0470003790/animations/pdc/pdc.htm). 
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The irreversible oxidative decarboxylation of pyruvate into acetyl-CoA occurs 
via a postulated “flip-flop” mechanism, through a series of sequential reactions 
catalyzed by PDC components and requiring diverse cofactors (Figure 1.2.).  
The level of PDC activity regulates the balance between carbohydrates and 
alternative substrates, such as fatty acids and amino acids, to be used for energy 
production. Because approximately 50% of daily energy production derives from 
carbohydrates intake, PDC is a key regulatory step in the central pathways of energy 
metabolism (Patel and Korotchkina, 2006). Although PDC plays an important role in all 
metabolically active tissues, its function is particularly critical in the brain. Actually, the 
brain cannot metabolize fatty acids and, in a normal state, is almost exclusively 
dependent on the aerobic oxidation of glucose for energy production (Brown et al., 
1994; De Vivo, 1998).  
A reduction in PDC activity leads to the accumulation of pyruvic and lactic 
acids and, consequently, to a severe energy impairment. The biological importance of 
PDC is particularly evident in the pathological condition known as Pyruvate 
Dehydrogenase Complex Deficiency (PDCD), a neurometabolic disorder that will be 
further characterized in section 1.1.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Sequential reactions catalyzed by PDC. E1, a TPP-requiring enzyme, catalyzes the first two 
partial reactions (oxidative decarboxylation and reductive acetylation), resulting in acetylation of the 
lipoyl group covalently linked to lysyl residue(s) of E2 component. E2 then catalyzes the transfer of the 
acetyl group to coenzyme A, forming acetyl-CoA and leaving reduced the dithionate ring of the lipoyl 
moiety. E3, a flavoprotein, reoxidizes the lipoyl moiety and transfers the electrons to NAD+ in a two-step 
reaction (adapted from http://chemistry.uah.edu/faculty/ciszak/acetyl_drawing .jpg). 
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1.1.2. Structural organization 
 
Pyruvate dehydrogenase complex is one of the largest and more intricate 
multienzyme structures ever known. The nuclear encoded mammalian PDC, with a 
molecular mass of 9.5 million Da, is composed by multiple copies of three catalytic, 
one structural and two regulatory components: pyruvate dehydrogenase (E1), 
dihydrolipoyllysine-residue acetyltransferase (E2), dihydrolipoyl dehydrogenase (E3); 
E3 binding protein (E3BP); pyruvate dehydrogenase kinase (PDK) and pyruvate 
dehydrogenase phosphatase (PDP).  
The highly organized PDC structure relies on a central core, which plays a 
crucial role in the organization, integration of chemical reactions and regulation of the 
complex activity. In mammals, the central core consists of 48 E2 subunits and 12 E3BP 
subunits, arranged in a pentagonal dodecahedron structure (Hiromasa et al., 2004; 
Ciszak et al., 2006). All other components bind noncovalently to this central core: 30 
E1 subunits bind to E2-binding domain, and 6 E3 subunits bind to E3BP-binding 
domain (Sanderson et al., 1996; Zhou et al., 2001). This organization, in which E1/E2 
and E3/E3BP form sub-complexes with a 1:2 stoichiometry, implies the existence of a 
network of “cross-bridges” across the surface of PDC assembly (Smolle et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic representation of eukaryotic PDC structure. The central core is formed by E2 
(green) and E3BP (pink) subunits. The E2 and E3BP subunits display binding domains (BD) that bind E1 
(orange) and E3 (blue), respectively. Additionally, E2 present lipoyl domains (LD) that bind PDK/PDP 
(purple). This representation puts in evidence the E1/E2 and E3/E3BP “cross-bridges” (adapted from 
Smolle et al., 2006). 
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The regulatory enzymes of the complex (PDK and PDP) bind to lipoyl domains 
of E2 and E3BP, which are extremely flexible domains that move between the active 
sites of E1, E2 and E3, transferring substrates, products and reducing equivalents 
(Perham, 2000; Patel and Korotchkina, 2006) (Figure 1.3.). 
Therefore, the assembly of this multienzyme complex favors substrate 
channelling and active site coupling; this allows catalytic reactions to proceed 
sequentially with the rapid transfer of intermediates between PDC individual 
components without diffusion into the bulk medium. 
 
1.1.3. Biochemical and molecular structure  
 
The complexity of PDC structure is even more astonishing if we consider that is 
encoded by 13 different nuclear genes. The precursor proteins are synthesized in 
cytoplasmic ribosomes and are further transported into the mitochondrial matrix, where 
the perfect assembly of a fully functional complex occurs after the proteolytic cleavage 
of their leader sequences. In this section it will be presented a short resume of PDC 
components and their encoding genes.  
Pyruvate dehydrogenase or E1 (EC 1.2.4.1) is the first component of PDC and 
performs the rate limiting reaction, the decarboxylation of pyruvate and the reductive 
acetylation of lipoic acid in the E2 subunit. Mammalian E1 is a heterotetramer 
composed of two α and two β subunits (43 and 36 kDa, respectively) (Ciszak et al., 
2001). This enzyme presents two catalytic sites, each requiring a thiamine 
pyrophosphate (TPP) molecule and a magnesium ion as cofactors. Each α subunit binds 
magnesium ion and pyrophosphate fragment, while each β subunit binds the pyrimidine 
fragment of TPP, thus originating one catalytic site at the interface of each α/β dimer 
(Ciszak et al., 2003). E1 subunit is also responsible for global PDC regulation, which 
relies on a mechanism of dephosphorylation (activation) / phosphorylation 
(inactivation) acting upon 3 specific serine residues in the E1α subunit (Korotchkina 
and Patel, 2001). 
The E1α subunit exists as two isoforms encoded by two different genes, PDHA1 
and PDHA2, whose sequences display 87% identity and 93% homology. The PDHA1 
gene is located on region p22.1 of the human X chromosome, contains 11 exons 
separated by introns, spans approximately 17 kb of genomic DNA and is selectively 
expressed in somatic tissues. Additionally, an autosomal locus, PDHA2, lies on 
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chromosome 4 (4q22-23), completely lacks introns, spans 1.4 kb of genomic DNA and 
displays characteristics of a functional processed gene; it is expressed only in testis after 
the onset of spermatogenesis (Dahl et al., 1990).  
The E1β subunit is in turn coded for by PDHB gene. The main characteristics of 
these genes are displayed in Table 1.1.  
 
 
Table 1.1.  Summary of the genes encoding PDC components. Characteristics of the genes and 
respective transcripts and proteins (Source: http://www.ncbi.nlm.nih.gov/gene) 
Gene Locus Total length Transcript length Protein length 
PDHA1 
(GeneID: 5160) 
Chr. X 
p22.1 
17.8 kb                       
(11 exons/10 introns) 
3310 bp 
(NM_000284.3) 
390 aa 
(NP_000275.1) 
PDHA2 
(GeneID:5161) 
Chr. 4 
q22-q23 
1.4 kb 
(intronless) 
1456 bp 
(NM_005390.4) 
388 aa 
(NP_005381.1) 
PDHB 
(GeneID: 5162) 
Chr. 3 
p21.1-14.2 
6.2 kb                        
(10 exons/ 9 introns) 
1527 bp 
(NM_000925.3) 
359 aa 
(NP_000916.2) 
DLAT 
(GeneID: 1737) 
Chr. 11 
q23.1 
39.5 kb                       
(12 exons/11 introns) 
4458 bp 
(NM_001931.4) 
647 aa 
(NP_001922.2) 
DLD 
(GeneID: 1738) 
Chr. 7 
q31-q32 
30 kb                         
(14 exons/13 introns) 
2467 bp 
(NM_000108.3) 
509 aa 
(NP_000099.2) 
PDHX 
(GeneID: 8050) 
Chr. 11 
p13 
80 kb                         
(11 exons/10 introns) 
2389 bp 
(NM_003477.2) 
501 aa 
(NP_003468.2) 
PDP1 
(GeneID: 54704) 
Chr. 8 
q22.1 
8.3 kb                          
(3 exons/2 introns) 
4272 bp 
(NM_018444.3) 
537 aa 
(NP_060914.2) 
PDP2 
(GeneID: 57546) 
Chr. 16 
q22.1 
7.4 kb                          
(2 exons/1 introns) 
3830 bp 
(NM_020786.1) 
529 aa 
(NP_065837.1) 
PDPR 
(GeneID: 55066) 
Chr. 16 
q22.1 
47.6 kb                          
(19 exons/18 introns) 
8020 bp 
(NM_017990.3) 
879 aa 
(NP_060460.4) 
PDK1 
(GeneID: 5163) 
Chr. 2 
q31.1 
43.1 kb                          
(11 exons/10 introns) 
1989 bp 
(NM_002610.3) 
436 aa 
(NP_002601.1) 
PDK2 
(GeneID: 5164) 
Chr. 17 
q21.33 
15.7 kb                          
(11 exons/10 introns) 
3440 bp 
(NM_002611.4) 
407 aa 
(NP_002602.2) 
PDK3 
(GeneID: 5165) 
Chr. X 
p22.11 
85.2 kb                          
(12 exons/11 introns) 
1809 bp 
(NM_005391.4) 
406 aa 
(NP_005382.1) 
PDK4 
(GeneID: 5166) 
Chr. 7 
q21.3 
13.1 kb                          
(11 exons/10 introns) 
3576 bp 
(NM_002612.3) 
411 aa 
(NP_002603.1) 
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The dihydrolipoyllysine-residue acetyltransferase or E2 (EC 2.3.1.12), the 
second enzyme participating in pyruvate metabolisation, is an acetyltransferase 
responsible for the transfer of acetyl groups from the lipoyl domains to CoA (Patel and 
Roche, 1990). The mammalian E2 is a monomer of 59.5 kDa and its structure 
comprises different domains: an inner domain, a subunit-binding domain and two lipoyl 
domains. This structure allows E2 to be the core of the complex to which all the other 
components bind. Moreover, the lipoyl domains are extremely flexible and allow the 
transfer of the reaction intermediates between the active sites of E1, E2 and E3 
(Thekkumkara et al., 1989). Therefore, E2 is crucial for PDC organization, integrative 
reaction and regulation. In humans, E2 is encoded by the DLAT gene, located in the 
long arm of chromosome 11 (see Table 1.1.) 
The dihydrolipoyl dehydrogenase or E3 (EC 1.8.1.4) finishes the PDC reaction 
by reoxidizing the lipoamide bound to E2 subunit. This reaction is dependent on two 
cofactors, FAD and NAD+, acting as electron acceptors. The active E3 component is a 
homodimer of 51 kDa and encompasses four structural domains: one catalytic domain, 
one binding domain to E3BP and two other binding domains to each of the cofactors, 
FAD and NAD+ (Reed, 2001). This enzyme, encoded by the DLD gene (see Table 1.1.), 
is also a component of other enzyme systems, namely the α-ketoglutarate 
dehydrogenase complex, the branched-chain α-keto acid dehydrogenase complex, and 
the glycine cleavage system (Patel and Roche, 1990). 
The E3-binding protein (E3BP), previously called Protein X, is an accessory 
protein present in eukaryotes that displays the structural function of binding E3 subunit 
to the complex core; moreover, it was also suggested a possible role on the transfer of 
acetyl groups (Harris et al., 1997). E3BP is a monomer of 50 kDa showing a similar 
structure to E2 subunit, once it has an inner domain, a binding domain (to E3 subunit), 
but only one lipoyl domain (Harris et al., 1997). The PDHX gene codes for this 
structural element and, curiously, is also located in chromosome 11 (see Table 1.1.), 
like the DLAT gene encoding the E2 subunit. 
PDP (EC 3.1.3.43) is a specific phosphatase that removes Pi from 
phosphorylated serine residues of E1 (Site 1: Ser-264; Site 2: Ser-271 and Site 3: Ser-
203), thus reactivating the component and the whole PDC on a Mg2+ dependent 
reaction. Mammalian PDP is a heterodimer composed by two different subunits: a 
catalytic subunit (PDPc) of 52 kDa and a regulatory one (PDPr) of 96 kDa (Chen et al., 
1996; Lawson et al., 1997). The catalytic subunits of PDP exist as two isoforms (PDP1 
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and PDP2), which display some differences concerning their activity, regulation, and 
tissue distribution (Karpova et al., 2003). It is known that binding of PDP1 to the 
mammalian PDC occurs through the lipoyl domain of E2 subunit and requires the 
presence of Ca2+ which plays a bridging role (Roche et al., 2003). The catalytic subunits 
of PDP are encoded by PDP1 and PDP2 genes, whose loci are non-syntenic, while the 
regulatory subunit is coded for by PDPR gene that is located near PDP2 gene in 
chromosome 16 (see Table 1.1.).  
PDK (EC 2.7.11.2) is a specific kinase that inactivates PDC by phosphorylating 
the same previously referred three serine residues in E1α subunit, using ATP as donor 
of phosphate groups (Kolobova et al., 2001). Mammalian PDK has been shown to exist 
in four isoforms. Each PDK isoform is a homodimer composed by subunits of 
molecular masses between 39 and 48 kDa. PDK binds mainly to the mobile lipoyl 
domains of E2 subunit, and only the PDK4 isoform prefers the lipoyl domain of the 
E3BP subunit (Roche et al., 2003). Such localization of PDKs on the “swinging arms”, 
and their transfer from one lipoyl domain to another, gives the possibility of reaching 
almost all phosphorylation sites in the E1α subunits (Patel and Korotchkina, 2006). It is 
known that these four mammalian isoenzymes are differently distributed among tissues 
and also that they present different activities towards the three phosphorylation sites 
(Korotchkina and Patel, 2001); this adds another control level underlying the regulation 
of the complex. The genes coding for the different PDKs isoforms are PDK1, PDK2, 
PDK3 and PDK4 and their characteristics are displayed in Table 1.1.  
 
 
1.1.4. Regulation 
 
The central role of PDC in the maintenance of glucose homeostasis relies on a 
meticulous control of its activity by elaborated mechanisms (Patel and Korochkina, 
2003) (Figure 1.4.). This regulation can be divided in two different types: a short-term 
control that involves a post-translational regulation and a long-term control that occurs 
at a transcriptional level. 
The short-term regulation involves a phosphorylation/dephosphorylation 
mechanism, that relies on specific kinases (PDK) and phosphatases (PDP), which bind 
to PDC mainly via the E2-lipoyl domains (Harris et al., 2002) and catalyze the 
phosphorylation and dephosphorylation of three specific serine residues in E1α (Patel 
and Korotchkina, 2006), as previously referred. The phosphorylation and concomitant 
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inactivation of E1 enzyme is catalyzed by PDKs and renders the entire complex 
inactive. On the other hand, the dephosphorylation and reactivation of E1 enzyme by 
PDPs reinstates the complex activity (Linn et al., 1969).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Schematic representation of PDC global regulation. Regulation of PDC activity by 
interconversion between active (unphosphorylated) and inactive (phosphorylated) forms catalyzed by 
PDPs and PDKs. The (de)phosphorylation (P) occurs in three specific serine residues (S1, S2, S3) of E1α 
subunit (adapted from Patel and Korotchkina, 2003). 
 
The enzymes of this complex are not only dependent on the interactions among 
the catalytic and regulatory components of the complex, but also sensitive to the 
intramitochondrial redox state and metabolite levels, as indicators of energy status. The 
activities of PDKs are regulated by the concentrations of the physiological ligands 
pyruvate, ADP and Pi, as well as by NADH/NAD+ and acetyl-CoA/CoA ratios (Holness 
and Sugden, 2003). PDK activity is inhibited by high levels of pyruvate and a low 
energy state (high levels of ADP, NAD+, CoA and Pi) thus increasing PDC activity. 
NADH and acetyl-CoA, the end-products of the PDC reaction, stimulate PDK activity 
through reduction and acetylation of the E2 lipoyl moieties, which in turn allosterically 
affect PDK bound to the lipoyl domain (Patel and Korotchkina, 2006). The activity of 
PDPs is mainly regulated by the interaction of Mg2+ and Ca2+, by polyamines (spermine, 
spermidine and putrescine) and by the NADH/NAD+ ratio (Patel and Korotchkina, 
2006). 
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Besides the short-term regulation by PDK and PDP, there is also a long-term 
control of the amount of these same enzymes at the transcriptional level, which will 
further allow the regulation of PDC activity in response to different nutritional and 
disease states. For example, PDK4, and to a lesser extent PDK2, were shown to be up-
regulated in several tissues under conditions such as starvation, diabetes and 
hyperthyroidism; on the contrary, PDP1 and PDP2 were shown to be down-regulated in 
starvation and diabetes (Harris et al., 2002; Holness and Sugden, 2003; Patel and 
Korotchkina, 2006). 
 
1.1.5. Pyruvate Dehydrogenase Complex Deficiency (PDCD) 
 
  Pyruvate Dehydrogenase Complex Deficiency (PDCD) is one of the most 
common genetic disorders associated with an abnormal mitochondrial metabolism. 
PDCD, first described by Blass and co-workers, results from a reduction in the 
enzymatic activity of Pyruvate Dehydrogenase Complex (PDC) and leads to energy 
deprivation, especially in the central nervous system (Blass et al., 1970). 
PDCD can be caused by mutations in any of the genes encoding the complex 
subunits. Though defects may occur in all of its proteins, the E1α subunit is 
predominantly the culprit. Concerning all PDCD reported mutations, around 70% are 
assigned to PDHA1 gene (OMIM #312170), and more than a half are of missense type 
(Figure 1.5.). 
As the majority of mutations occur in the X-linked PDHA1 gene, an X-linked 
pattern of inheritance is observed, but the number of affected males and females is 
similar (Dahl et al., 1992). PDCD is a rare disorder being most of mutations sporadic 
ones and the recurrence rate very low. 
Nevertheless, the true occurrence of this disorder is unknown because mild 
mutations may be asymptomatic, especially in females. The variability of the phenotype 
in heterozygous females appears to be largely determined by differences in X-
inactivation patterns (Brown et al., 1994; Willemsen et al., 2006). Moreover, it has been 
observed that male patients who survived the neonatal period and early infancy 
generally have a milder phenotype, which seems inconsistent with a general rule of 
most X-linked dominant diseases (i.e. hemizygous male patients usually have a more 
severe phenotype than heterozygous female patients). A possible explanation for this 
apparent discrepancy may be that males carrying a mutant PDHA1 allele that leads to 
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severe deficiency of the enzyme are selected antenatally and, consequently, only male 
patients who harbor a milder mutant PDHA1 allele survive the neonatal period. In 
females, on the other hand, possession of a mutant allele leading to severe enzyme 
deficiency could still be consistent with a live birth, depending on the pattern of X-
inactivation; such individuals would then present a more severe phenotype than male 
patients who have the mild phenotype (Wada et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Illustration of mutations prevalence in PDCD. PDCD reported mutations are represented 
by gene type and mutation type (Source: The Human Gene Mutation Database 
http://www.hgmd.cf.ac.uk/ac/index.php in 2011-03-21). 
 
Not only PDCD results in severe energy impairment, but it is also one of the 
major causes of lactic acidosis in children. The clinical presentation is extremely 
heterogeneous, with a spectrum ranging from fatal lactic acidosis in the newborn period 
to a chronic neurodegenerative condition. The primary phenotypic manifestation is the 
PDHA1 (120) 
PDHB (10) 
PDHX (18) 
DLAT (4) 
DLD (15) 
PDP1 (2) 
Missense/Nonsense (94) 
Splicing (17)  
Small deletions (19) 
Small insertions (18) 
Small indels (1) 
Gross deletions (8) 
Gross insertion (10) 
Complex (1) 
Regulatory (1) 
       PDCD Mutations: Genes                                                 PDCD Mutations: Type !!!!  
n = 169 n = 169 
PDHA1 (120) 
PDHB (10) 
PDHX (18) 
DLAT (4) 
DLD (15) 
PDP1 (2) 
Missense/Nonsense (94) 
Splicing (17)  
Small deletions (19) 
Small insertions (18) 
Small indels (1) 
Gross deletions (8) 
Gross insertion (10) 
Complex (1) 
Regulatory (1) 
PDHA1 (120) 
PDHB (10) 
PDHX (18) 
DLAT (4) 
DLD (15) 
PDP1 (2) 
Missense/Nonsense (94) 
Splicing (17)  
Small deletions (19) 
Small insertions (18) 
Small indels (1) 
Gross deletions (8) 
Gross insertion (10) 
Complex (1) 
Regulatory (1) 
       PDCD Mutations: Genes                                                 PDCD Mutations: Type !!!!  
n = 169 n = 169 
PDHA1 (120) 
PDHB (10) 
PDHX (18) 
DLAT (4) 
DLD (15) 
PDP1 (2) 
Missense/Nonsense (94) 
Splicing (17)  
Small deletions (19) 
Small insertions (18) 
Small indels (1) 
Gross deletions (8) 
Gross insertion (10) 
Complex (1) 
Regulatory (1) 
General Introduction & Objectives 
 
 13 
impairment of neurological function and/or development, but a wide range of clinical 
characteristics may be observed: hypotonia, seizures, CNS degeneration and 
malformations, ataxia, respiratory alterations (apnea, hypoventilation), facial 
dysmorphic features (narrow head, frontal bossing, wide narrow bridge), peripheral and 
skeletal/cardiac neuropathy. Several authors classify the phenotype in three major 
categories, according to the observed severity: neonatal, infantile and benign (Brown et 
al., 1994; Wexler et al., 1997). 
The current available therapy for PDCD relies on a palliative treatment aiming 
to stimulate PDC activity, to provide alternative fuels or to correct acidosis. However, it 
rarely influences the course of the disease and merely prevents the acute worsening of 
the syndrome. Ketogenic diets, that minimize carbohydrate and maximize fat daily 
intake, have been used to control lactic acidosis with minimal success. Although the 
ketogenic diet may reduce the blood levels of lactic acid and extend lifespan, CNS 
metabolic abnormalities persist, as evidenced by high lactic acid levels in the 
cerebrospinal fluid and progressive neurological degeneration. Moreover, due to the 
dependence of the brain on glucose as a fuel, this type of diet increases CNS 
vulnerability (Wexler et al., 1997; Weber et al., 2001).  
In order to optimize PDC function, the standard care option is diet 
supplementation with cofactors, such as thiamine, carnitine, and lipoic acid. In selected 
PDCD cases, caused by the so-called thiamine-responsive mutations, high doses of 
thiamine are particularly effective and a more favorable outcome can be expected for 
these extremely rare patients (Robinson et al., 1996). There is some evidence that 
dichloroacetate, which inhibits PDC kinases and thereby activates any residual 
functioning complex, will also reduce the metabolic disturbance in some patients but, 
again, this is rarely accompanied by any objective improvement in neurological 
performance (Berendzen et al., 2006). 
Despite these therapeutic approaches, all directed to correction of the phenotype, 
it is clear they are insufficient and that new avenues must be open, namely at the 
genotype level.  
As previously mentioned, the majority of mutations underlying PDCD are 
missense ones. Recently, many lines of evidence have suggested that this kind of 
mutations result in disturbances of protein folding, either at translational or post-
translational levels. Disorders based on this pathogenic mechanism are known as 
conformational diseases (Gregersen et al., 2006) and, accordingly, most cases of PDCD 
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may fit this denomination. Moreover, it was also shown that missense mutations affect 
the maturation of polypeptides in different cellular compartments and that chemical or 
molecular chaperones may modulate the disease phenotype (Baynes et al., 2005). 
Actually, our own group has recently described a male patient with mild neurological 
involvement, who displayed low PDC activity and absence of E1α subunit on 
immunoblotting analysis (Silva et al., 2009); molecular studies revealed a novel 
mutation, R253G. Surprisingly, following a period of arginine aspartate (Asparten®) 
intake, clinical signs and symptoms clearly reversed, fact confirmed by complete 
normalization of global PDC activity and E1α expression levels. Moreover, when 
stopping treatment, clinical signs and symptoms quickly return. This case may depict a 
new therapeutic approach, the use of chemical or molecular chaperones, which 
represents a more personalized therapy, once is genotype-specific.  
However, and specifically for most PDCD cases which are caused by mutations 
in the PDHA1 gene, the long dreamed therapy referred by several authors (Robinson et 
al., 1996; Datta et al., 1999) would be the somatic activation of the autosomic PDHA2 
gene that encodes the E1α subunit in spermatogenic cells. The activation of PDHA2 
gene in somatic cells would allow circumventing the absence or inactivation of the 
altered PDHA1 subunit.  
 
 
b 
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1.2. PDHA2 gene 
 
Pyruvate dehydrogenase complex (PDC) plays a crucial role in cell energy 
metabolism, particularly in those tissues that obtain almost all their energy from 
carbohydrates. This is the case of the brain, as previously mentioned, but also of 
spermatogenic cells, which are therefore likely to be more dependent on PDC function. 
During spermatogenesis, spermatogenic cells go through meiotic divisions and 
become haploid, so half the cells will not contain an X chromosome. In addition, the X 
chromosome is inactivated early in spermatogenesis, so even those cells containing an 
X chromosome appear not to express the X-linked genes.  
Accordingly, the X chromosome location of the normally expressed E1α gene 
(PDHA1) could represent a serious setback for energy production in sperm. Notably, 
this apparent problem to express the essential E1α subunit could be overcome in two 
different ways: by pre-making E1α subunit (or a precursor) when the X chromosome is 
still functional and storing it for later use; or, by generating E1α subunit from an 
autosomally located gene, once autosomes, unlike sex chromosomes, are functional in 
the haploid spermatogenic cells. Indeed, there is a second isoform of E1α in 
spermatogenic cells, encoded by the PDHA2 gene located on chromosome 4, which 
thus allows the accomplishment of energy requirements in these cells. 
 In this way, PDHA genes quite resemble the extensively studied 
phosphoglycerate kinase (PGK) genes regarding their organization and expression 
patterns. In placental mammals both have two variants: a somatic isoform (PGK1 and 
PDHA1) encoded by an X chromosome-located gene and a testis-specific isoform 
(PGK2 and PDHA2) that are expressed only in spermatogenic cells and are encoded by 
autosome-located and intronless genes (Fitzgerald et al., 1996). 
 
1.2.1. Structure and evolution 
 
PDHA2 gene, first identified by Dahl and co-workers (1990), was mapped to 
region q22-q23 on chromosome 4. Unlike PDHA1 gene, that contains 10 introns and 
spans ∼17 kb of genomic DNA, PDHA2 is an intronless gene spanning only 1.4 kb 
(Maragos et al., 1989; Dahl et al., 1990). The PDHA1 and PDHA2 gene sequences have 
84% and 86% similarity at the coding nucleotide and amino acid sequence levels, 
respectively (Dahl et al., 1990). The majority of the changes are conservative ones, with 
sequences surrounding important functional domains remaining highly conserved, such 
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as the three phosphorylation sites and the thiamine pyrophosphate binding site (Young 
et al., 1998). 
Mouse orthologs for PDHA1 and PDHA2 genes, Pdha1 and Pdha2, 
respectively, have been extensively described. These genes also show different 
chromosomal locations: Pdha1 is X-linked with a similar structure to PDHA1, whereas 
Pdha2 is intronless and located in chromosome 19. A comparative analysis of PDHA1 
and Pdha1 sequences indicate that both are highly homologous, 86% at transcript level 
and 98% at protein level. However, the sequences of testis genes, PDHA2 and Pdha2, 
show less similarity with each other presenting 78% and 75% at the coding nucleotide 
and amino acid sequence levels, respectively (Brown et al., 1990; Dahl et al., 1990; 
Fitzgerald et al., 1992). 
The genetic derivation of both human and mouse intronless autosomal genes is 
not clear; however, comparative mapping of eutherian and marsupial PDHA homologs 
has shed some light over this matter. In contrast to eutherians, marsupials only have one 
PDHA gene, which is autosomic, contains introns and is expressed in both testis and 
somatic tissues. This led to the conclusion that a common ancestor of marsupials and 
eutherians also had a single autosomal PDHA gene and that PDHA1 and PDHA2 arose 
after marsupials and eutherians diverged (Fitzgerald et al., 1993). The X-linked PDHA1 
is presumed to have arisen following translocation of the autosomal gene to the short 
arm of the X chromosome and the testis-specific autosomal intronless PDHA2 is 
believed to have become selected over time to overcome the absence or apparent 
inactivation of X chromosome in the haploid spermatogenic cells (Dahl et al., 1996). 
Several proposals have been suggested to account for the appearance of these 
testis-specific variants. One hypothesis suggests that such genes represent functional 
retroposons, meaning that they are functional processed genes generated by reverse 
transcription of mRNAs, which were subsequently reinserted into the genome. It is 
probable that these retroposons were inserted into multiple sites, with selective pressure 
favoring the promulgation of functional genes that were only active during 
spermatogenesis, when the X chromosome is either absent or inactive (McCarrey and 
Thomas, 1987). 
Nevertheless, although both human and mouse testis-specific genes appear to be 
retroposons, it is possible that the human promoter region of PDHA2 gene did not 
evolve from the same retroposon as the mouse Pdha2 promoter, but rather from an 
independent retroposon-mediated insertion of the coding region of PDHA1 (Datta et al., 
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1999). If this is the case, then the mechanisms underlying regulation of human PDHA2 
may be significantly different from that of the mouse species.  
 
1.2.2. Tissue- and cell-specific expression 
 
Spermatogenesis is a complex biological process of cellular transformation that 
produces male haploid germ cells from diploid spermatogonial stem cells. This cell 
differentiation occurs within seminiferous tubule boundaries of the testis and involves 
different stages such as mitosis, meiosis and spermiogenesis. Briefly, spermatogenesis 
begins when primitive type A spermatogonia proliferate by mitosis into type A and type 
B cells. Type B cells then sequentially differentiate into primary spermatocytes, which 
after two stages of meiosis result in haploid round spermatids. Finally, round spermatids 
undergo marked morphological differentiation to become mature sperm (Figure 1.6.).  
 
 
 
 
 
Figure 1.6. Schematic representation of human spermatogenesis. Spermatogenesis is the process of 
male germ cell differentiation from spermatogonia to fully functional spermatozoa, which occurs in testis 
seminiferous tubules (adapted from http://www.esu.edu/~milewski/intro_biol_one_lect/web 
links/oogenesis-spermatogenesis/1-Spermatogenesis.jpg). 
 
This complex process requires the coordinated expression of a number of testis-
specific genes. The understanding of the regulatory mechanisms underlying these 
genes’ expression is crucial and the testis-specific gene that codes for the E1α subunit 
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was soon pointed out as a reliable model to elucidate gene regulation during 
spermatogenesis (Iannello et al., 1995). 
The first approach to understand E1α testis-specific gene was performed in 
mouse, rather than in human. The reason underlying this choice was not only due to the 
relatively easy access to mouse tissues, but also because germ cell differentiation in 
mouse development is synchronized as the mouse proceeds towards sexual maturity, 
which provides an excellent opportunity to examine the temporal expression of genes in 
mouse testis. As a consequence, the transcriptional and translational expression patterns 
of the testis-specific and somatic forms of E1α subunit genes have already been studied 
in detail in mouse testis (Takakubo and Dahl, 1992). 
Briefly, Pdha2 transcripts were found in all spermatocytes and spermatids stages 
with a particular increased level in pachytene spermatocytes. In contrast, the expression 
of Pdha1 was only detected in those cells where Pdha2 expression was not detected 
(spermatogonia, Leydig and Sertoli cells). Immunostaining with a specific anti-E1α 
antibody showed that the synthesis of E1α protein was dramatically increased in 
primary spermatocytes, reaching the highest abundance in pachytene spermatocytes. 
The amount of protein remained at high levels throughout spermiogenesis; however, it 
remarkably declined in epididymal spermatozoa. Also, spermatogonia, Leydig and 
Sertoli cells displayed low levels of E1α protein. These results suggest that the 
transcriptional switch from the somatic Pdha1 to the testis-specific Pdha2 gene occurs 
during the first meiotic prophase of spermatogenesis, and also that the E1α protein 
involved in the development of spermatogenic cells is coded for by the Pdha2 gene 
(Takakubo and Dahl, 1992). 
Moreover, two transcripts for Pdha2 have been identified. In the early stages of 
Pdha2 expression, a 2.0 kb mRNA is the only form evident; however, as 
spermatogenesis proceeds and the mouse enters sexual maturity, a second smaller 
transcript becomes apparent. This smaller 1.7 kb transcript is produced in haploid cells 
and results from the use of an alternative polyadenylation signal (Fitzgerald et al., 1992; 
Iannello and Dahl, 1992). Although the functional implications of transcript shortening 
are not clearly understood, it was suggested it might facilitate long-term stability of the 
mRNA (Young et al., 1998). 
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1.2.3. Transcriptional regulation 
 
1.2.3.1. Promoter structure 
 
In an attempt to elucidate the mechanisms leading to the human PDHA2 
repression in the somatic tissues, Datta and co-workers (1999) isolated and 
characterized the proximal portion of the human promoter, including the location of the 
transcription start site (Figure 1.7.). According to these authors, the transcription start 
site is located 71 nucleotides upstream the start methionine, 10 bp further upstream the 
transcription start site of mouse Pdha2 (Iannello et al., 1993). Similar to the mouse 
Pdha2, the human PDHA2 promoter lacks the classic TATA or CAAT boxes and the 
transcription initiation may rely on a Sp1-binding dependent mechanism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Proximal promoter sequence of the human PDHA2 gene. Sequence of the 5´-regulatory 
region and localization of the potential regulatory elements (Ets, Sp1 and MEP-2) identified by Datta and 
co-workers (1999). (*) Indicates the transcription start site and the long arrow bellow ATG marks the 
start methionine (adapted from Datta et al., 1999).  
 
 
DNAse I footprinting analysis, using both testis and liver extracts, allowed the 
identification of two sites protected by nuclear proteins: considering the A from the start 
ATG codon as +1, one site was located between -177 to -144 which may correspond to 
the putative Sp1 binding site (located around -175), and the second one located between 
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-116 to -89 and containing part of the consensus binding sequence for the MEP-2 
(mouse E1α promoter) transcription factor. In the mouse Pdha2 regulatory region, it has 
been also observed an Sp1 binding site, -143 nucleotides upstream of the start 
methionine, and flanked by a ATF/CREB (activating transcription factor/ cAMP-
response element-binding protein) consensus sequence beginning at -125 (Iannello et 
al., 1993); nevertheless, this region was never found in the human promoter. 
Two additional sites were protected only by proteins from testicular extracts: 
one between -144 to -119 in the coding strand (-146 to -110 in the non-coding strand) 
and the other between -80 to -62. The location of this second protected region is similar 
to that of the MEP-3 identified in mouse. Additionally, Pdha2 has regions that match a 
consensus sequence for the YY1 (transcriptional repressor protein Ying Yang 1) 
transcription initiation factor, whereas no similar sequence could be found in the 
protected region of the human sequence. However, the fact that this region is protected 
by the testicular, but not liver, nuclear protein suggests that this region may be 
important for tissue specific transcription of the gene. 
Functional studies of the PDHA2 promoter indicate the presence of both 
enhancer elements between nucleotide position -325 and -517 bp and repressor elements 
from nucleotide position -325 to -207; apparently, this suggests that PDHA2 
transcription is governed by multiple regulatory elements (Datta et al., 1999). It was 
identified a putative Ets (E-twenty six transcription factor) site located between -236 and 
-226 bp, which seems to be a repressor element. In the promoter sequence of mouse 
Pdha2 was also identified a potential site that can serve as an Ets element located 
between -191 and -182 bp proximal to the transcription site. The optimal binding site 
sequence of a Ets-1 transcription factor (ER71) that acts as a repressor element in 
somatic tissue closely resembles the consensus Ets binding site found, suggesting that 
this transcription factor may play a significant role in transcriptional regulation of these 
genes (Iannello et al., 1994). 
 
1.2.3.2. Methylation and tissue specificity 
 
After the studies of Datta and collaborators (1999) it emerged an idea that 
additional mechanisms, such as DNA methylation, should be underlying the human 
PDHA2 transcriptional regulation, but yet no studies were further performed.  
Nevertheless, the involvement of DNA methylation has already been proved to 
General Introduction & Objectives 
 
 21 
be operative in the mouse Pdha2 gene. Actually, Iannello and co-workers, in 1997, 
showed a correlation between CpG hypomethylation within the core promoter and 
Pdha2 transcription level. Although how CpG methylation inactivates the Pdha2 
promoter in vivo was still uncertain, one possibility was that it could alter the 
conformational arrangement of DNA by increasing its helical pitch, thereby affecting 
transcription factor binding to its cognate site (Iannello et al., 1997). 
A later study of this group proved that the methylation-dependent repression of 
the Pdha2 core promoter is mediated regionally through the ATF/CREB consensus 
binding site (Iannello et al., 2000), a regulatory element that was never identified in the 
human PDHA2 promoter. These authors found that targeting of the CpG dinucleotide 
within this cis-element significantly disrupted the ability of the basal promoter to 
activate gene expression in vitro and completely abolished promoter activity in vivo. 
Moreover, these CpG dinucleotides in the flanking region of the ATF/CREB binding 
site appeared to confer some conformational structure to the promoter, since mutations 
at these specific CpG dinucleotides resulted in elevated basal levels of transcription. 
This raised the possibility of a potential bifunctional role for CpG dinucleotides in 
either methylation-dependent or -independent processes (Iannello et al., 2000). 
Further studies during mouse spermatogenesis showed that the pattern of CpG 
methylation in the Pdha2 promoter varied according to the spermatogenic cell type. 
And once more, evidence was shown that gene activation during spermatogenesis might 
involve both hypomethylation and the availability of specific transcription factors, 
being hypomethylation an essential step prior to the availability of transcription factors 
(Sp1, YY1, MEP-2 binding factor, and ATF/CREB factors) in order for Pdha2 
expression to occur (Iannello et al., 1997). 
In conclusion, methylation appears to be an important mechanism by which 
transcriptional repression of Pdha2 in somatic mouse tissue is achieved. Activation of 
testis-specific genes, in particular those which are temporarily expressed during 
spermatogenesis, such as Pdha2, is likely to require various levels of regulation, such as 
DNA hypomethylation and conformational alterations, and accessibility or availability 
of specific transcription factors.  
 
 
b 
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1.3. Transcriptional regulation of gene expression 
 
Eukaryotic organisms employ a complex network of diverse mechanisms to 
regulate gene expression. The expression of a particular gene can be controlled at many 
levels, including transcription, mRNA splicing and stability, translation and post-
translational levels. Nevertheless, the transcription initiation appears to be one of the 
most important determinants of the overall gene expression profile (Lewin, 2000; 
Alberts, 2002). 
  Gene transcription relies on an intricate process of combinatorial regulation that 
involves complex arrays of promoters, enhancers, silencers and insulators together with 
transcription factors, co-regulators and chromatin remodelling elements (Figure 1.8.) 
(Lemon and Tjian, 2000; Levine and Tjian, 2003). Each of these aspects will be briefly 
discussed in the current section. 
 
 
 
 
Figure 1.8. Elements of eukaryotic gene transcriptional regulation. Schematic illustration of the basic 
elements involved in transcriptional regulation: components of the core initiation machinery (TFIIA, IIB, 
IID, IIE, IIF, IIH) required by RNA polymerase II for promoter recognition and basal transcription; 
promoter elements (TATA, INR, DPE); silencer and enhancer DNA sequences; sequence-specific DNA-
binding transcription factors (i.e. Hairy, GR, REST, NHR, SREBP, Sp1); co-regulators (i.e. SAGA, SRC, 
p300/CBP, ARC/DRIP, CRSP, Groucho) and chromatin modifying complexes (i.e. SWI/SNF, ISWI, 
HDAC) (adapted from Lemon and Tijan, 2000; and Levine and Tijan, 2003).  
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1.3.1. Core promoter elements and general transcription factors 
 
The core promoter is a dynamic and vital participant in the regulation of 
transcription and consists in the minimal stretch of contiguous DNA sequence that is 
sufficient to direct accurate transcription initiation by the RNA polymerase II (RNA pol 
II) machinery. Typically, the core promoter encompasses the site of transcription 
initiation and extends either upstream or downstream for an additional ∼35 nucleotides 
(Smale, 2001; Butler and Kadonaga, 2002). 
Despite the relative diversity of core promoter structures, there are several 
sequence motifs that can be commonly identified and that may be present either alone 
or simultaneously. The TATA box was the first eukaryotic core promoter motif to be 
described, although it is present in only about 10–15% of mammalian core promoters. 
The TATA box is typically located about 25–30 nucleotides upstream of the 
transcription start site and its consensus sequence in metazoans is TATAWAAR. The 
most probably occurring core promoter motif is the Initiator (Inr), which encompasses 
the transcription start site, being the human consensus sequence YYANWYY. The 
“downstream core promoter element” (DPE) is another example of a core promoter 
motif, it was identified downstream of the Inr and appears to function in conjunction 
with the Inr element in TATA-less promoters (Hampsey, 1998; Juven-Gershon and 
Kadonaga, 2010). 
Accurate and efficient transcription from the core promoter requires the 
multisubunit complex RNA pol II, along with auxiliary factors that are commonly 
termed the “basal” or “general” transcription factors (GTFs), which include the 
transcription factors TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH. The complex of 
RNA pol II and auxiliary GTFs are known as the basal transcription apparatus 
(Orphanides et al., 1996; Hampsey, 1998). The individual components of the GTFs 
congregate at the proximal promoter in a highly regulated and defined order, forming a 
complex that provides a platform for the recruitment of RNA pol II that subsequently 
initiates transcription at a precise site known as the transcription initiation site (Lemon 
and Tjian, 2000). 
In germ cells, the mechanisms of transcription initiation may be substantially 
different, once it has been described that tissue-specific core promoters and alternate 
forms of core promoter transcription factors are used (DeJong, 2006). The male germ 
cell-specific differences in the components of the general transcription machinery 
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include up regulated expression of the TATA-binding protein (TBP) family and its 
associated cofactors (Kimmins et al., 2004). 
The promoters of genes expressed in germ cells contain similar regulatory cues 
to the somatic ones, but their architecture reveals several notable features, including 
small size and relatively high GC content. Some also have a short CT-rich region 
upstream of the GC-rich domain, and some but not all contain a TATA-like element 
(Han et al., 2004). Moreover, it has been described that germ cells may display variants 
of the core promoter transcription factors (Aoyagi and Wassarman, 2000; Tupler et al., 
2001; Davidson, 2003; Hochheimer and Tjian, 2003). Nevertheless, genes for other 
general transcription factors, including TFIIAγ and TFIIB, are expressed constitutively 
and do not appear to change in somatic and germ cell systems.  
 
1.3.2. Other regulatory elements 
 
The presence of a core promoter sequence and assembly of the basal 
transcription apparatus is all that is required to initiate transcription of any given gene. 
However, the levels of transcription that are achieved at such promoter are minimal, and 
upstream factors are required to modify transcriptional rates.  
Other cis-acting elements that regulate transcription include enhancers, 
silencers, and insulators. These elements contain recognition sites for a variety of 
sequence-specific DNA-binding factors that are involved in transcriptional regulation. 
Enhancers function as binding sites for specific transcriptional activators and up-
regulate gene expression. Once associated with their cognate enhancer, transcriptional 
activators facilitate transcription initiation, either by direct contact with GTFs or 
indirectly through co-activators (Blackwood and Kadonaga, 1998). With an opposite 
effect, silencers are capable to down-regulate gene expression and impair transcription 
by recruiting specific repressors that may interfere for instance with the activator-
enhancer binding or even with the core transcriptional machinery (Ogbourne and 
Antalis, 1998). 
Both enhancers and silencers function at variable distances from the core 
promoter, over several kilobases, and either in 5´or 3´orientation. Consequently, it is 
obvious that mechanisms must exist to prevent activation and/or repression of 
neighbouring transcriptional units. This is the role of insulators that act over long 
distances to block interactions between cis-elements and inappropriate promoters 
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(Geyer, 1997). 
In addition, transcriptional co-regulators exist to bridge the interface between 
activators and repressors with a limited number of targets within the general 
transcription apparatus. This specialized adapters could be co-factors that associate with 
activator or repressor molecules, co-factors that associate or are intrinsic to the 
components of the core machinery and, also, large multisubunit co-activators that 
strictly fit into neither the general transcription factor-associated nor the activator-
associated classes. Another type of co-regulators can perform chromatin-remodelling 
functions involved in antagonizing or enhancing the repressive effects of chromatin (i.e. 
HDAC and SWI/SNF) (Lemon and Tjian, 2000; McKenna and O'Malley, 2002). 
Although it is not yet clear how promoters of genes expressed in germ cells are 
able to specify somatic silencing and germ cell activation, their short size suggests that 
long-range enhancer-dependent interactions are not required (Nothias et al., 1995; 
Schultz, 2002). The activity of these promoters may instead be depend on promoter–
proximal activator binding sites, but there are still many questions about the 
mechanisms by which activators function in the germ cell nuclear environment. It has 
also been considered the idea that the short core promoter from germ-cell-specific genes 
may not have a conventional activator requirement (DeJong, 2006). A number of 
regulatory factors, including Sp1, NF-κB, CREMτ, BORIS, SREBP2, and many others, 
have been proposed to regulate genes in germ cells (Foulkes et al., 1992; Lilienbaum et 
al., 2000; Loukinov et al., 2002; Wang et al., 2004a; Thomas et al., 2005).  
 
1.3.3. Chromatin remodelling 
 
In eukaryotic cells, genes are complexed with core histones and other 
chromosomal proteins in the form of chromatin. The basic repeating unit of chromatin, 
the nucleosome, includes two copies of each of the four core histones H2A, H2B, H3, 
and H4 wrapped by 146 bp of DNA. Additionally, a linker histone H1 associates at the 
position where the DNA enters and exits the nucleosome core, thus sealing the two 
turns of DNA.  
Generally speaking, we can find two different types of chromatin environments 
in the genome: a silent heterochromatin and an active euchromatin. Heterochromatin 
corresponds to a “closed” or condensed chromatin, which is less accessible to the 
factors that usually bind DNA and consequently transcriptionally inactive. On the 
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contrary, euchromatin presents an “open” and unfolded structure that allows regulatory 
proteins and RNA polymerase complexes to bind to the DNA sequence, being 
transcriptionally active (Figure 1.9.).  
This chromatin ‘fluidity’ is mainly brought about by nucleosome remodelers, 
multiprotein complexes that function as ATP-dependent chromatin ‘remodelling’ 
factors. These enzymes couple ATP hydrolysis to alterations of the chromatin structure 
at the level of the nucleosomal array (Langst and Becker, 2004). 
Furthermore, chromatin remodelling is accomplished through the interplay of 
different mechanisms, namely by histone modifications, and DNA methylation (Perry et 
al., 2010) (Figure 1.9.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Epigenetic marks in chromatin remodelling. Specific epigenetic modifications are 
characteristic of different chromatin structures. Transcriptionally inert chromatin consists of tightly 
condensed, methylated DNA coiled around histone octamers that are deacetylated and methylated at 
particular lysine residues. Conversely, expanded chromatin is characterized by nonmethylated DNA 
loosely coiled around acetylated nucleosome complexes. This structure makes gene promoters accessible 
to the transcriptional apparatus. Abbreviations: DM, demethylase; DNMT, DNA methyltransferase; 
HAT, histone acetyl transferase; HDAC, histone deacetylase; HMT, histone methyltransferase (adapted 
from Perry et al., 2010). 
 
1.3.3.1 Histone variants and histone modifications 
 
One mechanism of chromatin modulation results from the existence of histone 
variants, which have specific expression, localization, and species-distribution patterns 
(Yuan and Zhu, 2011). 
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The similarity between the major histone subtypes and their variants can range 
from almost no amino acid differences to extremely divergent changes. Some variants 
have distinct biophysical characteristics that are thought to alter the properties of 
nucleosomes, while others localize to specific regions of the genome. Other variants 
exchange with the pre-existing histones during development and differentiation, and are 
therefore referred to as replacement histones (Kamakaka and Biggins, 2005).  
For instance, during male gametogenesis several of the core histones (H2A, 
H2B, H3, and H4), along with linker histone H1, are partially or completely replaced by 
testis-specific histone isoforms such as H1t, TH2A, TH2B, and H3t, which form 
nucleosomes more closely packed than those found in somatic cells, and that will confer 
a specific layer of regulation in germ cells (DeJong, 2006). Nevertheless, in human 
sperm, only 15% of the DNA remains associated with testis-specific histones (Wykes 
and Krawetz, 2003; Zhang et al., 2006). Actually, during the final stages of 
spermatogenesis, the majority of testis-specific histones is displaced by transition 
proteins and subsequently replaced by protamines (Gardiner-Garden et al., 1998; Lewis 
et al., 2004), which will confer a higher condensed chromatin structure. 
Both core histones and their variants can suffer post-translational modifications, 
which comprise another way to create specific chromatin environments and regulate 
gene expression. The effect of histone modifications on transcription regulation can be 
explained either by the disruption of contacts between nucleosomes that ‘‘unravel’’ 
chromatin or the recruitment of nonhistone proteins that further modify chromatin 
(Kouzarides, 2007). 
The core histones are predominantly globular except for their N-terminal 
‘‘tails,’’ which are unstructured and susceptible to several modifications. A variety of 
post-translational modifications have been described, some examples include 
methylation, acetylation, ubiquitination, ADP-ribosylation, small ubiquitin-like 
modifier modification (SUMOylation) and phosphorylation (Strahl and Allis, 2000). 
Despite the reasonable potential of any given modification to interfere with transcription 
in particular conditions, acetylation and methylation of specific lysines have been 
demonstrated to be key modulator marks for transcriptional activation or repression 
(Wang et al., 2008). 
Histone acetylation is almost invariably associated with activation of 
transcription and, conversely, deacetylation with transcriptional repression (Kouzarides, 
2007). These reactions are normally catalyzed by histone acetyltransferases (HATs) 
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(Roth et al., 2001) and histone deacetylases (HDACs) (Thiagalingam et al., 2003), 
respectively. Both in H3 and H4, selected lysines become acetylated during specific 
cellular processes. For example, some of the reported acetylation sites in histone H3 of 
most organisms include lysines 9, 14, 18, 23 and 36, although an expanded set of lysine 
residues is likely to be acetylated (Strahl and Allis, 2000). 
Concerning lysine methylation, the lysine methyltransferases usually modify 
one single lysine on a single histone and their output can be either activation or 
repression of transcription. Three lysine methylation sites are implicated in activation of 
transcription: H3K4, H3K36, and H3K79, and other three are connected to 
transcriptional repression: H3K9, H3K27, and H4K20 (Zhang and Reinberg, 2001) 
(Figure 1.9.).  
The idea that multiple dynamic modifications regulate gene transcription in a 
systematic and reproducible way has been defined as “histone code” (Jenuwein and 
Allis, 2001). Nevertheless, this idea of a “histone code” is controversial, in particular 
because there are too many exceptions, which do not fall into the strict code definition.  
 
1.3.3.2 DNA methylation 
 
DNA methylation is the most common eukaryotic DNA modification and 
probably the most extensively studied epigenetic mark. It plays important roles in 
embryonic development, transcription, chromatin structure, X chromosome inactivation, 
genomic imprinting, chromosome stability and in the silencing of retrotransposon, 
repetitive elements and tissue-specific genes (Lister et al., 2009).  
The phenomenon involves the addition of a methyl group to the fifth carbon 
position of the cytosine ring in the context of the sequence 5’-CG-3’, which is also 
referred to as a CpG dinucleotide (Figure 1.10). 
The patterns of DNA methylation are established and maintained by the 
interplay of different DNA methyltransferases (DNMTs) (Jurkowska et al., 2011), 
which catalyze the transfer of the methyl group from S-adenosylmethionine to the 
cytosine in CpG dinucleotides, thus originating 5-methylcytosine (5mC) - the 5th base of 
the genome (Bestor, 2000). During early embryogenesis, de novo DNA methylation is 
mediated by DNMT3A and DNMT3B associated with DNMT3L (Okano et al., 1999; 
Jia et al., 2007). To maintain patterns of DNA methylation in daughter cells, the hemi-
methylated DNA is methylated by DNMT1, which methylates the appropriate cytosine 
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in newly synthesized DNA strands during successive replications (Goyal et al., 2006). 
Other studies suggest that DNMT3A/B are also required for the maintenance of patterns 
of DNA methylation in somatic cells, particularly of repeat regions and imprinted genes 
(Jeong et al., 2009). 
In the genome of higher eukaryotes, most CpG dinucleotides are methylated 
except those located in CpG islands, which are defined as regions of DNA >500 bp with 
a GC content and a ratio of observed and expected CpG>0.65 (Takai and Jones, 2002). 
Nearly 60% of mammalian gene promoters are located in CpG islands (Wang and 
Leung, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. Methylation modification of DNA at the 5-carbon position of cytosine by DNMTs where 
S-adenosylmethionine (SAM) donates one methyl group (-CH3) and is converted to S-
adenosylhomocysteine (SAH) (adapted from http://www.caymanchem.com /app/template/Article.vm/ 
article/2153).  
 
 
A role for DNA methylation in the differential regulation of gene expression was 
hypothesized many years ago (Holliday and Pugh, 1975). It is well documented that 
DNA methylation correlates with transcriptional repression, although the inverse 
relationship, DNA demethylation and transcription activation may not be a universal 
feature (Singal and Ginder, 1999). It has been described that the inhibition of gene 
expression by DNA methylation can be achieved both directly, by excluding 
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transcription factor binding, and indirectly, by attracting methyl-CpG-binding domain 
proteins (MBDs) that interact with histone deacetylases (HDACs) and chromatin 
remodelling factors that alter chromatin to a repressive state (Jones et al., 1998; Nan et 
al., 1998; Singal and Ginder, 1999). 
It is well known the role of DNA methylation in the regulation of tissue-specific 
gene expression, in particular in testis-specific genes where exists a clear-cut correlation 
between the capacity of a gene to undergo transcription and its level of 
hypomethylation. There are several examples of genes expressed specifically in the 
male germ line during the process of spermatogenesis that are fully methylated in all 
non-expressing somatic tissues and undergo demethylation in the proper germ-line cell 
types (Ariel et al., 1991). Some examples of testis-specific genes regulated at least in 
part through differential methylation include: mouse phosphoglycerate kinase (Pgk2) 
(Zhang et al., 1998); mouse lactate dehydrogenase c gene (Ldhc) (Kroft et al., 2001); 
rat testis-specific H2B (TH2B) histone gene (Choi and Chae, 1991); mouse testis-
specific H1t gene (Singal et al., 2000); mouse and human ALF (TFIIAα/β-like factor) 
genes (Xie et al., 2002); and a subset of male germ line-specific genes (MAGE-type 
genes) (De Smet et al., 1999). 
The crucial role of DNA methylation is emphasized by the growing number of 
human diseases that are known to occur when this epigenetic information is not 
properly established and/or maintained (Paulsen and Ferguson-Smith, 2001; Robertson, 
2005). 
 The best example is the relationship between DNA methylation and cancer. 
Actually, aberrant methylation patterns have been associated with a large number of 
human malignancies, in which normal methylation patterns are frequently disrupted in 
tumor cells with global hypomethylation accompanying region-specific 
hypermethylation (Laird and Jaenisch, 1994; Das and Singal, 2004; Issa, 2007). 
 Several imprinting disorders have also been described in which occurs the 
disruption of imprinted epigenetic marks through gain or loss of DNA methylation, or 
simply the loss of normal allele-specific gene expression (Feinberg et al., 2002); some 
examples include transient neonatal diabetes mellitus (Temple and Shield, 2002) and 
some syndromes like Beckwith–Wiedemann (Lee et al., 1999), Prader–Willi 
(Goldstone, 2004) and Angelman (Lossie et al., 2001). DNA methylation defects have 
also been linked to members of a large group of human diseases that are associated with 
repeat instability, for example the fragile X syndrome (Crawford et al., 2001) and the 
General Introduction & Objectives 
 
 31 
facioscapulohumeral muscular dystrophy (van Overveld et al., 2003). Additionally, 
specific defects of the methylation machinery may also originate human diseases such 
as systemic lupus erythematosus (Sekigawa et al., 2003) and the immunodeficiency, 
centromeric instability and facial anomalies syndrome (Jiang et al., 2005). 
 These examples enhance our understanding of the myriad roles of DNA 
methylation in disease, as well as pointing the way to novel therapies to prevent or 
repair these defects. 
However, and very recently, new levels of complexity related to DNA 
methylation were discovered. Firstly, the recognition that methylation can occur in 
previously unappreciated sequence contexts, namely at non-CpG cytosines. Non-CpG 
methylation revealed to be characteristic of an embryonic stem cell state, probably 
maintained by continual de novo methyltransferase activity and not observed in 
differentiated cells, which suggests that it may have a key role in the origin and 
maintenance of this pluripotent state. Additionally, CpG and non-CpG methylation 
seem to have different correlations with gene expression, possibly alternating roles 
(Lister et al., 2009; Laurent et al., 2010). 
Secondly, one hallmark of epigenetic signaling is that it is heritable but flexible, 
what implies that pathways for removal of epigenetic marks are required. Effectively, 
two independent groups (Kriaucionis and Heintz, 2009; Tahiliani et al., 2009) have 
conclusively detected, in human DNA, 5-hydroxymethylcytosine (5hmC), an oxidized 
form of 5mC. This hydroxylation was shown to be catalyzed by three members of the 
Ten-Eleven-Translocation (TET) di-oxygenases family, using molecular oxygen and 2-
oxoglutarate as co-substrates (Tahiliani et al., 2009).  
This 6th base of mammalian genome (5hmC) is present in very small amounts, 
and the highest levels were observed in nervous system and spinal cord (Ito et al., 2011; 
Munzel et al., 2011). A recent study showed that, while the content of 5mC varies 
between 1-2.5 fold in human tissues, the 5hmC content displayed a 13-fold greater 
difference in different tissues (Li and Liu, 2011). Interestingly, at gene promoters and 
CpG islands, 5mC is under-represented, while 5hmC is enriched and is associated with 
increased transcriptional levels, thus being mostly associated with euchromatin (Ficz et 
al., 2011; Wu et al., 2011).  
A current idea holds that 5hmC may act as a 5mC antagonist or even that it may 
have a direct role in DNA demethylation, thus regulating gene expression (Jurkowski 
and Jeltsch, 2011). Namely, it has been proposed a balance between 
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hydroxymethylation and methylation in the genome that is inextricably linked with the 
balance between pluripotency and lineage commitment (Ficz et al., 2011).  
 Accordingly, 5hmC may play important roles in epigenetic reprogramming and 
tissue-specific gene regulation (Branco et al., 2012) and its existence has added a new 
and possibly significant dimension to our perception of DNA methylation in human 
development and disease (Dahl et al., 2011). 
 
 
b 
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1.4 Objectives 
 
Pyruvate dehydrogenase complex deficiency is a severe metabolic disorder 
mainly caused by mutations within PDHA1 gene, which encodes the pivotal PDC E1α 
subunit in somatic cells. Due to the X chromosome localization of PDHA1 gene, there 
is an autosomal gene, PDHA2, which encodes an E1α isoform that is exclusively 
expressed in testis during spermatogenesis and ensures the energy requirements of 
spermatogenic cells. 
The idea of PDHA2 gene activation in somatic tissues constitutes a potential 
therapy for PDC deficiencies when PDHA1 is defective, although the mechanisms that 
regulate the tissue-specific expression of the human PDHA2 remain elusive. In fact, the 
unique study concerning the human PDHA2 gene promoter hardly provides substantial 
information. In accordance, further studies were required to unravel the regulatory 
mechanisms of the human PDHA2 gene expression. 
A fortuitous discovery of a PDC deficient patient presenting an atypical somatic 
expression of the PDHA2 gene constituted a unique model for studying PDHA2 
regulatory mechanisms. Accordingly, the present work was designed to clarify the index 
case and to understand the mechanisms that regulate PDHA2 gene expression, namely 
its activation in spermatogenic cells and its normal silencing in somatic cells. 
 
The major questions addressed in the present work are: 
• What is the underlying explanation for the activation of the human PDHA2 gene 
in somatic tissues of the index case? 
• What is the expression pattern of PDHA1 and PDHA2 mRNA and protein levels 
in human tissues? 
• What is the role of DNA methylation in the regulation of PDHA2 expression? 
• Can PDHA2 gene expression be induced in somatic tissues? 
 
At the end, this work presents a significant contribution to the knowledge of the 
regulatory mechanism of the human PDHA2 gene and strives to shed a light towards a 
new therapeutic approach for some inborn errors of PDC. 
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2.1. Abstract 
 
The E1α subunit of the human pyruvate dehydrogenase complex (PDC) exists as 
two isoforms encoded by different genes: PDHA1 located on Xp22.1 and selectively 
expressed in somatic tissues, and the intronless PDHA2, located on chromosome 4 and 
only expressed in testis germ cells after the onset of spermatogenesis. We report the 
study of a family displaying in circulating lymphocytes and cultured fibroblasts, the 
presence of a full-length testis-specific PDHA2 mRNA together with a 5'-truncated 
PDHA1 transcript.  Moreover, this last one is translated into a full-length PDHA1 
protein, thus originating the co-existence of both isoforms in somatic cells. 
Additionally, we observed that DNA demethylation is a potential mechanism 
underlying the somatic activation of the PDHA2 gene transcription in these individuals. 
Moreover, it is tempting to hypothesize that the PDHA2 gene hypomethylation is 
triggered off by the same event that leads to the transcription of the 5’-truncated 
PDHA1 messenger, which may also rely on an epigenetic modification. Resuming, this 
study represents the first natural model of the derepression of the testis-specific PDHA2 
gene in somatic cells, which may open new avenues towards a potential therapy for 
PDC deficiencies resulting from PDHA1 gene mutations. 
 
2.2. Introduction 
 
Pyruvate dehydrogenase complex (PDC) catalyzes the irreversible 
decarboxylation of pyruvate into acetyl-CoA with concomitant formation of NADH. All 
subunits are encoded by nuclear genes and imported into mitochondria after cleavage of 
their leader sequences. The complex is formed by multiple copies of three catalytic, one 
binding and two regulatory components: pyruvate dehydrogenase (E1), 
dihydrolipoamide acetyltransferase (E2), dihydrolipoyl dehydrogenase (E3), a structural 
protein (E3 binding protein), pyruvate dehydrogenase kinase (PDK) and pyruvate 
dehydrogenase phosphatase (PDP) (Patel and Roche, 1990; Robinson, 2001). The E1 
enzyme (EC 1.2.4.1) is a heterotetramer (α2β2) that catalyzes the decarboxylation of 
pyruvate by a postulated flip-flop mechanism (Ciszak et al., 2003). The α subunit, 
besides forming with the β subunit the substrate and the cofactor binding sites, is also 
the target for the regulatory mechanisms based upon dephosphorylation (activation) and 
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phosphorylation (inactivation) of three serine residues (Patel and Korotchkina, 2001; 
Harris et al., 2002). 
PDC deficiency is one of the most common neurodegenerative disorders 
associated with altered mitochondrial metabolism leading to energy deprivation, 
especially in the CNS (Brown et al., 1994; Pliss et al., 2007). Genetic defects of PDC 
are associated with a variety of neurologic manifestations, ranging from mild ataxia to 
profound psychomotor retardation and even death during early infancy. The most 
frequent form of genetically determined PDC deficiency is caused by mutations in the 
E1α subunit (OMIM #312170), being most of them sporadic and the recurrence rate 
very low (Lissens et al., 2000). 
The PDC E1α subunit exists as two isoforms encoded by different genes. 
PDHA1 is located on region p22.1 of the human X chromosome, contains 11 exons 
separated by introns, spans approximately 17 kb of genomic DNA and is selectively 
expressed in somatic tissues. An autosomal locus, PDHA2, lies on chromosome 4 
(4q22-23), completely lacks introns, spans 1.4 kb of genomic DNA, displays 
characteristics of a functional processed gene and is expressed only in testis after the 
onset of spermatogenesis (Dahl et al., 1990). 
The autosomal localization of PDHA2 gene is particularly significant in males, 
once X chromosome inactivation occurs early in spermatogenesis and, in addition, only 
half of the haploid spermatids contain the X chromosome. During the last meiotic 
division the spermatids go through a period of maturation, storage and release, in which 
the haploid spermatogenic cells, like brain, is dependent on energy generated from 
pyruvate via the PDC. Therefore, the existence of an autosomal variant of E1α ensures 
that cellular energy requirements are maintained during spermatogenesis (Fitzgerald et 
al., 1994; Dahl et al., 1996). 
It is of paramount interest if PDHA2 gene could be switched on in somatic 
tissues of patients with PDC deficiency caused by mutations in PDHA1 gene (Robinson 
et al., 1996; Datta et al., 1999), which could open up new therapeutic avenues for this 
metabolic disease. For this purpose it is necessary to unravel the molecular mechanisms 
underlying PDHA2 gene expression in humans. Previous studies reported these 
mechanisms in the mouse orthologue (Iannello et al., 1993; Iannello et al., 1997; 
Iannello et al., 2000), but it is believed that both mouse and human promoter regions 
evolved from different retroposons (Fitzgerald et al., 1996), because no gross homology 
exists between the promoters of both genes. Accordingly, it was postulated that the 
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regulatory mechanisms of human PDHA2 gene should be significantly different from 
that of rodent species (Datta et al., 1999). Indeed, our group has recently shed some 
light on this subject, revealing that the transcriptional activity of human testis-specific 
PDHA2 gene correlates with the methylation status of a CpG island located in its open 
reading frame (Pinheiro et al., 2010b), which suggests that the tissue-specific 
expression of PDHA2 gene is strongly controlled by epigenetic mechanisms, namely by 
DNA methylation (Pinheiro et al., 2010a). 
The present report refers the study of one family displaying the expression of a 
full-length PDHA2 transcript and protein, in circulating lymphocytes and cultured 
fibroblasts. To our knowledge, this is the first case where the presence of the PDHA2 
mRNA and PDHA2 protein, responsible for the specific expression of the PDC E1α 
protein in post-meiotic spermatogenic cells, is observed in somatic cells. Additionally 
and most importantly, elucidation of the molecular mechanisms underlying the somatic 
activation of the testis-specific PDHA2 gene expression could configure the long 
dreamed therapeutic approach for most forms of PDC deficiency.  
 
2.3. Patient and methods 
 
2.3.1. Case report 
 
This report was initiated by the study of a 22-year-old Portuguese white girl, 
first child of non-consanguineous parents, displaying psychomotor delay with walking 
ataxia, encompassing a static encephalopathy. On neonatal period she developed 
seizures associated with respiratory distress and until 3 years of age she was admitted 
several times due to episodes of lactic acidosis. The patient was referred to our 
laboratory and her metabolic profile revealed isolated hyperalaninemia (639 μM; 
normal range 158 – 314), hyperlactic acidemia (4.43 mM; normal range < 2.23), 
hyperpyruvic acidemia (0.271 mM; normal range < 0.180) and normal lactate / pyruvate 
molar ratio (16.3; normal range < 20). PDC deficiency was confirmed by determination 
of enzyme activity in two different tissues: 21.3% and 16.3% of control activity in 
lymphocytes and fibroblasts, respectively. Her parents revealed also reduced enzymatic 
activities in their lymphocytes: the mother and the father showed 54.1% and 74.6% of 
control activity, respectively. At 11 years of age, she had been observed at Hôpital 
Necker-Enfants Malades in Paris, France, where the PDC deficiency was confirmed and 
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assigned most probably to E1α subunit, which displayed 15% of the control activity. 
Furthermore, cytogenetic analysis performed in Paris revealed a normal karyotype with 
no skewed X-inactivation. In adulthood, the patient was admitted twice (18 and 21 years 
of age) with metabolic decompensation induced by lactic acidosis after physical 
exercise. The patient remains stable under therapy with thiamine (100 mg/day) and 
sodium bicarbonate (4x25 mL/day).  
This study was approved by the local Ethics Committee and written informed 
consent was obtained from the parents, who were enrolled in the study together with the 
patient’s younger brother. 
 
2.3.2. Sample preparation 
 
Three independent peripheral blood samples were obtained from index case, her 
parents and brother, as well as from control individuals. Mononuclear cells were 
separated at room temperature on a Ficoll-Paque™ gradient (GE Healthcare Bio-
Sciences, Uppsala, Sweden). Patient’s fibroblast cultures were established from a 
diagnostic skin biopsy and grown until confluence in Dulbecco’s Modified Eagle 
Medium (Sigma-Aldrich Inc., St. Louis, MO, USA), supplemented with 10% fetal calf 
serum (Biochrom AG, Berlin, Germany) and 100 units/mL penicillin (Sigma) and 100 
μg/mL streptomycin (Sigma).   
Positive controls for PDHA2 gene expression were obtained from two different 
sources: a commercially available human testis total RNA sample (Clontech 
Laboratories Inc., Mountain View, CA, USA) and human testis specimens retrieved 
from eight cases requiring open testicular biopsy for the retrieval of testicular sperm for 
intracytoplasmic sperm injection. Human sample collection, treatment and preparation 
have been previously described (Pinheiro et al., 2010b). 
 
2.3.3. Western immunoblotting 
 
Lymphocyte homogenates from all family members, control individuals and 
whole testis samples were directly loaded onto 10% Mini-PROTEAN TGX® PrecastTM 
Gels (Bio-Rad Laboratories Inc., Hercules, CA, USA) and run under reducing 
conditions. Proteins were electrotransferred onto PVDF membrane (Amersham 
HybondTM-P, GE Healthcare Bio-Sciences), which were probed with primary 
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antibodies: MitoProfile® Pyruvate dehydrogenase (PDH) WB Antibody Cocktail 
(MitoSciences, Eugene, OR, USA) and the PDHA1 (ab110334) and the PDHA2 
(ab72931) antibodies (Abcam, Cambridge, UK). Immunocomplexes were detected by 
the LumiGLO® reagent (Cell Signaling Technology, Beverly, MA, USA).   
 
2.3.4. Two-dimensional electrophoresis 
 
Homogenates from family and control lymphocytes were pre-cleared with 
ReadyPrep™ 2-D kit (Bio-Rad). Pellets were solubilized in 200 μL of a solution 
containing 8M urea, 2% (w/v) CHAPS, 50 mM DTT and 1X Bio-Lyte® Ampholyte 
20% pH7-10. An 11 cm, pH 7-10, immobilized pH gradient strip (ReadyStrip™ IPG, 
Bio-Rad) was rehydrated using 200 μL of sample. Isoelectric focusing (IEF) was 
performed in a Protean® IEF apparatus (Bio-Rad) with an initial voltage of 250 V for 20 
minutes, then 8,000 V for 2.5 hours and a final voltage of 8,000 V for 20,000 V-hr. 
Then, IPG strips were soaked in equilibrium buffer (6M urea, 2% (w/v) SDS, 
20% (w/v) glycerol, 0.375 M Tris-HCl pH 8.8) to which was added 2% (w/v) DTT in 
the first step and 2.5% (w/v) iodoacetamide in the second step. The equilibrated IPG 
strips were embedded on the top of SDS-PAGE gels (Criterion Tris-HCl gel, 8-16%, 11 
cm, Bio-Rad) in 1% (w/v) agarose molten in running buffer (192 mM Tris/glycine, 
0.1% (w/v) SDS, pH8.3). Gels were run in a Criterion™ electrophoresis cell (Bio-Rad) 
at 200 V for 65 minutes. 
Proteins were then electrotransferred onto PVDF membrane, which were probed 
with anti-PDHA1 antibody (MSP07/ab110334, Abcam). Immunocomplexes were 
detected as previously referred. 
 
2.3.5. Preparation of genomic DNA, total RNA and cDNA 
 
Genomic DNA was isolated from peripheral blood leukocytes and from cultured 
fibroblasts, using a salting-out procedure (Puregene® Cell and Tissue kit, Gentra 
Systems, Minneapolis, MN, USA). Total RNA was prepared from peripheral 
lymphocytes and skin fibroblasts using the RNeasy® MiniKit (Qiagen, Hilden, 
Germany), and contamination by genomic DNA was eliminated by treatment with 
deoxyribonuclease I. One μg was reverse transcribed using the Reverse Transcription 
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System A3500 kit (Promega, Madison, WI, USA) with random primers following the 
manufacturer´s instructions. 
 
2.3.6. PCR of genomic DNA and cDNA 
 
Amplification of the 11 individual exons of the PDHA1 gene (GenBank 
accession no. NG_016781.1), and respective intron-exon boundaries, was performed as 
previously described (Silva et al., 2009). 
Six PDHA1 cDNA overlapping fragments were amplified with specific primers 
and named from A to F; primers and PCR conditions were as previously described 
(Lissens et al., 1996). Furthermore, PDHA1 and PDHA2 cDNAs were amplified using 
specific primers, hybridizing to regions displaying no homology between transcripts 
(Dahl et al., 1990).  PDHA1 primers cover nucleotides +75 to +1008 (GenBank 
accession no. NM_000284.3) resulting in a 934 bp fragment, while PDHA2 primers 
cover nucleotides -27 to +1254 (GenBank accession no. NM_005390.4) resulting in a 
1281 bp fragment. For sequence numbering, nucleotide +1 was assigned to the 
adenosine of the initiation translation codon ATG. Table 2.1. lists all the primers used 
for these analyses. 
 
2.3.7. Single strand conformational polymorphism analysis (SSCP) 
 
Screening for PDHA1 mutations was performed by SSCP analysis, either for the 
eleven individual exons or for the six consecutive overlapping cDNA fragments, using 
8% or 12% polyacrylamide gels (37.5:1) with 5% glycerol, and carried out at 0.625 mA 
/ cm gel, for 18-24 h, at room temperature. Bands were visualized by silver staining 
(DNA Silver Staining Kit, GE Healthcare Bio-Sciences). 
PCR products revealing an abnormal electrophoretic pattern were directly 
sequenced with ABI PRISM® BigDye™ Terminator Cycle Sequencing Ready Reaction 
Kits, in an ABI PRISM® 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, 
USA). Each PCR product was sequenced in both directions using the PCR primers. 
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Table 2.1. List of primers used in the family´s study. 
 
Primer Sequence Position 
  
cDNA amplification 
 
PDHA1 messenger   
PDHA1-F 5’-AGCATCCCGTAATTTTGC-3’ +75 to +92 
PDHA1-R 5’-CTTTAGTTCTTCCACACTGG–3’ +989 to +1008 
PDHA1-5’-F 5’-GGGCACCTGAAGGAGACTT-3’ -85 to -66 
PDS1 5’-TGTGAGGAGTCGCCGCTGCC-3’ -37 to -18 
PDSTr-F 5’-GCCACTGCCTGTGCTTCAT-3’ -17 to +2 
PDSTr-R 5’-ACTCCATTCGGCGTACAGTCT-3’ +207 to +226 
PDHA2 messenger   
PDHA2-F 5’–TGCCATCTACAGCACTCCGT–3’ -27 to -8 
PDHA2-R 5’–CCTCCTTGAGTTGAGAACAC–3’ +1298 to +1317 
   
 Genomic DNA amplification  
PDHA1 gene   
PDHA1-P2-F 5’-TGAGCATGCTGCTAATCTTCA-3’ -504 to -484 
PDHA1-P2-R 5’-CGGCGTGACAGAGTCGTAAT-3’ -132 to -113 
PDHA1-P3-F 5’-CTGGACGCCGTTCTGGTT-3’ -180 to -163 
PDHA1-P3-R 5’-GCGGAGGCGAAGTAAAGG-3’ +178 to +195 
PDHA1-P4-F 5’-TGCTTCATGAGGAAGATGCT-3’ -6 to +114 
PDHA1-P4-R 5’-AGGGTGCTGTTTGAACGAAG-3’ +479 to +500 
 
PDHA2 gene 
  
PDHA2-A-F 5’-GAGTAAGGAAAAGTGGAATGTCA-3’ -841 to -819 
PDHA2-A-R 5’-ATCCTGCTCCATAATGTGCC-3’ -200 to -181 
PDHA2-B-F 5’-GCCATCAGGATAAATGTGGC-3’ -657 to -638 
PDHA2-B-R 5’-CCCTTTTCCCTGTTAAACCC-3’ -322 to -303 
PDHA2-C-F 5’-AACTCTCAGAACTCTCATGTGCC-3’ -415 to -393 
PDHA2-C-R 5’-ACGGAGTGCTGTAGATGGCA-3’ -27 to -8 
PDHA2-D-F                5’-CAGGACCTGCCTCTATCACC-3’ -142 to +123 
PDHA2-D-R 5’-AAACCGCGAATGAATTTCTG-3’ +244 to +263 
PDHA2-F-F 5’-GCATGGAATTGAAGGCAGAT-3’ +212 to +231 
PDHA2-F-R 5’-CCTCCTTGAGTTGAGAACAC-3’ +1298 to +1317 
   
 PDHA2 gene methylation analysis  
CpGI-M-F 5’-ATAAATTAGTTAGTTTAGGTTGCGT-3’ -188 to -164 
CpGI-M-R 5’-ATAACGTCATTTAAAAAATTACGAA-3’ +74 to +98 
CpGI-U-F 5’-ATAAATTAGTTAGTTTAGGTTGTGT-3’ -188 to -164 
CpGI-U-R 5’-ATAACATCATTTAAAAAATTACAAA-3’ +74 to +98 
CpGII-F 5’-TGGAATTGAAGGTAGATTAGTTGTATAAAT-3’    +205 to +234 
CpGII-R 5’-ATACCATTACCCCCATAAAAATTCT-3’ +406 to +431 
 
 Gene dosage  
PDHA1 gene   
PDHA1-exon7F 5’-AGGAGGCCTTTCTGTGCTTT-3’ 11341 to 11359 
PDHA1-exon7R 5’-CGGCCCCACCACAGGGTTCCT-3’ 11616 to 11636 
PAH gene    
PAH-exon1F 5'-GCTTTACTGTGCGGAGATCACCAC-3' 5315 to 5339 
PAH-exon1R 5'-CTTATGAAACCAGGAAGCAC-3' 5606 to 5625 
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2.3.8.  qPCR for PDHA1 and PDHA2 expression analysis and PDHA1 gene  dosage  
 
First strand cDNA and genomic DNA were used as templates for quantitative 
real-time PCR with an ABI PRISM® 7300 sequence detection system (Applied 
Biosystems).  For gene expression analysis we used the TaqMan® Gene Expression 
Assays (Applied Biosystems) IDs: Hs00264851_m1 (for PDHA1), Hs01043024_s1 (for 
PDHA2) and as endogenous control the TaqMan® β-actin Control Reagents. Each 
sample was assayed in triplicate and results show a minimum of three independent 
experiments. Transcript levels were normalized to β-actin and expressed in pg PDHA2 
mRNA per ng of β-actin mRNA.  
For gene dosage determination, two methods were adapted (Liew et al.; Nguyen 
et al., 2004). Briefly, genomic fragments from the target PDHA1 gene (X-chromosomal 
location) and from the reference phenylalanine hydroxylase gene (PAH, GenBank 
accession no. NG_008690) were amplified. Table 1 is shows the sequence and genomic 
location of the oligonucleotides used for qPCR amplification. Each target replicate 
(PDHA1) was normalized to PAH to obtain a ΔCt and then an average ΔCt for each 
sample (3 replicates) was calculated. Afterwards, all samples were normalized to a 
calibrator sample (known sample with 2 copies of PDHA1 gene) to determine ΔΔCt. 
Relative quantity (RQ) is 2-ΔΔCt and gene copy number is 2 X RQ. 
 
2.3.9. Sequence analysis of PDHA1 and PDHA2 promoter regions 
 
The genomic region encompassing the promoter region, exon 1 and a portion of 
the first intron of PDHA1 gene (GenBank accession no. NG_016781.1, nucleotides -504 
to +400) was sequenced by primer walking using primers listed in Table 2.1.. The 
genomic region encompassing the promoter and coding sequences of PDHA2 gene 
(GenBank accession no. NC_000004.11, nucleotides -841 to +1317) was sequenced 
after amplification in five overlapping fragments, named A to E (Table 2.1.). 
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2.3.10. Sodium bisulfite genomic DNA sequencing of the CpG islands in PDHA2 
gene 
 
Bisulfite PCR sequencing was carried out using the EpiTect® Bisulfite Kit 
(Qiagen), the AmpliTaq® DNA polymerase (Applied Biosystems) and primers 
specifically designed (Pinheiro et al., 2010b), using appropriate software (Li and 
Dahiya, 2002). Briefly, one microgram of genomic DNA was treated with sodium 
bisulfite solution for three rounds of denaturation at 99˚C followed by incubation at 
60˚C, in a thermal cycler, during approximately five hours; DNA was further purified 
by column separation. CpG island I was amplified using a methylation-specific primer 
set and CpG island II was amplified with bisulfite PCR primers (Table 2.1.). The 
reactions were run for 50 cycles, each encompassing a denaturation step at 95˚C for 30 
seconds, an annealing step at 50˚C (Island I) or 55˚C (Island II) for 45 seconds and an 
extension step at 72˚C for 45 seconds. The reaction products were purified by 2% 
NuSieve® GTG® agarose gel electrophoresis and directly sequenced as previously 
mentioned.   
 
2.4. Results 
 
Molecular diagnosis of a PDC deficiency is always a challenge due to the high 
number of genes involved in the codification of all subunits that must assemble in order 
to achieve a fully functional complex. Accordingly, the first analytical step is a Western 
blot analysis in order to detect any alteration at the protein level and to target the 
gene(s) for further molecular characterization. The results of our index case revealed a 
normal profile (Figure 2.1.A), with all the subunits displaying expression levels within 
the normal range. Accordingly, a rationale approach for molecular characterization was 
hampered.  
However, because most cases of PDC deficiency are caused by mutations in the 
PDHA1 gene, encoding the PDC E1α subunit, this gene was the starting point for the 
molecular characterization of the index case. Additionally, because the majority of 
mutations are sporadic with a very low recurrence rate, the first analytical approach was 
a screening method to localize the mutated gene region. 
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Figure 2.1. Western blot analysis of lymphocyte and testis homogenates. (A) C1 to C4 – control 
lymphocytes, P – patient lymphocytes (using the MitoProfile® Pyruvate dehydrogenase (PDH) WB 
Antibody Cocktail); (B) T – testis, C1 and C2 – control lymphocytes, P – patient lymphocytes, M – 
mother lymphocytes, F – father lymphocytes, B – brother lymphocytes, MM – molecular weight marker 
(using the PDHA1 antibody) 
        
2.4.1.  Identification of a 5’-truncated PDHA1 transcript and a full-length PDHA2 
transcript in somatic cells 
 
SSCP analysis was performed at cDNA and genomic levels. Analysis of the six 
PDHA1 cDNA fragments revealed an abnormal electrophoretic pattern for fragment A 
(covering nucleotides -37 to +281) amplified from the patient when compared with 
control samples (data not shown). All other cDNA fragments displayed migration 
patterns compatible with those of the controls. Regarding genomic DNA, SSCP analysis 
showed that all the 11 exons presented migration profiles identical to the control 
samples, even for exons 1, 2 and 3 corresponding to fragment A from cDNA. 
Sequence analysis of patient’s fragment A revealed a nucleotide sequence 
exclusively compatible with the transcript of the autosomal PDHA2 gene and not with 
the one of the X-linked PDHA1 messenger. Although the other cDNA fragments (B – 
F) displayed normal migration profiles, they were all sequenced and the results showed 
that the detected nucleotide sequences corresponded to an overlapping of wild-type 
PDHA1 and PDHA2 transcripts. In spite of their normal SSCP electrophoretic patterns, 
all the eleven exons and respective intronic boundaries of patient’s PDHA1 gene were 
C1     C2       P      C3      C4 
E1! 
E2 
E3 + PX 
E1" 
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#"
T        C1      C2      P       M       F        B 
PDHA1 43 KDa 
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also sequenced in both directions and their nucleotide sequence proved to be perfectly 
consistent with the wild-type genomic sequence. 
Close inspection on the nucleotide sequence of the primers traditionally used for 
PDHA1 transcript amplification (Lissens et al., 1996), clearly revealed that they are not 
specific, once the regions where they hybridize display at least 75% homology (with 
complete homology in their 3’ ends) between PDHA1 and PDHA2 messengers. 
Accordingly, and in order to confirm the expression of PDHA2 gene in circulating 
lymphocytes and skin fibroblasts, the amplification of patient and control cDNAs was 
performed, using specifically designed primers to hybridize to non-homologous regions 
in each transcript (Dahl et al., 1990); additionally, a testis sample was used as a positive 
control for PDHA2 gene expression. 
The results showed that, when using the PDHA1 specific primers (PDHA1-F 
and PDHA1-R – Table 2.1.), all samples displayed the presence of the PDHA1 
transcript, covering nucleotides +75 to +1008, though not corresponding to the full-
length coding sequence (Figure 2.2.A); and sequence analysis of all these fragments 
showed a full compatibility with the wild-type sequence. Moreover, we further 
amplified the cDNAs from patient and controls using as forward primer PDS1 
(previously used for amplification of cDNA fragment A and encompassing nucleotides 
-37 to -18 with 75% homology with PDHA2 transcript) and as reverse primer the same 
specific PDHA1-R primer, previously used. The results showed a complete lack of 
amplification product from the patient’s sample, while all the controls displayed the 
expected 1045 bp fragment (Figure 2.2.B).  
These results suggested that the patient expressed a truncated PDHA1 mRNA. 
Trying to localize the truncation point, we designed new primers (Table 2.1.): the 
PDSTr-F forward primer which hybridizes between nucleotides -17 and +2, region 
displaying almost no homology with PDHA2 transcript, and the PDSTr-R reverse 
primer which hybridizes between nucleotides +207 and +226, region displaying 80% 
homology with the same transcript. This reaction allowed the detection of a 243 bp 
amplification product in all samples, either from patient or controls (data not shown). 
Accordingly, the truncation point should be located upstream nucleotide -17 of 
this patient PDHA1 messenger (Figure 2.3.). Moreover, we further designed a new 
forward primer (PDHA1-5’) hybridizing between -85 and -66, very close to the 5´end of 
PDHA1 mRNA and with no homology to PDHA2 transcript. PCR amplification using 
this new primer, together with the specific PDHA1-R reverse primer, revealed the 
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absence of the expected 1093 bp product. These results seem to confirm the presence of 
a 5’ truncated PDHA1 messenger, displaying about 17 nucleotides upstream the ATG 
codon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. RT-PCR analysis of PDH E1α  transcripts. (A) Using PDHA1 or PDHA2 specific primers. 
PL - patient lymphocytes; PF - patient fibroblasts; T - whole testis tissue; C1 and C2 - control 
lymphocytes; B1 - PCR control using whole testis total RNA; B2 - PCR control using no biological 
sample. M - 100 Base Pair Ladder (New England Biolabs); (B) Using forward PDS1 primer and reverse 
PDHA1 specific primer. PL - patient lymphocytes; PF - patient fibroblasts; C - control sample; B - PCR 
control using no biological sample. M - 100 Base Pair Ladder (New England Biolabs).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Schematic representation of the PDHA1 mRNA sequence. Localization of the forward 
primers (PDS1, PDSTrF and PDHA1F) and the reverse primers (PDHA1R and PDSTrR) used for RT-
PCR analysis, as well as the localization of the hybridization probe used for qPCR analysis.  
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5 – primer forward PDHA1F 
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Amplification of patient, control and testis samples with PDHA2 specific 
primers (PDHA2-F and PDHA2-R) revealed an absence of amplification product from 
control samples, while the patient and testis samples displayed a 1281 bp long PCR 
product (covering nucleotides -27 to +1254) and corresponding to the full-length 
PDHA2 coding sequence (Figure 2.2.A). Sequence analysis of this fragment, which 
revealed 100% homology with the published PDHA2 transcript sequence (data not 
shown), allowed us to confirm that the patient displayed the somatic expression of a 
full-length PDHA2 transcript. Moreover, the alignment between reference PDHA1 and 
PDHA2 mRNA sequences, together with the localization of both sets of specific 
primers, showed that the regions where the primers hybridize display very low or null 
homology, thus hampering misamplifications (Appendix 1). 
Facing this uncommon situation, samples from patient’s parents and brother 
were analyzed in the same conditions and the results perfectly overlapped the patient’s 
ones. So, from this point onwards, samples from all the family members were 
simultaneously analyzed and compared with controls.  
In order to unequivocally confirm the presence of the PDHA2 transcript in the 
somatic cells of this patient and respective family, we performed quantitative real-time 
PCR analysis using specific TaqMan® gene expression assays, either for PDHA1 or 
PDHA2 mRNA, which were normalized relative to β-actin expression in those cells. 
The results clearly revealed that PDHA2 transcript was only detected in the positive 
control testis sample and in the family cells, while it was completely absent from 
control liver and control lymphocyte samples (Figure 2.4.). On the contrary, PDHA1 
transcript could be detected in all types of samples, as expected. First, the testis RNA 
sample was prepared from a pool of testicular human tissues, which embodies not only 
germ cells but also somatic ones, like Sertoli and Leydig cells. Second, we have 
previously predicted that the truncation point in PDHA1 transcript was located upstream 
nucleotide -17, and the PDHA1 TaqMan® probe hybridized to exons 1 and 2 boundaries, 
being nucleotide +63 the target site and the amplicon size 62 bp, according to 
manufacturer’s information (Figure 2.3.).  
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Figure 2.4. Quantitative Real-Time PCR analysis to evaluate PDHA1 and PDHA2 gene expression. 
T - whole testis tissue; Li - control liver; Ly - control lymphocytes; P - patient lymphocytes ; M - mother 
lymphocytes ; F - father lymphocytes ; B - brother lymphocytes. 
 
2.4.2. Protein expression analysis reveals the co-existence of both PDHA proteins 
in somatic tissues 
 
Once detected the expression of a full-length PDHA2 transcript, it was 
mandatory to prove the presence of the resulting protein. Accordingly, new Western 
blot analyses were performed, using primary antibodies raised against PDHA1 and 
PDHA2 proteins. As positive control sample for the PDHA2 expression we used a cell 
homogenate obtained from testicular biopsies. The results revealed that all samples, 
either from testis, control lymphocytes or family members, hybridized with the PDHA1 
antibody (Figure 2.1.B), but none of the samples revealed the formation of 
immunocomplexes with the PDHA2 antibody (data not shown). Though different lots of 
PDHA2 antibody have been used, and from different suppliers, we could not detect any 
immunocomplex, even with the testis sample, which was our positive control.  
Therefore, a new approach by two dimensional electrophoresis was attempted in 
order to prove the presence of PDHA2 protein. This analysis relies on the different 
isoelectric points (IP) displayed by both proteins: PDHA1 has a basal IP of 8.35, while 
the one of PDHA2 is 8.76. Moreover, these proteins are regulated by phosphorylation / 
dephosphorylation of three specific serine residues, thus originating different IP range 
(7-7.95 for PDHA1 and 8-8.58 for PDHA2). The analysis of the family samples 
revealed the simultaneous presence of both full-length PDHA1 and PDHA2 proteins, 
displaying the expected 43 kDa form and respective IP ranges (Figure 2.5.A). 
Nevertheless, samples from control individuals only displayed the presence of the 
expected PDHA1 protein (Figure 2.5.B). 
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Figure 2.5. Bidimensional analysis of several cellular homogenates using the anti-PDHA1 antibody:  
A – Patient lymphocytes; B – Control lymphocytes. Note that both proteins separate into different spots 
corresponding to the several phosphorylation states that proteins may assume. The molecular mass 
standards and pI values are indicated.   
 
2.4.3. Trying to explain the truncated PDHA1 transcript 
  
We attempted to elucidate the cause for the expression of a 5’-truncated PDHA1 
transcript. Therefore, the genomic region encompassing the promoter region, exon 1 
and a portion of the first intron of PDHA1 gene (nucleotides -504 to +500) was 
sequenced in both directions. The results revealed that the nucleotide sequence of all 
family members perfectly matched the wild-type sequence, displaying no alteration 
susceptible to cause the aberrant transcript. Accordingly, the origin of this truncated 
transcript remained elusive. 
Additionally, as PDHA1 gene is located on X chromosome, and no skewed 
lyonization has been detected (see Case Report), a normal transcript should have always 
been visualized in the RT-PCR analyses performed upon the patient and her mother 
samples. As that was not the case, we investigated a potential PDHA1 gene deletion that 
could explain our data, using as a reference the autosomal gene PAH. Effectively, the 
results of the PDHA1 gene dosage analysis strongly suggested that the patient and her 
mother carry only one copy of the PDHA1 gene, in opposition to the two copies 
displayed by all female controls (Table 2.2.). 
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Table 2.2. Calculations for determining the copy number of PDHA1 gene using as reference the 
autosomal PAH gene. 
PDHA1 gene 
Sample Ave ΔCt ΔΔCt RQ (2-ΔΔCt) Copy # (2 x RQ) 
Patient 0.26 0.91 0.5 1 
Mother 0.05 0.70 0.6 1 
Control Female 1 -0.65 0.00 1.0 2 
Control Female 2 -0.33 0.32 0.8 2 
Control Female 3 -0.59 0.06 0.9 2 
Control Male 1 0.93 1.58 0.3 1 
Control Male 2 -0.23 0.42 0.7 1 
Control Male 3 -0.01 0.64 0.6 1 
 
 
2.4.4. Potential mechanism underlying PDHA2 expression in somatic cells  
 
Once detected the presence of PDHA2 transcript in somatic cells of the patient 
and all family members, we tried to elucidate the mechanism responsible for its 
expression. The first step was to investigate any possible sequence alteration in PDHA2 
genomic region, which could be responsible for the binding or unbinding of specific 
transcription factors. Sequence analysis of this genomic region was performed on 
several different samples, namely control testis, control lymphocytes and family 
members’ lymphocytes. The results revealed that the sequence of the promoter and all 
coding region (nucleotides -841 to +1317) was identical in all samples, although some 
of them displayed several polymorphic sites corresponding to variations among the 
published sequences (GenBank accession no. M86808 and U23825). Accordingly, the 
mechanism underlying PDHA2 gene expression should reside at another level, namely 
and possibly at the epigenetic one. 
Using an online program, MethPrimer (available at www.urogene 
.org/methprimer), we had previously (Pinheiro et al., 2010b) detected the presence of 
two CpG islands in PDHA2 gene sequence. We analyzed the methylation status of both 
CpG islands present in genomic DNA of the index case and respective family, besides 
control testis samples and control lymphocytes. The results revealed that the CpG island 
located in the promoter region (spanning nucleotides -128 to +73) was completely 
methylated either in control lymphocytes or in family lymphocytes, while the one in the 
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coding region (spanning nucleotides +197 to +460) displayed a significant level of 
demethylation in almost all CpG sites of the family samples when compared to control 
samples (Figure 2.6.). Moreover, testis samples (mixture of germ and somatic cells) 
revealed a full methylation of the CpG island located in the promoter region and around 
50% of demethylation of the island located in the coding region of PDHA2 gene. These 
results suggested that DNA methylation might be the epigenetic modification 
potentially controlling the non-canonical PDHA2 transcription in this family. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. DNA methylation status of several CpG sites in the CpG island II located in the coding 
region of PDHA2 gene: pooled family samples versus pooled control samples. Results are expressed as 
percentage of methylation and represent means of at least two independent reactions per family member 
and two independent reactions per each control ± SEM. 
 
2.5. Discussion 
 
The molecular characterization of the PDC E1α subunit in this family revealed 
the accumulation of two uncommon genetic situations: the simultaneous presence of a 
5’-truncated PDHA1 transcript and a full-length PDHA2 messenger. Moreover, and 
importantly, we could detect the presence of both proteins, PDHA1 and PDHA2, in all 
family members.  
Transcriptional analysis revealed a truncated PDHA1 messenger, displaying 
around 17 nucleotides upstream the initiation ATG codon. However, sequence analysis 
of the gene sequence encompassing the proximal promoter (-504) until 443 nucleotides 
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deep in intron 1 (+500) did not reveal any mutation susceptible to induce this 
truncation. Thus, the origin of this shorter transcript remained elusive. 
Otherwise, the presence of a full-length PDHA2 transcript was always and 
exclusively observed in family’s samples and in testicular germ cells, our positive 
control for PDHA2 gene transcription. 
Concerning PDHA1 transcriptional analysis, a major question remained. The 
analysis of this X-linked gene in all PDC deficient females, reported until now, revealed 
that only one gene is mutated and the other one is always normal (Brown and Brown, 
1993). So, besides the 5’-truncated PDHA1 transcript, a full-length one should have 
been detected in the females’ samples. Nevertheless, a full-length PDHA1 transcript 
was never observed in the patient and her mother samples (Figure 2.2.B). The most 
likely explanation would reside on a deletion of the PDHA1 gene, or on a complete 
skewed lyonization, with total absence of the normal PDHA1 transcript. Previously 
cytogenetic analyses performed upon patient and mother fibroblast and lymphoblast 
cultures revealed normal results, either regarding the karyotype or the X-inactivation 
pattern (see Case Report). However, gene dosage analysis allowed us to identify a 
deletion of the PDHA1 gene in the patient and her mother (Table 2.2.), which then 
could explain the absence of a normal PDHA1 transcript in all analyses performed.  
Accordingly, two types of X chromosome are running in this family: one has a 
deletion of PDHA1 gene, while the other harbors a wild-type PDHA1 gene. Figure 2.7. 
displays the putative molecular pedigree of this family. The proposed chromosomal 
segregation could then explain the rather low PDC enzymatic activity displayed by the 
mother (54.1%) when compared with the father (74.6%), most probably due to a 
slightly skewed X-inactivation pattern in lymphocytes, favoring the presence of cells 
carrying the deletion of PDHA1 gene.  
Nevertheless, translational analysis showed that 17 nucleotides upstream the 
translation initiation start site of PDHA1 gene were sufficient to drive the synthesis of a 
full-length PDHA1 protein. On the other hand, the full-length PDHA2 transcript was 
naturally translated into a full-length PDHA2 protein. 
The results obtained in this study, where we observed the co-existence of both 
isoforms, together with an impaired PDC activity in patient and her parents, can be fully 
explained by the studies of Robinson and colleagues (1996). Actually, transfection 
studies showed that when both isoforms are coproduced in equal amounts, a substantial 
reduction in PDC enzymatic activity is observed, and that the testis-specific PDHA2 
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Wt PDHA1 (m) 
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Wt PDHA1 (f) 
 
PATIENT 
Del PDHA1 (m) 
Wt PDHA1 (f) 
BROTHER 
Wt PDHA1 (m) 
 
protein was not fully compatible with the somatic PDHA1 protein when the mixed 
tetramers were assembled. Nevertheless, PDC isozymes have very similar kinetic and 
regulatory properties (Korotchkina et al., 2006), and when PDHA2 is expressed alone, 
PDC has almost full activity comparable to that of PDHA1 (Robinson et al., 1996). 
This situation raises some questions regarding the hypothetical somatic 
activation of PDHA2 gene expression to correct PDC deficiencies due to mutations in 
PDHA1 gene. It suggests that this therapy would only be effective in punctual cases 
caused by severe mutations leading to no production of PDHA1 protein. However, the 
majority of the described PDHA1 mutations are missense ones, leading to non-
functional enzymes, but where normal or only decreased protein levels are observed. In 
these cases a previous silencing of PDHA1 gene expression would be mandatory, for 
example by RNA interference therapy (Zeng et al., 2003; Carthew and Sontheimer, 
2009). 
 
 
 
 
 
 
 
 
 
Figure 2.7. Segregation of the X chromosome in the family under study. Del PDHA1 corresponds to a 
deletion of the gene; Mut PDHA1 (m) and (f) correspond to a mutant gene inducing PDHA2 expression. 
 
Furthermore, and to fundament the unequivocal presence of the PDHA2 
transcript and protein in somatic cells of this family’s, we attempt to disclose the 
mechanisms responsible for the somatic activation of this testis-specific gene.  
The first approach was to elucidate any possible sequence alteration in the 
PDHA2 promoter region, which could induce gene expression, namely by inhibiting the 
binding of a putative repressor. As previously referred, sequence analysis of genomic 
DNA isolated either from control lymphocytes or control testis cells revealed that they 
closely matched the reference sequence of chromosome 4 (GenBank accession no. 
NT_016354.19), despite some point alterations. Nevertheless, the polymorphisms 
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observed are located outside sequences thought to be relevant for gene regulation (Datta 
et al., 1999)  and, moreover, correspond to variations among the published sequences 
(GenBank accession no. M86808 and U23825) as previously referred. The analysis of 
this family genomic DNA sequence, encompassing promoter and coding regions, 
displayed a perfect match with the reference sequence. These results seemed to exclude 
that the activation of PDHA2 gene expression was induced by direct binding or 
unbinding of transcription factor(s) to DNA. Actually, this is in agreement with our 
previous experiments showing that transient transfected PDHA2 reporter plasmids 
present transcriptional activity in several human cell types, including teratocarcinoma. 
(Pinheiro et al., 2010a). So, PDHA2 tissue-specific expression should not involve cell-
specific transcription factors, either activators or repressors, but maybe another layer of 
modulation, such as epigenetic mechanisms. 
Biocomputing analysis revealed the presence of two CpG islands in PDHA2 
gene sequence, one located in the promoter region and the other in the coding region. 
Recently, we demonstrated the correlation between PDHA2 gene transcription and the 
full demethylation of a CpG island in its coding region (Pinheiro et al., 2010b). We 
showed that the CpG island located in the promoter region was always fully methylated 
in all kind of tissues, testis germ cells included, while the one in the coding region was 
completely demethylated in haploid and diploid germ cells, and displayed almost full 
methylation in all types of somatic cells. Concerning the study of the methylation status 
of the genomic region of the PDHA2 gene in this family samples, we observed that the 
CpG island located in the promoter region was fully methylated, as expected. 
Interestingly, this island is insensitive to demethylating agents (Pinheiro et al., 2010a) 
and hence underscores the notion that demethylation of PDHA2 promoter should not be 
a prerequisite for transcription initiation. 
 The CpG island located in the coding region of the PDHA2 gene in this family 
members, when compared to the controls, displayed an appreciable level of 
demethylation in almost all the CpG sites (Figure 2.6.). Though this degree of 
demethylation could seem insignificant, actually it is sufficient enough to induce this 
gene transcription. Effectively, studies performed by our group allowed to detect the 
presence of the PDHA2 transcript in cultured somatic cells (SH-SY5Y, human 
neuroblastoma) treated with a DNA demethylating agent, 5-aza-2’-deoxycytidine. And 
further methylation analysis by bisulfite sequencing of the CpG island located in the 
coding region of the gene also revealed less than 30% of demethylation agents (Pinheiro 
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et al., 2010a). Accordingly, the results observed in the in vitro experiments closely 
matched the ones observed in vivo in this family’s members.   
Taking into consideration all these results, namely the lack of any sequence 
alteration in the promoter and coding regions, we hypothesize that the mechanism 
underlying PDHA2 gene activation in this family’s somatic cells is most likely the 
observed hypomethylation of the coding region. Similar situation has already been 
described for other human genes, namely monocarboxylate transporter MCT3 (Zhu et 
al., 2005), though this is not an intronless gene. However, DNA hypomethylation was 
reported as regulating the mouse Tact1/Actl7 gene (Hisano et al., 2003), which is also 
intronless and testis-specific like the PDHA2 gene. 
Yet, the origin of the hypomethylation observed in the PDHA2 gene of this 
family samples remains unknown. And it is tempting to postulate that the event 
triggering off this demethylation might also underlie an epigenetic modification of the 
PDHA1 gene sequence, leading to the transcription of the 5’-truncated messenger. 
Nevertheless, further studies are being designed to elucidate this important question. 
In conclusion, the discovery of individuals expressing the PDHA2 gene in their 
lymphocytes represents a unique opportunity to fully understand the regulatory 
mechanisms that govern PDHA2 gene expression, either its activation in testis germ 
cells or its silencing in somatic tissues. Additionally, the study of these individuals shed 
some light upon questions related with alternative therapies, such as the somatic 
activation of PDHA2 gene expression to overcome the severe phenotype observed in 
patients carrying PDC deficiency caused by mutations in PDHA1 gene (Robinson et al., 
1996; Datta et al., 1999). 
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3.1. Abstract 
 
During spermatogenesis, germ cells undergo a complex process of cell 
differentiation and morphological restructuring, which depends on the coordinated 
expression of different genes. Some vital examples are those involved in cell energy 
metabolism, namely the genes encoding the E1α subunit of pyruvate dehydrogenase 
complex: the somatic PDHA1 (X-linked) and the testis-specific PDHA2 (autosomal). 
There are no data related to the study at the RNA and protein levels of PDHA genes 
during spermatogenesis. The present study aimed to describe the mRNA and protein 
expression patterns of the human PDHA genes during spermatogenesis. 
Expression profiles of the PDHA1 and PDHA2 genes were characterized using 
different human tissues and cells. Diploid and haploid germ cells fractions were 
obtained from testis tissues. The mRNA profiles were analyzed by qRT-PCR methods, 
whereas the protein profiles were evaluated by immunohistochemistry, western blotting 
and two-dimensional electrophoresis.  
Both PDHA proteins appeared localized to the cytoplasm. All somatic tissues 
showed similar levels of PDHA protein. Testis tissue, comprising somatic and germ 
cells, presented an increased protein level. PDHA2 was the sole protein species present 
in ejaculated spermatozoa. The developmental stage at which occurs the switch from 
PDHA1 to PDHA2 expression was determined by the study of mRNA expression levels 
during spermatogenesis, namely in diploid and haploid germ cells fractions, as well as 
in ejaculated spermatozoa. 
Expression of the PDHA1 gene was found in all somatic cells, whereas 
expression of PDHA2 gene was restricted to germ cells. The switch from the X-linked 
to the autosomic gene expression occurred in spermatocytes. Data suggests the 
activation of PDHA2 gene expression is most probably a mechanism to ensure the 
continued expression of the protein, thus allowing germ cell viability and functionality. 
 
3.2. Introduction 
 
Eukaryotic cell homeostasis is strongly dependent on an ubiquitous energy-
yielding machinery, which is controlled at various checkpoints in response to specific 
cellular energy requirements. One of these checkpoints is the pyruvate dehydrogenase 
complex (PDC), an essential and rate-limiting enzyme system in aerobic glucose 
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metabolism that catalyzes the irreversible conversion of pyruvate to acetyl-CoA, 
connecting glycolysis to the oxidative tricarboxylic acid cycle. PDC is a multienzymatic 
system composed of multiple copies of three catalytic components: E1 or pyruvate 
dehydrogenase (a heterotetramer of α and β subunits), E2 or dihydrolipoyllysine-
residue acetyltransferase and E3 or dihydrolipoyl dehydrogenase; an additional 
structural element exists, PDHX or Protein X, which serves as a E3-binding protein 
(Robinson, 2001). This system is regulated by dedicated phosphatases and kinases, 
enzymes monitoring the activation / inactivation of the complex by dephosphorylation / 
phosphorylation of three serine residues in the E1α subunit (Patel and Korotchkina, 
2001).  
PDC deficiency is one of the most common neurodegenerative disorders 
associated with altered mitochondrial metabolism leading to energy deprivation, 
especially in the central nervous system (Brown and Brown, 1994; Pliss et al., 2007). 
The most frequent form of genetically determined PDC deficiency is caused by 
mutations in E1α subunit (OMIM #312170) (Lissens et al., 2000).  
The pivotal and rate-limiting E1α subunit exists as two isoforms encoded by two 
different genes. PDHA1 is located on region p22.1 of the human X chromosome, 
contains 11 exons separated by introns, spans approximately 17 kb of genomic DNA 
and is selectively expressed in somatic cells. An autosomal locus, PDHA2, lies on the 
long arm of chromosome 4 (4q22-23), completely lacks introns, spans 1.4 kb of 
genomic DNA, possesses characteristics of a functional processed gene and is 
selectively expressed in spermatogenic germ cells (Dahl et al., 1990). 
Comparisons between human PDHA1 and PDHA2 messengers revealed an 86% 
homology, supporting the notion that PDHA2 gene was originated by a retroposon 
mediated insertion of the PDHA1 coding region (Datta et al., 1999). Also, the majority 
of the changes observed between both human genes are conservative, with sequences 
surrounding important functional domains such as the three phosphorylation sites and 
the thiamine pyrophosphate (cofactor) binding site remaining highly homologous 
(Brown et al., 1990; Fitzgerald et al., 1992).  
The autosomal localization of PDHA2 is considered particularly significant in 
males, once X chromosome inactivation occurs early in spermatogenesis and only half 
of haploid spermatids contain the X chromosome. As haploid germ cells are dependent 
on energy generated from pyruvate via the PDC, the existence of an autosomal variant 
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of PDHα ensures that cellular energy requirements are maintained during 
spermatogenesis (Dahl et al., 1990).  
Spermatogenesis is a complex process during which germ cells undergo 
proliferation (spermatogonia), meiosis (spermatocytes) and differentiation (spermatids, 
sperm). All this process depends on the coordinated expression of different genes in a 
stage-specific manner and an important step is the switch from PDHA1 to PDHA2 
expression during spermatogenesis.  
It was postulated that the somatic activation of PDHA2 gene expression could 
constitute a reliable new therapeutic approach for PDC deficiency due to PDHA1 gene 
mutations (Robinson et al., 1996; Datta et al., 1999). The expression patterns and 
regulatory mechanisms governing the expression of PDHA2 genes in the testis have 
been performed in adult mice (Takakubo and Dahl, 1992), but never in humans. The 
regulatory mechanisms underlying the human and mouse PDHA2 gene expression are 
substantially different in mice and humans (Datta et al., 1999; Pinheiro et al., 2010b; 
Pinheiro et al., submitted-a), which may originate some alterations in the expression 
profile. Here, we report the temporal- and cell-specific mRNA and protein expression 
patterns of PDHA1 and PDHA2 genes in human tissues, namely during 
spermatogenesis. 
 
3.3. Materials and methods 
 
3.3.1. Human samples 
 
According to the National Law on Medically Assisted Procreation (PMA, Law 
32/2006) and the National Council on Medically Assisted Procreation (CNPMA, 2008) 
guidelines, human seminiferous tubules fragments were obtained, after patients’ 
informed and written consent. 
In accordance with the Medical Ethics Committee, all tissue specimens were 
collected with patients’ informed consent.  
Human testis specimens were obtained from eight cases requiring open testicular 
biopsy for the retrieval of testicular sperm for intracytoplasmic sperm injection: four 
with severe oligoazoospermia; one with obstructive secondary azoospermia; two with 
hypospermatogenesis (with AZFc microdeletions) and one with Sertoli cell-only 
syndrome, all with normal karyotypes. Some pieces were immediately fixed in Bouin’s 
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solution (4 hours) and embedded in paraffin for immunohistochemistry. Other pieces 
were snap-frozen in liquid nitrogen and stored at -80°C, and other were subjected to cell 
fractioning for isolation of diploid and haploid germ cells (Sá et al., 2008; Pinheiro et 
al., 2010b). Sperm was obtained from semen samples of three healthy individuals with 
normal seminal parameters (kindly provided by Prof. R. Pinto, Laboratory Dr. Joaquim 
Chaves, Lisbon). 
Tissue specimens were obtained from human stomach (four individuals who 
underwent diagnostic endoscopy), left deltoid muscle (biopsy from one patient 
undergoing bariatric surgery) both kindly provided by Prof. H. Cortez-Pinto, Hospital 
Santa Maria, Lisbon and human liver total RNA (Clontech, Mountain View, CA, USA). 
Cell specimens consisted of lymphocytes (six peripheral blood samples from healthy 
volunteers recruited from faculty staff by advertisement) and fibroblasts (two diagnostic 
skin biopsies) kindly provided by Dr. A. Gaspar, Hospital Santa Maria, Lisbon. 
 
3.3.2. Cell isolation 
 
Testicular biopsies (2 mm) were collected in sperm preparation medium (SPM-
Hepes; Medicult, Copenhagen, Denmark) and prepared as previously reported (Sá et al., 
2008; Pinheiro et al., 2010b). Briefly, seminiferous tubules were squeezed under a 
heated stereomicroscope to release luminal epithelial cells. The resultant fluid fraction 
was washed in SPM (2 X 5 min, 300 g) and incubated (5 min, 37ºC, 5% CO2, filtrated 
humidified air) in 2 ml erythrocyte-lysing buffer (155 mM NH4Cl, 10 mM KHCO3, 2 
mM EDTA, in water, pH 7.2 with KOH, 0.2 µm filtered; endotoxin free, embryo and 
cell culture tested; Sigma, Barcelona, Spain), followed by addition of 2 mL SPM. The 
suspension was then washed (2 X 5 min, 500 g), digested (20 min, 25 µg crude DNase, 
1000 units collagenase-IV in 1 mL SPM; Sigma), and separated (5 min, 50 g) into 
supernatant (haploid germ cells) and pellet (diploid germ cells) fractions. The fractions 
were washed with SPM (2 X 5 min, 1000 g), and the final pellets were resuspended in 
100 µL in vitro fertilization (IVF) medium (without Hepes buffer; Medicult). 
 
3.3.3. Western immunoblotting 
 
Tissue homogenates from whole testis and somatic tissues were directly loaded 
onto 10% Mini-PROTEAN TGX® PrecastTM Gels (Bio-Rad Laboratories Inc., Hercules, 
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CA, USA) and run under reducing conditions. Proteins were electrotransferred onto 
PVDF membrane (Amersham HybondTM-P, GE Healthcare Bio-Sciences, Uppsala, 
Sweden), and probed with primary antibodies: MitoProfile® Pyruvate dehydrogenase 
(PDH) WB Antibody Cocktail (#MSP02, MitoSciences®, Eugene, OR, USA), which 
contains antibodies for PDC subunits (including E1α) and a control antibody against the 
OSCP subunit of ATP synthase, and the monoclonal anti-PDHA1 antibody (ab110334, 
Abcam, Cambridge, UK). Immunocomplexes were detected by the LumiGLO reagent 
(Cell Signaling Technology, Beverly, MA, USA). The relative intensities of protein 
bands were analyzed using the ImageJ 1.44 software (Abramoff et al., 2004). 
 
3.3.4. Two-dimensional electrophoresis  
 
Tissue homogenates from lymphocytes, muscle, whole testis and ejaculated 
spermatozoa were pre-cleared with ReadyPrep™ 2-D kit (Bio-Rad). Pellets were 
solubilized in 200 μL of a solution containing 8M urea, 2% (w/v) CHAPS, 50 mM DTT 
and 1X Bio-Lyte Ampholyte 20% pH 7-10. An 11 cm, pH 7-10, immobilized pH 
gradient strip (ReadyStrip™ IPG, Bio-Rad) was rehydrated using 200 μL of sample, as 
previously described. Isoelectric focusing (IEF) was performed in a Protean® IEF 
apparatus (Bio-Rad) with an initial voltage of 250 V for 20 minutes, then 8,000 V for 
2.5 hours and a final voltage of 8,000 V for 20,000 V-hr. Total running time was 5.3 
hours and ≈ 30,000 V-hr. 
After IEF, IPG strips were prepared for transfer by soaking in equilibrium buffer 
[6M urea, 2% (w/v) SDS, 20% (w/v) glycerol, 0.375 M Tris-HCl pH 8.8] to which was 
added 2% (w/v) DTT in the first step and 2.5% (w/v) iodoacetamide in the second step. 
The equilibrated IPG strips were embedded on the top of SDS-PAGE gels (Criterion™ 
Tris-HCl gel, 8-16%, 11 cm, Bio-Rad) in molten 1% (w/v) agarose in running buffer 
(192 mM Tris/glycine, 0.1% (w/v) SDS, pH8.3). Gels were run in a Criterion™ 
electrophoresis cell (Bio-Rad) at 200 V for 65 minutes. 
Proteins were then electrotransferred onto PVDF membrane, which were probed 
with the monoclonal antibody anti-PDHA1 (MSP07/ab110334, Abcam, Cambridge, 
UK). Immunocomplexes were detected by the LumiGLO reagent (Cell Signaling 
Technology) and visualized in a ChemiDocTM XRS imaging system (Bio-Rad). 
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3.3.5. Immunohistochemistry 
 
Immunohistochemistry analysis was performed by a biotin/streptavidin method 
using the VECTASTAIN® Universal Quick Kit (Vector Laboratories, Burlingame, CA, 
USA). After deparaffinization and hydration of the sections, heat-induced antigen 
retrieval was processed with Antigen Unmasking Solution (Vector Laboratories). The 
sections were then treated with 3% H2O2 in methanol for 5 min to block endogenous 
peroxidase activity, followed by 10 min incubation with working solution of Blocking 
Serum, and a further blocking with Avidin/Biotin Blocking Kit (Vector Laboratories). 
Sections were incubated overnight at 4°C with 1:200 diluted E1α subunit monoclonal 
antibody (MitoSciences). A universal biotinylated second antibody was applied for 10 
min, followed by incubation with Streptavidin/Peroxidase Complex (5min). The 
immunoreaction was visualized by a peroxidase-based chromogen/substrate system 
with diaminobenzidine-DAB Substrate Kit for Peroxidase (Vector Laboratories). 
Sections were then counterstained with Vector® Hematoxylin QS (Vector Laboratories), 
dehydrated in ascending concentrations of ethanol, cleared in xylene and mounted for 
microscopic examination. Negative controls were performed with working solution of 
blocking serum without the primary antibody.  
 
3.3.6. RNA isolation and qRT-PCR 
 
Total RNA was prepared from all samples using the RNeasy MiniKit (Qiagen, 
Hilden, Germany) and contamination by genomic DNA was eliminated from each RNA 
sample by pre-treatment with deoxyribonuclease I. One µg was reverse transcribed 
using the Reverse Transcription System A3500 kit (Promega, Madison, WI, USA) with 
random primers following the manufacturer´s instructions. 
First strand cDNA (1 μg) was used as template for quantitative real-time PCR 
using an ABI PRISM 7300 sequence detection system (Applied Biosystems, Foster 
City, CA, USA). The cycling conditions were 95ºC/10min followed by 40 cycles of 
95ºC/15sec and 60ºC/1min. We used the TaqMan® Gene Expression Assays (Applied 
Biosystems) IDs: Hs00264851_m1 (for PDHA1), Hs01043024_s1 (for PDHA2) and as 
endogenous control the TaqMan® β-actin Control Reagents (Applied Biosystems). In 
every reaction we used the TaqMan® Gene Expression Master Mix (Applied 
Biosystems) following enclosed instructions. The relative expression of target mRNA 
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was calculated from the target Ct values and β-actin mRNA Ct values, using the 
standard curve method.  
 
3.4. Results  
 
3.4.1. Expression pattern of PDHA proteins in testis and somatic tissues 
 
Analysis of the expression patterns of PDHA proteins is hampered by their 
similarity, once PDHA1 and PDHA2 have sequences displaying 87% identity and 93% 
homology (Appendix 2) (Korotchkina et al., 2006), and by the absence of specific 
antibodies to PDHA2. Expression levels of human PDHA proteins were assessed by 
western blotting of protein samples derived tissues (whole testis, stomach) and cells 
(lymphocytes, fibroblasts). When using the cocktail containing antibodies raised against 
all PDC subunits, all samples presented an identical band with apparent molecular mass 
of 43 kDa, corresponding to their reported sizes (43.2 kDa for PDHA1 and 42.9 kDa for 
PDHA2), confirming the ubiquitous expression of PDHA proteins, with a higher 
expression in whole testis (Figure 3.1.). For muscle and ejaculated sperm, a monoclonal 
antibody raised against PDHA1 protein was used, and the canonical 43 kDa band was 
observed in both samples, as well as an additional 32 kDa band in ejaculated sperm 
(Figure 3.2.A.). 
To specifically identify which PDHA proteins were expressed, a two-
dimensional electrophoresis was performed (the two proteins have different isoelectric 
points).  
The results revealed that somatic cells from muscle only expressed the PDHA1 
isoform, while haploid germ cells (ejaculated spermatozoa) exhibited the shorter 
PDHA2 isozyme with 32 kDa (Figure 3.2.B). The whole testis homogenate revealed the 
presence of both isoforms (results not shown), the canonical PDHA1 with 43 kDa and 
the smaller PDHA2 with 32 kDa. 
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Figure 3.1.  Western blot analysis of E1α  in several human tissues and cells (testis, lymphocytes, 
stomach and fibroblasts) using a cocktail that contains antibodies for PDC subunits (including E1α). A 
band corresponding to E1α with 43 kDa was identified in all cases. OSCP subunit of ATP synthase was 
used as loading control. Immunoblot bands were quantified by ImageJ 1.44 program and normalized to 
OSCP.  
 
 
Immunohistochemistry in human testis sections was performed to evaluate the 
localization of PDHA proteins during spermatogenesis. In all cells, PDHA proteins 
were localized in the cytoplasm (Figure 3.3.B-C).  
Spermatogonia displayed low levels of PDHA proteins, while they were 
abundantly synthesized in primary spermatocytes. PDHA levels remained high in 
secondary spermatocytes and showed a slight decline in round and elongated 
spermatids. Leydig cells showed PDHA levels similar to round spermatids, whereas 
peritubular cells presented very low PDHA levels. The supporting Sertoli cells 
displayed low PDHA levels  No immunoreactivity was observed on the negative control 
of testis slides (Figure 3.3.A).  
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Figure 3.2.  Immunoblot analysis of human muscle (1) and human ejaculated sperm (2) 
homogenates using anti-PDHA1 antibody. A – SDS-PAGE of crude (1 and 2) and pre-cleared (1’ and 
2’) homogenates. Note that while muscle shows the canonical 43 kDa band, ejaculated sperm shows two 
bands, tha canonical one and a smaller one with 32 kDa. B – 2D-PAGE of pre-cleared homogenates. Note 
that both proteins separate into different spots corresponding to the several phosphorylation states that 
proteins may assume. Also note that PDHA2 in ejaculated sperm show two groups of spots with different 
pI, what seems to confirm the observation on the SDS-PAGE gel. Furthermore, the small spot in PDHA1 
region should represent a residual contamination with epithelial cells. The molecular mass standards and 
pI values are indicated.  
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Figure 3.3.  Immunostaining of E1α  protein in a human testis section. A - Negative control: nuclear 
counterstain with hematoxyin (blue). B and C - Cellular localization of E1α by immunoperoxidase 
staining (the brown color in the cytoplasm indicates E1α protein). Note that, due to the small amount of 
cytoplasm in ST2 and Sa cells, the staining seems to be nuclear in these cells. All sections were 
counterstained with hematoxylin (blue).  SGA – Spermatogonia; ST1 – Primary spermatocytes; ST2 – 
Secondary spermatocytes; Sa – Round spermatids; Sd – Elongated spermatids; SC – Sertoli cells; PTC – 
Peritubular cells; LC – Leydig cells.  
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3.4.2. Specific detection of testis and somatic PDHA mRNAs 
 
PDHA1 and PDHA2 mRNA sequences have 84% identity; however, the 5’ and 
3’UTR regions of both mRNAs show stretches with no homology, thus allowing the 
design of specific primers and the discriminating amplification of each transcript.   
The qRT-PCR analysis showed that PDHA1 mRNA expression was detected in 
all types of somatic cells, with the liver presenting the highest levels, while testis, 
lymphocytes and fibroblasts displayed similar levels of PDHA1 mRNA. Expression of 
PDHA2 could only be detected in whole testis tissue, being completely absent from all 
somatic cells (Figure 3.4.).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.  Quantitative RT-PCR analysis of PDHA genes expression in different tissues and cells 
(testis, liver, lymphocytes and fibroblasts). Expression of the PDHA1 (A) and PDHA2 (B) genes was 
quantified by real-time RT-PCR. The relative expression of target mRNA was calculated from the target 
Ct values and β-actin mRNA Ct values, using the standard curve method.  
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Concerning the PDHA2 mRNA profile during human spermatogenesis, mRNA 
expression levels in enriched fractions from testicular tissue (Sertoli cells, diploid germ 
cells, haploid germ cells) and ejaculated spermatozoa was analyzed. The PDHA2 gene 
started to be expressed in spermatogonia and spermatocytes (diploid germ cell fraction), 
progressively increased to spermatids and testicular spermatozoa (haploid germ cell 
fraction) and reached the highest levels in ejaculated spermatozoa. As expected, Sertoli 
cells displayed no PDHA2 expression (Figure 3.5.). For PDHA1 mRNA, an opposite 
expression profile was observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Quantitative RT-PCR analysis of PDH genes expression during spermatogenesis. 
Expression of the PDHA1 (A) and PDHA2 (B) genes in different testis fractions was quantified by real-
time RT-PCR. The relative expression of target mRNA was calculated from the target Ct values and β-
actin mRNA Ct values, using the standard curve method. SC - Sertoli cells; DGC - diploid germ cells; 
HGC - haploid germ cells; Sz - ejaculated sperm.  
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In order to better understand PDHA genes expression in all the tissues and cells 
analyzed, we summarize the results of protein and mRNA expression analysis in Tables 
3.1. and 3.2.. 
 
Table 3.1. Tissue-specific profile of human PDHA genes. 
 Protein expressiona mRNA expressionb 
Tissue PDHA  protein PDHA1 mRNA PDHA2 mRNA 
Liver n.a. 0.005 n.d. 
Stomach 0.42 n.a. n.a. 
Lymphocytes 0.43 0.0017 n.d. 
Fibroblasts 0.40 0.0014 n.d. 
Whole Testis 0.57 0.0015 0.15 
a Relative protein levels obtained by western blotting analysis;  
b Relative transcript levels obtained by qRT-PCR; n.a. – not analyzed; n.d. – not detected 
 
 
Table 3.2. Cell-specific profile of human PDHA genes during spermatogenesis. 
Protein expressiona mRNA expressionb 
Cell 
Type 
PDHA 
protein 
Cell Fraction 
Type 
PDHA1 
mRNA 
PDHA2 
mRNA 
Peritubular cells Very low --- --- --- 
Leydig cells + --- --- --- 
Sertoli cells Low SC 0.19 0.1 
Spermatogonia Low 
DGC 0.02 1.4 
Primary spermatocytes +++ 
Secondary 
spermatocytes ++ 
HGC 0.006 1.9 Round spermatids + 
Elongated spermatids + 
Ejaculated sperm ++ Sz 0.0005 8.2 
a Semi-quantitative analysis of the protein levels observed by immunohistochemistry. 
b Quantitative analysis by qRT-PCR; mRNA expression levels in relation to β-actin mRNA; SC – Sertoli 
cells; DGC – diploid germ cells; HGC – haploid germ cells; Sz – ejaculated sperm 
 
3.5. Discussion 
 
PDHA genes encode the E1α subunit of pyruvate dehydrogenase complex, a 
crucial enzyme system in the regulation of cellular energy production.  Despite their 
Chapter 3 
 
74 
biological importance, and the putative role of PDHA2 gene activation in somatic cells 
to overcome PDC deficiencies due to PDHA1 gene mutations, the expression patterns of 
PDHA genes have never been elucidated in human tissues, namely in testis during 
spermatogenesis. Accordingly, the purpose of this study was to further clarify the 
expression profile of human PDHA genes, through protein and mRNA expression 
analysis in different tissues and cells, including the spermatogenic lineage. 
Expression of the X-linked PDHA1 gene in somatic tissues and of the autosomal 
PDHA2 gene in testis confirmed previous reports in mice (Takakubo and Dahl, 1992) 
humans (Dahl et al., 1990).  
The X and Y chromosomes are subjected to meiotic sex chromosome inactivation 
(MSCI) at the pachytene level (Turner, 2007), and are later maintained in a repressive 
state during spermiogenesis due to postmeiotic sex chromatin, which displays a 
transcriptionally repressed conformation (Wang et al., 2004b; Namekawa et al., 2006). 
In this context, as expression of X-linked genes is active in spermatogonia (Wang et al., 
2001), we observed a decline of PDHA1 mRNA expression after the spermatogonia 
stage, being null in ejaculated sperm. The residual levels found in haploid germ cells are 
supposed to be due to a slight contamination of this fraction with small round 
lymphocytes. An extensive cDNA microarray analysis reported that PDHA2 was one of 
the testis-specific genes that showed higher expression levels in human spermatozoa 
(Wang et al., 2004b). The present results evidenced a complementary expression pattern 
of the PDHA2 gene in relation to PDHA1, with PDHA2 mRNA levels increasing as 
spermatogenesis progresses, with a dramatic increase in ejaculated spermatozoa.  
Concerning protein expression in testicular cells, by immunohistochemistry 
PDHA was found in the cytoplasm of all cell types, thus confirming previous reports 
(Patel and Roche, 1990; Reed, 2001; Margineantu et al., 2002; Smolle et al., 2006; 
Kumar et al., 2008).   
Western-blot analysis showed that PDHA proteins were expressed in all somatic 
tissues and cells, as well in the testis. In ejaculated spermatozoa, we observed two 
bands, the canonical 43 kDa and a new 32 kDa isoform. Bi-dimensional electrophoresis 
confirmed that PDHA1 is only synthesized in somatic tissues, and that PDHA2 is only 
present in ejaculated spermatozoa, but solely under the 32 kDa isoform. One possible 
explanation for the absence of the 43 kDa PDHA2 isoform could be that this isoform is 
more prone to proteolysis during the isoelectric focusing step, as already described for 
other proteins (Finnie and Svensson, 2002), despite the use of a protease inhibitor 
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cocktail during the analytical process. However, PDHA1, with 87% identity to PDHA2, 
escaped this protein degradation. Further studies by mass spectrometry will certainly 
elucidate this problem.  
Despite the traditional concept of spermatozoa being translationally silent, a 
recent report showed that nuclear genes are translated into proteins in spermatozoa, 
namely to produce capacitation-specific proteins (Gur and Breitbart, 2006). These data, 
allied to the study of Kumar et al (2006) highlighting the crucial involvement of 
PDHA2 in the process of hamster sperm capacitation, and reporting the extra-
mitochondrial localization of PDHA2 in human spermatozoa (Kumar et al., 2006), seem 
to suggest that PDHA2 might have a potential role in human sperm capacitation.  
It is well known the importance of aerobic energy metabolism in germ cells and 
the existence of germ-specific isoforms, namely from glycolytic enzymes (Mori et al., 
1993; Bunch et al., 1998; Eddy, 2002; Boussouar and Benahmed, 2004).  
Similar to the PDHA encoding genes, the human phosphoglycerate kinase 
(PGK) has also two variants, an autosomic and intronless with testis-specific expression 
(PGK2), and an X-linked counterpart (PGK1) displaying somatic expression (Boer et 
al., 1987; McCarrey and Thomas, 1987). Although there are no studies reporting the 
expression profile of PGK2 in human spermatogenesis, the present results on human 
PDHA2 gene expression appeared more similar to mouse Pgk2 than to mouse Pdha2, at 
least concerning the mRNA’s profile (Yoshioka et al., 2007).  
These isoforms present in germ cells, besides compensating for other genes that 
may be inactivated in spermatogenesis, may also have additional structural or functional 
properties that serve unique roles in male germ cells. This is particularly true for most 
of the enzymes of the glycolytic pathway in germ cells and sperm (Eddy, 2002). The 
PDHA2 gene can have as well other properties beyond energy production, as in hamster 
sperm capacitation (Gur and Breitbart, 2006). A recent report (Hereng et al., 2011) 
showed that for fertilization, human spermatozoa rely substantially on ATP derived 
from glycolysis, and not from oxidative phosphorylation. These data, allied to the 
localization of PDHA in the spermatozoa posterior region of the head (Kumar et al., 
2008) open up new research lines to investigate PDHA protein function in sperm.  
In conclusion, the present results first show the mRNA and protein expression 
patterns of the genes encoding the human E1α subunit. We confirmed the ubiquitous 
expression of PDHA1 gene in all somatic cells, whereas expression of PDHA2 gene 
appeared restricted to germ cells. The switch from the X-linked (PDHA1) to the 
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autosomic (PDHA2) gene expression was also shown to occur at the spermatocyte 
stage. The detection of two PDHA2 isoforms, the canonical and a shorter one, leaves 
open the question related to PDHA2 function(s) in germ cells, namely in spermatozoa.  
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4.1. Abstract 
 
DNA methylation is an important epigenetic modification that has profound 
roles in gene expression and, in particular, is thought to be crucial for regulation of 
tissue-specific genes in animal cells. The pivotal E1α subunit of human Pyruvate 
Dehydrogenase Complex, an essential and rate-limiting enzyme system in energy 
metabolism, is encoded by two distinct genes: PDHA1 gene, located on chromosome X 
is expressed in somatic tissues, whereas PDHA2 gene, located on chromosome 4, is 
exclusively expressed in spermatogenic cells. 
The objective of this study is to elucidate the role of DNA methylation as an 
epigenetic mechanism controlling the regulation of PDHA2 gene expression in human 
tissues, namely its repression in somatic tissues and its activation in testicular germ 
cells. 
Genomic DNA was isolated from human somatic tissues (circulating 
lymphocytes and gastric cells) and from testis, including isolated fractions of haploid 
and diploid germ cells. After primer design with appropriate software, it was performed 
the sodium bisulfite PCR sequencing of the PDHA2 promoter and coding regions. Total 
RNA of the same tissues was isolated, reverse transcribed and PDHA1and PDHA2 
transcripts were amplified with specific primers and analyzed by agarose gel 
electrophoresis.   
The analysis of the genomic sequence of the PDHA2 gene revealed the presence 
of 61 CpG sites whose distribution matches the criteria for the presence of two CpG 
islands. Sequence analysis of both CpG islands upon bisulfite treatment displayed 
several differences, either between islands or among tissues. In particular, the 
methylation pattern of one of the CpG islands revealed a perfect correlation with 
transcriptional activity of the PDHA2 gene either in testis or in somatic tissues. 
Surprisingly, it is the full demethylation of the CpG island located in the coding region 
that seems to play a crucial role upon PDHA2 gene transcription in testis. 
 
4.2. Introduction 
 
The energy required for cells’ function is partly generated through catabolic 
processes in which carbohydrates, fatty acids and amino acids are converted to 
metabolites that can be further used in energy-producing reactions. Almost all tissues 
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mainly use glucose for energy production, but they can also use some of the alternative 
energy sources. However, brain and spermatogenic cells are unique in that they generate 
nearly all their energy from carbohydrates or derivatives and are, therefore, likely to be 
more severely affected by deficiencies in their cells’ ability to convert carbohydrates to 
energy (Dahl et al., 1996).  
Eukaryotic aerobic metabolism involves a complex series of metabolic pathways 
controlled at various checkpoints in response to specific cellular energy requirements. 
One of these checkpoints is the pyruvate dehydrogenase complex (PDC), an essential 
and rate-limiting enzyme system in aerobic glucose metabolism that catalyzes the 
conversion of pyruvate to acetyl-CoA, connecting glycolysis to the oxidative 
tricarboxylic acid cycle. PDC is a multienzymatic system composed of multiple copies 
of three catalytic components E1 (E1α and E1β), E2, E3 and an additional component 
(Protein X) that serves as an E3-binding protein (Robinson, 2001). This system is 
regulated by a PDH-phosphatase and a PDH-kinase, enzymes monitoring the activation 
/ inactivation of the complex by dephosphorylation / phosphorylation of the E1α 
component.  
Deficiencies of the PDC are well documented as causative of metabolic disease 
and though mutations have been found in all its subunits, the vast majority relies on 
PDHA1 gene (OMIM#312170), which encodes the E1α subunit. This pivotal subunit, 
together with the E1β subunit, forms the active and the cofactor binding sites and exists 
as two isoforms encoded by different genes. PDHA1 is located on region p22.1 of the 
human X chromosome, contains 11 exons separated by introns, spans approximately 17 
kb of genomic DNA and is selectively expressed in somatic tissues. An autosomal 
locus, PDHA2, lies on chromosome 4 (4q22-23), completely lacks introns, spans 1.4 kb 
of genomic DNA and possesses characteristics of a functional processed gene; it is 
expressed only in testis after the onset of spermatogenesis. The existence of an 
autosomal variant ensures that cellular energy requirements are maintained in haploid 
spermatogenic cells (Dahl et al., 1990; Robinson, 2001). 
Traditionally, the therapeutic approaches to PDC deficiency are restricted to a 
ketogenic diet supplemented with thiamine and, eventually, dichloroacetate, but the 
results are poor. A long dreamed therapy would be the somatic activation of the testis 
specific PDHA2 gene in order to overcome the somatic subunit inactivity (Datta et al., 
1999). Thus, a first step forward towards that objective is the elucidation of the 
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molecular mechanisms underlying the intronless PDHA2 gene expression in testis and 
its silencing in somatic tissues.  
The regulatory mechanisms governing its expression were extensively studied in 
mouse (Takakubo and Dahl, 1992; Iannello et al., 1993; Fitzgerald et al., 1994; Iannello 
et al., 1997; Iannello et al., 2000) but it is believed that both mouse and human 
promoter regions evolved from different retroposons (Fitzgerald et al., 1996), because 
no gross homology exists between both promoters of PDHA2 gene. Accordingly, the 
regulatory mechanisms of human PDHA2 gene may be significantly different from that 
of rodent species. 
Functional studies of the human PDHA2 promoter region fused to a reporter 
gene and transfected into cultured cells other than spermatogenic or testicular tissue 
(Datta et al., 1999) revealed the presence of both enhancer and repressor elements that 
are common to other genes only expressed in spermatogenic cells and, more 
importantly, that the normal repressing mechanisms are not operative. The authors of 
this study suggested that must have another tissue-specific level of regulation, most 
probably controlled by methylation of the core promoter.  
DNA methylation is one of the most extensively studied epigenetic alterations 
and is an evolutionally conserved mechanism to regulate gene expression in mammals 
(Nagase and Ghosh, 2008). CpG islands often include gene promoters and extend 
further downstream into transcribed regions; other CpG islands can also occur in 
downstream regions distant from the promoter, some of them located within exons 
(exonic CpG islands) (Hisano et al., 2003). Some CpG islands located in promoter 
region of tissue-specific genes display a different methylation pattern in non-expressing 
tissues. Moreover, many studies have put in evidence the crosstalk between DNA 
methylation and chromatin structure, crucial for the understanding of most biological 
phenomena (Nakao, 2001; Zhang et al., 2005). 
Accordingly, the present study aims to elucidate the role of DNA methylation as 
an epigenetic mechanism controlling the regulation of PDHA2 gene expression in 
human tissues, namely its repression in somatic tissues and its activation in testicular 
germ cells. The first in vivo results revealed that indeed methylation might play an 
important role in the formation of the human testis-specific PDHA2 transcript but 
surprisingly, and unlike the majority of the reported cases, the pivotal region is not in 
the promoter but within the coding region. 
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4.3. Material and methods 
 
4.3.1. Source of human samples 
 
In accordance with the Medical Ethics Committee, all tissue specimens were 
collected with patients’ informed consent.  
Human testis specimens were obtained from eight cases requiring open testicular 
biopsy for the retrieval of testicular sperm for intracytoplasmic sperm injection: four 
oligoazoospermic; one with obstructive secondary azoospermia; two with 
hypospermatogenesis and one with Sertoli cell only syndrome, all with normal 
karyotypes, and six patients with absence of Y chromosome microdeletions. The 
patients with hypospermatogenesis presented AZFc deletion and DAZ 2d, 3, 4d 
deletion. Some pieces were snap-frozen in liquid nitrogen and stored at -80°C, while 
others were subjected to cell fractioning for isolation of diploid and haploid germ cells, 
mainly spermatocytes and spermatids, respectively (Sá et al., 2008).  
Human stomach specimens were obtained from four individuals who underwent 
diagnostic endoscopy (kindly provided by Prof. H. Cortez-Pinto, Hospital Santa Maria, 
Lisbon). In addition, peripheral blood samples were obtained from four healthy 
volunteers recruited from faculty staff by advertisement and used to prepare 
lymphocytes. 
 
4.3.2. Cell isolation 
 
Testicular biopsies (2 mm) were collected in sperm preparation medium (SPM-
Hepes; Medicult, Copenhagen, Denmark). Seminiferous tubules were squeezed under a 
heated stereomicroscope to release luminal epithelial cells. The resultant fluid fraction 
was washed in SPM (2 X 5 min, 300 g) and incubated (5 min, 37ºC, 5% CO2, filtrated 
humidified air) in 2 ml erythrocyte-lysing buffer (155 mM NH4Cl, 10 mM KHCO3, 2 
mM EDTA, in water, pH 7.2 with KOH, 0.2 μm filtered; endotoxin free, embryo and 
cell culture tested; Sigma, Barcelona, Spain), followed by addition of 2 ml SPM. The 
suspension was then washed (2 X 5 min, 500 g), digested (20 min, 25 μg crude DNase, 
1000 units collagenase-IV in 1 ml SPM; Sigma), and separated (5 min, 50 g) into 
supernatant (haploid germ cells) and pellet (diploid germ cells and a few Sertoli cells) 
fractions. The fractions were washed with SPM (2 X 5 min, 1000 g), and the final 
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pellets were resuspended in 100 μl in vitro fertilization (IVF) medium (without Hepes 
buffer; Medicult). 
 
4.3.3. Nucleic acids extraction 
 
Genomic DNA was isolated from frozen human whole testis specimens and cell 
fractions, from frozen stomach specimens and from lymphocytes isolated from fresh 
whole blood samples, using a salting-out method (Puregene Cell and Tissue kit, Gentra 
Systems, Minneapolis, MN, USA). Total RNA was prepared from all the above 
mentioned tissues and cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and 
contamination by genomic DNA was eliminated from each RNA sample by pre-
treatment with DNase I. Additionally, commercial samples of human testis and liver 
total RNA (Clontech Laboratories Inc., Mountain View, CA, USA) were used. 
 
4.3.4. Sodium bisulfite genomic DNA sequencing 
 
Bisulfite PCR sequencing was carried out using the EpiTect Bisulfite Kit 
(Qiagen, Hilden, Germany) and specific primers were designed using appropriate 
software (Li and Dahiya, 2002). Briefly, one microgram of genomic DNA was treated 
with sodium bisulfite solution for three rounds of denaturation at 99˚C followed by 
incubation at 60˚C, in a thermal cycler, during approximately five hours; DNA was 
further purified by column separation. CpG island I was amplified using a methylation-
specific primer set: (Methylated-F: 5’-ATA AAT TAG TTA GTT TAG GTT GCG T-3’ 
and Methylated-R: 5’-ATA ACG TCA TTT AAA AAA TTA CGA A-3’; 
Unmethylated-F: 5’-ATA AAT TAG TTA GTT TAG GTT GTG T-3’ and 
Unmethylated-R: 5’-ATA ACA TCA TTT AAA AAA TTA CAA A-3’) and CpG 
island II was amplified with bisulfite PCR primers (Bisulfite-F: 5’-TGG AAT TGA 
AGG TAG ATT AGT TGT ATA AAT-3’ and Bisulfite-R: 5’-ATA CCA TTA CCC 
CCA TAA AAA TTC T-3’). Reaction mixture contained 1.5 mM MgCl2, 200 µM 
dNTPs, 10 μM each primer and 1 U of AmpliTaq DNA polymerase (Applied 
Biosystems, Foster City, CA, USA). The reaction were run for 50 cycles, each 
encompassing a denaturation step at 95˚C for 30 seconds, an annealing step at 50˚C 
(Island I) or 55˚C (Island II) for 45 seconds and an extension step at 72˚C for 45 
seconds. The reaction products were purified by 2% NuSieve® GTG® agarose gel 
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electrophoresis and sequenced in both directions, using the PCR primers, with ABI 
Prism BigDye Terminator Cycle Sequencing Ready Reaction Kits, in an ABI PRISM 
310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). 
  
4.3.5. Reverse transcription-polymerase chain reaction (RT-PCR) 
 
One microgram of total RNA was reverse transcribed using the Reverse 
Transcription System A3500 Kit (Promega, Madison, WI, USA) and controls lacking 
RNA template or reverse transcriptase were run in all experiments. PDHA1 and PDHA2 
cDNAs were amplified using specific primers, hybridizing to regions displaying no 
homology between transcripts (PDHA1-F: 5’-AGC ATC CCG TAA TTT TGC-3’; 
PDHA1-R: 5’-CTT TAG TTC TTC CAC ACT GG-3’; PDHA2-F: 5’-TGC CAT CTA 
CAG CAC TCC GT-3’; PDHA2-R: 5’-CCT CCT TGA GTT GAG AAC AC-3’) [2]. 
PDHA1 primers cover nucleotides 118 to 1051 (GenBank accession no. M24848) 
resulting in a 934 bp fragment (Ho et al., 1989), while PDHA2 primers cover 
nucleotides 1604 to 2881 (GenBank accession no. M86808) resulting in a 1278 bp 
fragment [3]. Reaction mixture contained 2 mM MgCl2, 200 μM dNTPs, 10 μM each 
primer and 1 U of Diamond DNA polymerase (Bioline, London, UK). The reactions 
were run for 30 cycles, each encompassing a denaturation step at 94˚C for 60 s, an 
annealing step at 58˚C for 60 s and an extension step at 72˚C for 90 seconds, with a 
final extension at 72˚C for 10 min. The PCR products were visualized by ethidium 
bromide under UV light on a 1.5% agarose gel. 
 
4.3.6. CpG island prediction analysis  
 
The structure of the PDHA2 gene was analyzed, in particular the number and 
distribution of scattered CpG sites and CpG islands, with use of an online program, 
MethPrimer, available at www.urogene.org/methprimer, which defines CpG islands as 
sequences longer than 200 bp, with a calculated CG composition >50% and an observed 
to expected CpG ratio of >0.6 (Li and Dahiya, 2002). 
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+ 1 (ATG) +1347 bp -643 bp 
MEP-2 Sp1 
4.4. Results 
 
Biocomputing analysis of PDHA2 gene sequence (GenBank accession no. 
M86808; for sequence numbering, nucleotide +1 was assigned to the adenosine of the 
initiation translation codon ATG), encompassing the beginning of 5’UTR (nt -643) until 
the end of 3’UTR (nt +1347), revealed the presence of 61 CpG sites whose distribution 
matches the criteria for the presence of two CpG islands. Island I spans 201 bp, 
beginning in the core promoter region and extending downstream into the open reading 
frame (nucleotides -128 to +73), contains nineteen CpG sites (9th to 27th), five of which 
inside the coding region. Island II spans 263 bp inside the coding region (nucleotides 
+197 to +460) and contains fourteen CpG sites (31st to 44th). As observed, almost half 
the CpG sites are part of CpG islands, and the distribution of the remaining is the 
following one: eight are upstream island I, three are between the two islands and the 
other seventeen sites are located downstream island II (Figure 4.1.). 
 
 
 
 
Figure 4.1. Schematic representation of the PDHA2 gene showing the distribution of all 61 CpG sites and 
the localization of the 2 CpG islands. 
 
Sequence analysis of both CpG islands upon treatment of genomic DNA with 
sodium bisulfite displayed several differences, either between islands or among tissues. 
Regarding CpG island I, the results revealed that all the nineteen sites in genomic DNA 
derived from somatic (gastric cells and lymphocytes) and whole testis samples were 
fully methylated. Additionally, the PCR product encompasses a CpG site not included 
in CpG island I (7th site) and localized in the consensus binding sequence for the Sp1 
transcription factor, which also displayed a completely methylated status in all types of 
tissues. 
Concerning the CpG island II, the results revealed that somatic tissues presented 
all the fourteen CpG sites of this exonic island in a fully methylated status (Figure 
4.2.A). However, sequencing analysis of whole testis DNA samples revealed a mixture 
of methylated and unmethylated cytosines. Further analysis of the CpG island II in 
Chapter 4 
 
86 
1     2     3     4     5     6     7    8     9    10   11   12   13  14   15   16   17   18   19 
Whole testis cells  
Lymphocytes 
Gastric cells 
A. CpG Island I 
1     2     3     4     5     6     7    8     9    10   11   12   13  14 
Whole testis cells 
Diploid germ cells 
Haploid germ cells  
Lymphocytes 
Gastric cells 
B. CpG Island II 
genomic DNA obtained from whole testis fractions showed that diploid and haploid 
germ cells displayed all the CpG sites fully demethylated (Figure 4.2.B).  
 
 
 
 
 
 
 
Figure 4.2. DNA sequencing analysis of CpG island II in the testis-specific PDHA2 gene showing its 
8th and 9th CpG sites in different cell types: A. Lymphocytes; B. Haploid germ cells. 
 
The results of the methylation status observed in every CpG site of both islands 
are resumed in Figure 4.3. and represent the analysis of at least three independent 
samples from each type of tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Methylation profiles of the two CpG islands present in the testis-specific PDHA2 gene. 
A. CpG island I (19 sites); B. CpG island II (14 sites). Blue circles – full methylation; yellow circles – 
full demethylation; orange circles – half methylation. 
 
Transcription of PDHA2 and PDHA1 genes was evaluated by RT-PCR analysis 
of total RNA isolated from several tissues and cell types and the results revealed distinct 
patterns of gene expression. The 934 bp PDHA1-specific band was observed in all 
tissues and cell types derived samples: lymphocytes, liver, whole testis, Sertoli cells and 
diploid and haploid germ cell fractions. Curiously, whole testis samples and both germ 
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cell fractions revealed two additional smaller transcripts, while in somatic tissues we 
could only visualize the band corresponding to the wild-type messenger.  
Concerning the 1278 bp PDHA2-specific band it was only detected in cDNA 
derived from whole testis samples and from diploid and haploid germ cell fractions. 
Additionally, when both sets of specific primers were used during PCR amplification, 
whole testis samples and diploid and haploid germ cell fractions revealed the 
simultaneous presence of both transcripts, though the one corresponding to the wild-
type PDHA2 gene is the predominant species, especially in diploid and haploid germ 
cells (Figure 4.4.). 
 
 
 
 
 
 
 
 
 
Figure 4.4. Transcription profiles of PDHA1 and PDHA2 genes, encoding the E1α  subunit of the 
pyruvate dehydrogenase complex, in different tissues. T – whole testis; D – diploid germ cells; H – 
haploid germ cells; SO – Sertoli cells; Ly – lymphocytes; Li – liver; B1 – PCR control using whole testis 
total RNA; B2 – PCR control using no biological sample. M – 100 bp Ladder, New England Biolabs. 
 
4.5. Discussion 
 
Mutations in the PDHA1 gene are the main cause of PDC deficiency but the 
existence of the autosomal paralogous PDHA2 gene, displaying testis-specific 
expression, may open new therapeutic avenues. Many studies have already been 
performed in mouse and rat, aiming the elucidation of the mechanisms underlying its 
expression. However, and as previously reported (Datta et al., 1999), human and rodent 
PDHA2 genes, having evolved from different retroposons, must comprise different 
regulatory mechanisms. Therefore, studies in human tissues, somatic and testicular, are 
mandatory for the elucidation of the mechanisms underlying PDHA2 gene silencing or 
activation. 
Previous transfection experiments have already shown that the PDHA2 
promoter-directed transcription can take place in human hepatic cultured cells, 
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suggesting that the tissue-specific regulation is modulated by other factors more distal 
to the promoter or that there are additional mechanisms involved, such as methylation. 
Accordingly, the present report aimed at elucidating the putative correlation between 
DNA methylation and PDHA2 gene transcription.  
In this report, we showed that the human testicular germ cell-specific PDHA2 
gene contains two CpG islands, one encompassing the core promoter region and 
extending into the open reading frame, the other exclusively located in the coding 
region.  
The results of CpG island I analysis displayed similar results either for 
expressing testis tissue or for non-expressing somatic tissues, revealing that all CpG 
sites are fully methylated, even those sites located in sequences thought to be important 
for regulation of PDHA2 gene expression, namely the binding sites for putative 
transcription factors (Datta et al., 1999). The 7th CpG site, being part of the Sp1 binding 
sequence and located upstream of island I, revealed to be fully methylated in all types of 
tissues. The same result was observed for the 11th and 12th sites which closely flank the 
consensus binding sequence for the MEP-2 transcription factor; previous studies by 
DNase footprinting analysis, using nuclear extracts of rat testis and liver, have shown 
that this region was protected in both situations (Iannello et al., 1993; Datta et al., 
1999). Moreover, and most interestingly, is has been described a sequence that was 
protected only by rat testis extract (Datta et al., 1999) and this sequence displays three 
CpG sites: sites 13th to 15th, all of them displaying full methylation, either in testis or in 
somatic samples that we have analyzed.  
Therefore, the methylated status of the PDHA2 core promoter region and the 
presence of the respective transcript in whole testis tissue and diploid and haploid germ 
cells suggest that the proteins responsible for transcription initiation should not be 
sensitive to methylation of their binding sites, which has already been demonstrated for 
Sp1 transcription factors (Singal and Ginder, 1999). All these results underscore the 
notion that demethylation of the PDHA2 core promoter region must not be a 
prerequisite for transcription initiation and, accordingly, must not be involved in the 
regulation of tissue-specific expression of PDHA2 gene. 
On the contrary, the exonic CpG island II displayed distinct methylation status 
in somatic and testis cells, thus suggesting its importance for promoter activity. All the 
CpG sites are completely methylated in somatic tissues, which do not express the 
PDHA2 transcript. Concerning the testicular tissue, we had the opportunity to examine 
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three different types of samples, namely whole tissue, as well as diploid and haploid cell 
fractions. The samples derived from whole biopsy pieces showed a mixture of 
methylated and unmethylated cytosines, which matches the fact that these samples 
contain not only germ cells but also somatic ones (Sertoli and Leydig cells). The 
samples prepared from a Sertoli cell only syndrome piece revealed the exclusively 
presence of methylated cytosines, thus correlating with the absence of PDHA2 
transcript. 
The complete demethylation observed for all CpG sites in the exonic island II, 
either in diploid or haploid germ cells, showed a perfect correlation with this tissue-
specific gene transcription and these results agree with previous observations by Dahl 
and collaborators of the PDHA2 transcript being the predominant species in testis (Dahl 
et al., 1990).  Those authors suggested that not only those spermatocytes and spermatids 
with a Y chromosome, but also those with an X chromosome, express the testis-specific 
PDHA2 gene. However, after amplification using both sets of primers, specific for 
PDHA1 and PDHA2 cDNA, we could also detect residual levels of PDHA1 transcript in 
these two cell types (Figure 4.4.) and this raises the question of its origin: only X 
chromosome containing cells or minimal transcriptional activity in all cells? Our 
haploid germ cell samples, being a mixture of X- and Y-chromosome cell types, 
preclude the complete elucidation of this point, though the results seem to point out the 
second hypothesis as the most likely. 
DNA methylation is considered an important epigenetic modification that 
regulates gene transcription and, in general, loss of methylation is associated with gene 
activation. Many previous studies have focused on the gene silencing effects of 
methylation of CpG islands and even scattered sites in promoter and exon 1 regions 
(Antequera and Bird, 1999). The usual wisdom is that DNA methylation in these 
regions can either directly interfere with transcription factor binding or indirectly via 
methyl-CpG binding proteins, which can mediate histone modification by recruiting 
deacetylases to methylated DNA. However, studies performed by some authors (Hsieh, 
1997; Irvine et al., 2002) indicated that DNA methylation in the coding regions is also 
an important silencer and recent evidences demonstrated the silencing of human gene 
expression by methylation of the coding region (Zhu et al., 2005). Furthermore, it has 
been described that the expression of the mouse Tact1/Actl7 gene, which is also testis-
specific and intronless, is governed by methylation of the open reading frame (Hisano et 
al., 2003). 
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The analysis of the results leads us to hypothesize that the methylation status of 
the coding region must be an important level of control in the tissue-specific expression 
of PDHA2 gene, once the non-expressing somatic cells display internal methylation 
while the expressing testis germ cells are fully demethylated. Concerning the underlying 
mechanism, and as the PDHA2 exonic CpG island is located 267 bp downstream the 
transcription initiation site, it is unlikely that DNA methylation would function to 
prevent transcription elongation, but most probably it should facilitate the formation of 
an unfavorable chromatin structure. Further studies are currently being designed to gain 
more direct evidence of the role of the methylation status of the exonic CpG island of 
the human PDHA2 gene upon the repression of its transcription in somatic tissues and 
activation in testis, namely in vitro methylation experiments of diverse reporter gene 
constructs followed by transient transfection of mammalian cells and luciferase assays.  
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5.1. Abstract 
 
Human PDHA2 is a testis-specific gene that codes for the E1α subunit of 
Pyruvate Dehydrogenase Complex (PDC), a crucial enzyme system in cell energy 
metabolism. Since activation of the PDHA2 gene in somatic cells could be a new 
therapeutic approach for PDC deficiency, we aimed to identify the regulatory 
mechanisms underlying the human PDHA2 gene expression. Functional deletion studies 
revealed that the -122 to -6 promoter region is indispensable for basal expression of this 
TATA-less promoter, and suggested a role of an epigenetic program in the control of 
PDHA2 gene expression. Indeed, treatment of SH-SY5Y cells with the hypomethylating 
agent 5-aza-2’-deoxycytidine (DAC) promoted the reactivation of the PDHA2 gene, by 
inducing the recruitment of the RNA polymerase II to the proximal promoter region and 
the consequent increase in PDHA2 mRNA levels. Bisulfite sequencing analysis 
revealed that DAC treatment induced a significant demethylation of the CpG island II 
(nucleotides +197 to + 460) in PDHA2 coding region, while the promoter region 
remained highly methylated.   
Taken together with our previous results that show an in vivo correlation 
between PDHA2 expression and the demethylation of the CpG island II in testis germ 
cells, our results show that internal methylation of the PDHA2 gene plays a part in its 
repression in somatic cells. 
In conclusion, our data support the novel finding that methylation of the PDHA2 
coding region can inhibit gene transcription. This represents a key mechanism for 
absence of PDHA2 expression in somatic cells and a target for PDC therapy. 
 
5.2. Introduction 
 
Pyruvate dehydrogenase complex (PDC) is a mitochondrial matrix enzyme 
system that catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA, a key 
metabolite for energy metabolism. The rate-limiting component is the E1 enzyme, which 
is a heterotetramer (α2β2). The α subunit, besides forming with the β subunit the active 
and the cofactor binding sites, is also the target for regulatory mechanisms governing 
global activity of PDC.  
The E1α subunit can be encoded by two different genes: PDHA1 located on X 
chromosome and expressed in somatic tissues; and PDHA2 an intronless gene located 
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on chromosome 4. This autosomal gene is repressed in all somatic tissues but actively 
transcribed in post-meiotic germ cells where the X chromosome is absent or inactive 
(Brown et al., 1989b; Dahl et al., 1990). It was suggested that the translocation of 
PDHA to the eutherian X chromosome, which is inactivated during spermatogenesis, 
led to the evolution of this second testis-specific locus by retroposition to an autosome 
(Fitzgerald et al., 1993). 
Besides the potential of PDHA2 as a model for unravelling the mechanisms that 
govern gene expression during spermatogenesis (Iannello et al., 1995), some authors 
also postulated that PDHA2 gene activation in somatic cells could be an effective 
therapy for PDC deficiency (Datta et al., 1999), an inborn error of metabolism mainly 
caused by mutations in PDHA1 gene (Brown et al., 1989a).  
The amount of published work on PDHA2 gene regulation is scarce and the 
studies performed relied on the mouse orthologue, Pdha2 (Iannello and Dahl, 1992; 
Iannello et al., 1994; Iannello et al., 1995; Iannello et al., 1997; Iannello et al., 2000). 
However, it is believed that the regulatory mechanisms that control these orthologous 
genes are different, once there is no gross homology between their promoters, which 
seem to have evolved from different retroposons (Fitzgerald et al., 1996). 
Datta and collaborators publish the first and, to our knowledge, unique study on 
human PDHA2 gene regulation (Datta et al., 1999). They isolated and characterized 
approximately 800 nucleotides of the PDHA2 promoter region, identified the location of 
the transcription start site and performed functional studies that suggested the existence 
of multiple regulatory elements. More importantly, these authors proposed that the 
PDHA2 tissue-specific expression could be modulated by mechanisms, such as DNA 
methylation, that would limit PDHA2 expression to spermatogenic cells.  
Indeed, DNA methylation is a widely known epigenetic mechanism that plays a 
central role in the selective expression of particular genes in different tissues. The 
methylation of cytosine residues acts as a negative regulator of transcription by three 
potential mechanisms: direct interference with the binding of specific transcription 
factors to promoters, direct binding of specific transcriptional repressors and alteration 
of the chromatin structure (Miranda and Jones, 2007). DNA methylation can be 
inhibited by 5-aza-2´-deoxycytidine (DAC), a potent inhibitor of DNA 
methyltransferase (DNMT) activity, through the irreversible binding of DNMTs to 
DAC substituted DNA (Christman, 2002). 
Recently, we have demonstrated an in vivo correlation between an increase in 
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PDHA2 mRNA levels and the demethylation of a CpG island in its coding region 
(Pinheiro et al., 2010b), which is a strong evidence for a role of DNA methylation in the 
epigenetic control of the human PDHA2 gene. In this study we show that inhibition of 
DNMTs with DAC reactivates PDHA2 gene expression in SH-SY5Y cells, in a 
demethylation-dependent manner.  
 
5.3. Materials and methods 
 
5.3.1. Cloning of the human PDHA2 proximal promoter 
 
A 975 bp fragment of human PDHA2 proximal promoter (GenBank accession 
no. M86808) was cloned in pCR®4Blunt-TOPO® vector (Invitrogen Corporation, 
Carlsbad, CA, USA) after PCR amplification of genomic DNA isolated from circulating 
lymphocytes of a healthy individual. This genomic region was amplified with Platinum® 
Pfx Polymerase (Invitrogen) using the primers pPDHA2-975bp and pPDHA2-R listed 
in Table 5.1.. 
 
Table 5.1. List of the primers used in the human PDHA2 promoter cloning 
 
 
 
 
 
 
 
 
 
 
 
 
The insert of the recombinant plasmid harboring the PDHA2 promoter region, 
encompassing nucleotides -980 to -6, was sequenced by primer walking and named 
pPDHA2-TOPO. For sequence numbering, nucleotide +1 was assigned to the adenosine 
of the initiation translation codon ATG.  
PRIMERS SEQUENCE 
pPDHA2 – R 5’-TCACGGAGTGCTGTAGATGGCTCGAGCCG-3’ 
pPDHA2 – 975bp 5’-TGGAAACCTGCTGAAGACATT-3’ 
pPDHA2 – 833bp 5’-AAGGAAAAGTGGAATGTCACAAA-3’ 
pPDHA2 – 695bp 5’-ATACATTTTCCCTCCCCACT-3’ 
pPDHA2 – 591bp 5’-GTTAACGTGCGTGTGCTTGT-3’ 
pPDHA2 – 506bp 5’-GGCACATTATGGAGCAGGAT-3’ 
pPDHA2 – 436bp 5’-TGGTAGGAAGAAATACCTTTGGA-3’ 
pPDHA2 – 349bp 5’-TTGTCGGGAAAGCTTGAGAT-3’ 
pPDHA2 – 269bp 5’-GCGATTAGGATGCCCTGTAG-3’ 
pPDHA2 – 196bp 5’-GGCAGGCACTGTACAAATCA-3’ 
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5.3.2. PDHA2 promoter reporter constructs  
 
Several different fragments derived from the human PDHA2 promoter region 
were subcloned into the luciferase expression vector pGL2-Basic vector (Promega 
Corporation, Madison, WI USA). We used the pPDHA2-TOPO plasmid as a template 
to amplify fragments of different lengths, using different forward primers and a reverse 
primer, which contains a XhoI overhang site, listed in Table 5.1.. The PCR products, 
amplified with the Platinum® Pfx Polymerase (Invitrogen), were subcloned in the pGL2 
reporter plasmid into SmaI/ XhoI sites generating plasmids 975.pGL2 (-980 to -6), 
833.pGL2 (-838 to -6), 695.pGL2 (-700 to -6), 591.pGL2 (-596 to -6), 506.pGL2 (-511 
to -6), 436.pGL2 (-441 to -6), 349.pGL2 (-354 to -6), 269.pGL2 (-274 to -6), and 
196.pGL2 (-201 to -6). The pPDHA2-TOPO recombinant was also digested with 
enzymes MslI/ XhoI and the 117 bp fragment was subcloned in the pGL2 reporter 
plasmid generating the 117.pGL2 recombinant (-122 to -6).  
 
5.3.3. Transactivation studies 
 
The basal promoter activity of the different reporter plasmids was assayed by 
measuring the luciferase activity after transient transfection in HeLa, SH-SY5Y and 
Ntera2/clone D1 (NT2) cell lines.  
To minimize variations in transfection efficiency, replicates were transfected in 
single batch suspension with FuGENE® HD (Roche Diagnostics GmbH, Penzberg, 
Germany) according to the manufacturer’s instructions. Plates containing 200.000 cells 
were co-transfected with 0.5 μg of the reporter plasmid together with an expression 
plasmid containing the β-galactosidase gene-coding region (pSV40-βGAL). Cells were 
inoculated in 24-well plates and maintained for 48 h. These cells were harvested and 
lysed in reporter lysis buffer (Promega). Cell extracts were assayed for luciferase and β-
galactosidase activity (β-Gal Reporter Gene Assay, Roche), which was used to 
normalize the results. All experiments were performed at least three times in duplicate 
well. 
 
5.3.4. Cell cultures and treatments 
 
SH-SY5Y (human neuroblastoma) cell line was maintained in low glucose 
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Dulbecco’s modified Eagle’s medium (Sigma-Aldrich Inc., St. Louis, MO, USA), while 
HeLa (human cervix adenocarcinoma) and NT2 (human teratocarcinoma) cell lines 
were cultured in high glucose Dulbecco’s modified Eagle’s medium (Sigma). All media 
were supplemented with 10% heat inactivated fetal bovine serum (Biochrom AG, 
Berlin, Germany), 2 mM L-glutamine (Sigma), 100 units/mL penicillin and 100 mg/mL 
streptomycin (Sigma), with the exception of NT2 culture medium that was 
supplemented with 4 mM L-glutamine. All cell cultures were carried out at 37ºC in 
humidified 5% CO2. 
Dose response assays of 5-aza-2’-deoxycytidine (DAC) and trichostatin A 
(TSA) were performed as previously stated (Milagre et al., 2008). Subsequently, cells 
were treated with 5 μM DAC and 0.25 μM TSA for the indicated periods (or vehicle as 
control) and every 24 hours the medium was changed. 
 
5.3.5. RNA isolation and qRT-PCR for PDHA2 expression analysis  
 
Total RNA was prepared from all cells, treated and untreated, using the 
RNeasy® Mini Kit (Qiagen) and contamination by genomic DNA was eliminated from 
each RNA sample by pre-treatment with DNase I using RNase-free DNase Set 
(Qiagen). 
Total RNA was reverse transcribed using the Reverse Transcription System 
A3500 Kit (Promega) with random primers following the manufacturer´s instructions. 
First strand DNA (1 μg) was used as template for quantitative real-time PCR with an 
ABI PRISM 7300 sequence detection system (Applied Biosystems). The cycling 
conditions were 95ºC/10min followed by 40 cycles of 95ºC/15sec and 60ºC/1min. It 
was used the TaqMan® Gene Expression Assay - ID: Hs01043024_s1 (Applied 
Biosystems) for specific detection of PDHA2 mRNA, and the TaqMan® β-actin Control 
Reagents as endogenous control (Applied Biosystems). In every reaction we used the 
TaqMan® Gene Expression Master Mix (Applied Biosystems) following enclosed 
instructions. 
Each sample was assayed in triplicate and results show a minimum of three 
independent experiments. Transcript levels were normalized to β-actin and expressed in 
pg PDHA2 mRNA per ng of β-actin mRNA. 
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5.3.6. Genomic DNA isolation and bisulfite sequencing for PDHA2 methylation 
analysis  
 
Genomic DNA was isolated from treated and untreated cells using a salting-out 
method (Citogene® DNA Blood Kit – Citomed, Lisbon, Portugal).  
The number and distribution of scattered CpG sites and CpG islands of PDHA2 
gene has been previously analyzed (Pinheiro et al., 2010b) using the online program, 
MethPrimer, available at www.urogene.org/methprimer, which defines CpG islands as 
sequences longer than 200 bp, with a calculated CG composition >50% and an observed 
to expected CpG ratio of >0.6 (Li and Dahiya, 2002). 
Bisulfite PCR sequencing was carried out using the EpiTect® Bisulfite Kit 
(Qiagen) and CpG islands were amplified by PCR using the specific primers and the 
conditions previously described (Pinheiro et al., 2010b). 
The reaction products were purified by MinElute® PCR Purification Kit 
(Qiagen) and sequenced in both directions by primer walking with ABI Prism BigDye 
Terminator Cycle Sequencing Ready Reaction Kits, in an ABI PRISM 310 Genetic 
Analyzer (Applied Biosystems, Foster City, CA, USA). 
 
5.3.7. Chromatin immunoprecipitation assays  
 
Chromatin immunoprecipitation assays were performed as described previously 
(Nunes et al., 2010). Briefly, chromatin isolated from cell cultures was 
immunoprecipitated using the following antibodies: anti RNA pol II clone CTD4H8  
(#05-623, Millipore, Bedford, MA, USA), Sp1 (PEP 2) X (#SC-59X, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) and normal rabbit immunoglobulin 
(#X0903, DakoCytomation, Denmark). The recovered DNA was analyzed by 
quantitative real-time PCR with SYBR green Master Mix in an ABI 7300 sequence 
detection system (Applied Biosystems). The qPCRs were performed using primers 
covering the proximal promoter region (+1 region) 5’-
GGCAGGCACTGTACAAATCA-3’ (forward) and 5’-CAGTGCACACGGGTGAT 
AGA-3’ (reverse) and a distal upstream region (-10Kb region) 5’-GCA 
TGGCAGGACTTCTCTC-3´(forward) and 5’-TTCAGGCAATGCT TGACCA-3’ 
(reverse). 
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5.3.8. Statistical analysis 
 
Statistical analysis was performed using the Student’s t-test and the ANOVA 
one-way test with the Tukey Honestly Significant Differences (HSD) post-hoc test, the 
Tukey HSD for unequal N (Spjotvoll/Stoline test). All analyses were performed using 
the STATISTICA (data analysis software system), version 7.1 StatSoft, Inc. (Tulsa, 
OK, USA; 2006). A value of p < 0.05 was considered significant. 
 
5.4. Results 
 
5.4.1. PDHA2 promoter constructs display basal activity in human somatic cell 
lines 
 
Human PDHA2 gene expression is restricted to post-meiotic germ cells (Dahl et 
al., 1990) suggesting the absence of positive modulating factors and/or the presence of 
repressors in somatic tissues. However, the lack of suitable human spermatogenic germ 
cell lines makes it difficult to easily elucidate the regulatory mechanisms involved upon 
PDHA2 expression.  
In order to evaluate the regions important for transcriptional modulation and, 
more precisely, to define the regions putatively involved in the repression of PDHA2 
gene in somatic cells, several deletion promoter constructs were generated (Figure. 
5.1.), and their ability to direct expression of the reporter luciferase gene was analyzed 
after transient transfection in different somatic cell lines. Accordingly, the various 
PDHA2 reporter plasmids and the parental pGL2-Basic vector were transfected into 
HeLa (cervix adenocarcinoma), NT2 (human teratocarcinoma) and SH-SY5Y (human 
neuroblastoma) cells, which do not normally express PDHA2 mRNA.  
Surprisingly, PDHA2 reporter constructs displayed high luciferase activities in 
all three somatic cell lines (Figure. 5.1.). Significant differences were found between the 
luciferase activities of the several constructs, in HeLa (ANOVA one-way test: F=20.29, 
df=10, p<0.001), NT2 (ANOVA one-way test: F=26.01, df=10, p<0.001), and SH-
SY5Y (ANOVA one-way test: F=48.89, df=10, p<0.001) cells. However, post hoc 
comparisons only revealed significant differences between the luciferase activities of 
the empty pGL2-Basic and all the other reporter constructs (Tukey HSD p < 0.001).  
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Figure 5.1. Functional deletion analysis of the human PDHA2 gene promoter. Progressive 5’ deletion 
constructs were transiently transfected into HeLa, NT2 and SH-SY5Y cell lines. Transfections were 
carried out using 0.5 μg of the PDHA2 reporter construct or the empty pGL2 vector. Normalized 
luciferase activities were expressed as mean values ± SEM of duplicates for a minimum of three 
experiments (*p < 0.001). 
 
These results firstly show that the region between nucleotides -122 and -6 seems 
to contain all the sequences necessary to drive transcription initiation, and thus most 
probably corresponding to the basal proximal promoter. Secondly, the fact that PDHA2 
promoter reporter constructs present high luciferase activity in somatic cell lines where 
the PDHA2 mRNA can not be detected, and that there are no significant differences 
between the luciferase activities of the different deletion constructs, suggest an 
important role of epigenetic modifications in the regulation PDHA2 tissue-specific 
expression.  
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5.4.2. Activation of PDHA2 expression in somatic cells after treatment with 
epigenetic drugs 
 
 To investigate the role of epigenetic mechanisms upon PDHA2 gene regulation, 
we treated SH-SY5Y cells, with a potent inhibitor of the de novo methylation (DAC) 
and with a pharmacological inhibitor of histone deacetylases (TSA).  
PDHA2 expression was quantified by real-time PCR (qRT-PCR) and the results 
revealed that after treatment with 5 μM DAC for 96 h or 120h, there is a significant 
increase of PDHA2 mRNA, when compared with untreated cells (ANOVA one-way 
test: F=27.84, df=3, p<0.001; Tukey HSD for unequal N p<0.001) (Figure 5.2.A).  
Since it is generally accepted that DAC and TSA synergistically affect gene 
expression, by a mechanism that depends on promoter demethylation induced by DAC 
and subsequent reinforcement by histone acetylation induced by TSA, we also treated 
SH-SY5Y with TSA for 24 h, and with DAC for 96 h prior to a 24h treatment with 
TSA. Incubation with 0.25 μM TSA for 24 h did not significantly affect PDHA2 mRNA 
levels. Moreover, pretreatment with DAC for 96 h, prior to the 24 h TSA treatment, did 
not further increase the observed PDHA2 mRNA accumulation with DAC treatment 
only (Figure 5.2.B).  
In order to corroborate the fact that DAC treatment induces a derepression of 
PDHA2 gene transcription, we analyzed the recruitment of RNA polymerase II (RNA 
pol II) to the proximal promoter of this gene by chromatin immunoprecipitation. We 
have designed two sets of primers, one targeting the +1 region, and another targeting a 
distal upstream region (-10 kb). Our results show that we could only detect RNA pol II 
binding to the +1 region after DAC treatment (Student´s t-test, p<0.001), which most 
likely triggers the observed increase in PDHA2 gene transcription. Interestingly, we 
could not detect the occupancy of the putative Sp binding site, by the Sp1 transcription 
factor, as previously suggested by Datta and co-workers (Datta et al., 1999) (Figure 
5.3.). Furthermore, we investigated the possible recruitment of the elongation marker 
H3K36me3 to the gene body, but the results showed no occupancy of the targeted 
region. 
These data demonstrate that PDHA2 gene transcription was reactivated by DAC 
treatment in SH-SY5Y cells, suggesting that DNA demethylation may play a pivotal 
role in PDHA2 tissue-specific expression. 
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Figure 5.2. DAC increases PDHA2 mRNA levels in SH-SY5Y cells. Real-time PCR analysis of 
PDHA2 steady-state mRNA transcript levels in SH-SY5Y cells treated with 5 μM DAC for the indicated 
time points (A), and with 5 μM DAC for 96 h and/or 0.25 μM TSA for 24 h (B). Values were normalized 
to the internal standard β-actin. Data represent means ± SEM of at least three independent experiments 
and was expressed as pg of PDHA2 mRNA per ng of β-actin mRNA (* p < 0.001; § p < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Recruitment of RNA pol II to the human PDHA2 gene promoter. Chromatin from SH-
SY5Y was prepared at 72 hours after treatment with 5 μM DAC and precipitated with antibodies directed 
against IgG, Sp1 and RNA pol II. After DNA recovery, the precipitates were evaluated by real-time PCR 
as described in Experimental Procedures. Results are expressed as fold change over IgG and represent 
means of at least three independent experiments ± SEM (* p < 0.001). 
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5.4.3. DAC induces demethylation of PDHA2 coding region 
 
In order to confirm that DAC leads to the reactivation of PDHA2 expression in 
SH-SY5Y cells, in a demethylation dependent manner, we analyzed the methylation 
status of PDHA2 gene by sodium bisulfite sequencing analysis.  
Since we have previously shown that the PDHA2 gene contains two CpG 
islands, one located in the promoter region (nucleotides -128 to +73) and the other 
located in the coding region (nucleotides +197 to + 460) (Pinheiro et al., 2010b), we 
have analyzed the methylation patterns of both CpG islands. In accordance with our 
previous results, we observed that the CpG island I, located in the promoter region, is 
fully methylated in untreated SH-SY5Y cells, and seems to be insensitive to DAC, since 
it remains methylated after treatment with this drug (Figure 5.4.A). Effectively, its CpG 
sites remained fully methylated not only after DAC treatment, but after TSA and DAC 
plus TSA treatment, as well. Interestingly, the analysis of the CpG island II, located in 
the coding region, showed significant demethylation after treatment with DAC (Table 
5.2.)  (Figure 5.4.A and 5.4.B); TSA alone has no effect, but after pre-treatment with 
DAC, the demethylation level of this exonic CpG island seems to be slightly increased, 
which is particularly significant in the CpG sites +410 and +492 (Tukey for unequal N, 
p<0.01) (Figure 5.4.B).  
These results are consistent with our previous work (Pinheiro et al., 2010b), and 
strongly suggest that PDHA2 reactivation in somatic cells proceeds via a mechanism 
independent of promoter demethylation, most probably dependent on demethylation of 
the coding region. 
 
5.5. Discussion 
 
PDHA2 gene activation in somatic tissues has been postulated as a conceptual 
therapy for PDC deficiencies caused by PDHA1 gene mutations (Robinson et al., 1996; 
Datta et al., 1999). Accordingly, it is crucial to understand the mechanisms controlling 
human PDHA2 tissue-specific expression, namely what factors are responsible for the 
silencing of this gene in somatic tissues, and its activation in spermatogenic ones 
(diploid and haploid germ cells). However, the lack of a suitable cell line to study the 
regulatory mechanisms underlying PDHA2 gene expression has hampered this 
elucidation for a long time.  
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Figure 5.4. DNA methylation status of the human PDHA2 gene after sodium bisulfite PCR 
sequencing. A) Sample chromatograms obtained for both PDHA2 CpG Islands, before and after 
treatment with 5 μM DAC; B) DNA methylation status of CpG sites in the CpG island II located in the 
coding region of PDHA2 gene, before and after treatment with 5 μM DAC for 96 h and/or 0.25 μM TSA 
for 24 h. Results represent means of at least three independent experiments ± SEM (* p< 0.05; † p<0.01; 
§ p<0.001 by Tukey HSD for unequal N test). 
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Table 5.2. Statistical analysis of PDHA2 gene methylation results by the ANOVA one-way test. 
CpG# F df p 
+276 3.596 3 0.050* 
+297 1.145 3 0.371 
+312 4.683 3 0.015* 
+326 6.498 3 0.004* 
+333 9.594 3 0.001* 
+373 20.64 3 0.000* 
+388 8.203 3 0.001* 
+399 20.73 3 0.000* 
+410 19.5 3 0.000* 
+449 5.181 3 0.011* 
# CpG Number in relation to ATG; * Statistical significance p < 0.05 
 
The first step towards understanding the regulation of a particular gene is the 
identification of regulatory elements and factors involved in basal expression. 
Accordingly, our studies began by the functional analysis of human PDHA2 promoter. 
The results showed that PDHA2 promoter-directed transcription of the luciferase 
reporter gene occurred in cultured somatic cells (HeLa, NT2 and SH-SY5Y), where 
PDHA2 mRNA is undetectable. Deletion analysis further revealed that the region 
spanning from -122 to -6 is indispensable for basal expression of this TATA-less 
promoter. Moreover, and in each cell line, no significant differences were found among 
the reporter gene activities driven by all the other PDHA2 deletion promoter constructs. 
Additionally, each construct displayed comparable reporter activities in the three 
different somatic cell lines.  
These observations suggested that the mechanisms involved in the repression of 
PDHA2 expression in somatic cells are not operative when the core promoter or the 5’ 
flanking region are transiently transfected into somatic cells. Moreover, these results 
corroborated the previous transactivation experiments described by Datta and 
colleagues (Datta et al., 1999), who also observed PDHA2 promoter-directed 
transcription in human hepatocellular carcinoma cells. However, we could not replicate 
their results concerning the detection of several enhancer and repressor elements, 
because no significant differences in luciferase reporter activities were detected between 
the various deletion constructs. Additionally, the same authors suggested the existence 
of a putative Sp responsive element that would be important for Sp1-dependent 
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transcription initiation (Datta et al., 1999). However, our chromatin 
immunoprecipitation assays did not demonstrate any binding of Sp1 transcription 
factors to the proximal promoter of the PDHA2 gene. 
Nevertheless, and more importantly, our observation that PDHA2 promoter 
reporter constructs presented high luciferase activity in all somatic cell lines where the 
PDHA2 mRNA cannot be detected, reinforces the idea that PDHA2 tissue-specific 
expression may be under strict control of epigenetic mechanisms of regulation.  
Accordingly, our next approach was to explore the involvement of epigenetics, 
namely DNA methylation and/or histone modifications, on the regulation of PDHA2 
gene expression. The results showed that treatment of SH-SY5Y cell cultures with DAC 
induced PDHA2 derepression with a concomitant accumulation of PDHA2 transcript. 
On the other hand, inhibition of histone deacetylation did not elicit any induction of 
PDHA2 expression, nor did it potentiate the DAC effect.  
Moreover, the accumulation of the PDHA2 mRNA after DAC treatment was 
correlated with an enrichment of RNA pol II at the PDHA2 proximal promoter, which 
likely triggers the observed increase in PDHA2 mRNA levels. The fact that treatment 
with DAC alone elicited a significant effect upon PDHA2 gene expression suggests that 
changes associated with methylation are sufficient to drive transcription initiation of 
this testis-specific gene in somatic cells. 
Once proved that DAC was able to induce PDHA2 gene expression in cultured 
somatic cells, it would be important to investigate the methylation status of this gene, 
before and after treatment with the demethylating drug, in order to assure that 
demethylation was underlying PDHA2 transcription. Our results demonstrated that 
DAC promoted a relevant demethylation of PDHA2 coding region, which was fully 
methylated before treatment. However, the promoter CpG island I remained fully 
methylated, suggesting its insensibility to demethylation, at least by DAC treatment in 
the tested conditions. These findings corroborate our previous reported results, where 
we observed that PDHA2 expressing tissues (i.e spermatogenic cells) presented the 
coding region completely demethylated, while non-expressing tissues displayed it fully 
methylated (Pinheiro et al., 2010b). 
 Moreover, these results also correlate with our recent finding concerning a 
family displaying PDHA2 gene expression in somatic tissues (Pinheiro et al., 
submitted-b), an interesting case that may configure the previously referred long 
dreamed therapy for PDC deficiency, i.e. the somatic activation of PDHA2 expression. 
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The results obtained either then by in-vivo or now by ex-vivo experiments are 
overlapping; actually, both methylation analyses revealed a correlation between 
demethylation of the coding region and PDHA2 derepression. Moreover, and 
interestingly, the level of demethylation in the coding region is very similar in the 
cultured cells treated with DAC and in the family individuals. 
Taken together, our results confirm that methylation of the coding region is a 
key point in somatic cell silencing of PDHA2 gene. Actually, DNA methylation appears 
to be particularly suitable for the regulation of germ line-specific genes, and this is 
probably related to the global demethylation process that occurs during the development 
of spermatogenic cells, which may provide the mechanism by which these germ line-
specific genes are demethylated (Rocamora and Mezquita, 1989; del Mazo et al., 1994). 
And, despite the fact that DNA methylation does not seem to be the primary control 
mechanism regulating the programmed expression of most tissue-specific genes 
resulting in tissue differentiation, there are several examples that indicate that DNA 
methylation can serve as the primary control mechanism for the expression of a number 
of germ line-specific genes (Choi and Chae, 1991; De Smet et al., 1999; Kroft et al., 
2001).  
Although the expression of previously referred genes proceeds via a promoter 
methylation-dependent mechanism, we also can find in the literature some references to 
human genes that are regulated by methylation of the coding region, namely the 
monocarboxylate transporter MCT3 (Zhu et al., 2005). Another particular interesting 
example is the mouse Tact1/Actl7 gene (Hisano et al., 2003), which is also intronless 
and testis-specific, like the PDHA2 gene.  
Indeed, it has already been described that methylation of the coding region, per 
se, can control gene expression by preventing promoter activity at the level of the 
chromatin structure. Indeed, CpG methylation induces a local repressive chromatin 
structure, mediated by the binding of methyl-CpG binding domain (MBD) proteins 
which recruit other proteins including sin3A and histone deacetylase; when a sufficient 
amount of CpGs is methylated, this repression is transmissible in cis, spreading for 
several hundred base pairs (Keshet et al., 1985; Kass et al., 1997; Bird and Wolffe, 
1999). Accordingly, more or less distant methylated sequences, like the PDHA2 coding 
region, can promote gene repression. Interestingly, and as stated by Nan and co-
workers, this type of repression is greater if the promoter itself is methylated (Nan et al., 
1997), which is the case of PDHA2 promoter.  
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 Furthermore, it has also been postulated that methylation of the coding region 
can inhibit gene expression by interfering with the elongation step rather than with 
transcription initiation, by causing RNA pol II to pause or to prematurely terminate 
(Graessmann et al., 1994; Choi et al., 2009).  Moreover, the inhibitory effect upon 
elongation is prominent when methylation occurs near the start codon (Hohn et al., 
1996).  
Based on this hypothesis, we attempted to explore elongation of PDHA2 
transcription by chromatin immunoprecipitation assays. The results did not show any 
particular differences in the chromatin recovered before and after DAC treatment, 
namely when using the elongation marker H3K36me3. A recent report has shown a 
clear correlation between H3K36me3 marking and transcriptional activity in intron-
containing genes; however, in intronless genes H3K36me3 is detected at much lower 
levels irrespective of expression levels (de Almeida et al., 2011). Indeed, there are other 
examples showing that transcriptional elongation is differently controlled in intronless 
genes when compared to longer intron-containing genes (Medlin et al., 2005) and, 
accordingly, different approaches need to be designed. 
In summary, we hypothesize that PDHA2 gene belongs not only to a restricted 
group of germ line-specific genes that use DNA methylation as a primary silencing 
mechanism, but to a unique subset of those genes whose expression is regulated by the 
methylation status of the coding region. Furthermore, these new insights on the 
regulatory mechanism underlying PDHA2 tissue-specific expression may open potential 
therapeutic avenues for PDC deficiency caused by PDHA1 mutations. 
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The present work elucidates, for the first time, key mechanisms that regulate 
PDHA2 gene expression, namely those controlling PDHA2 silencing in somatic cells 
and its activation in spermatogenic germ cells. This knowledge provides new insights 
towards the potential activation of PDHA2 gene expression in somatic cells, which 
configures a potential therapy for PDC deficiencies related with PDHA1 mutations 
(Robinson et al., 1996; Datta et al., 1999).  
We started by exploring the unique case of a family that expresses in somatic 
tissues both genes, PDHA1 and PDHA2. Indeed, the molecular characterization of their 
PDC E1α subunit revealed not only the presence of a full-length testis-specific PDHA2 
transcript in circulating lymphocytes and cultured fibroblasts, but also the presence of a 
5'-truncated PDHA1 transcript, which surprisingly is also translated into a full-length 
PDHA1 protein.  
The analyzed individuals did not show any PDHA2 mutation, although they 
presented a considerable demethylation of the CpG island located in the PDHA2 coding 
region. These results suggested that this alteration might be responsible for the somatic 
PDHA2 gene derepression. Indeed, our subsequent work fully supported this 
hypothesis.  
Remarkably, our in vivo analyses, and ex vivo experiments, were overall in 
accordance, and point to a role of DNA methylation in the PDHA2 coding region as an 
important epigenetic phenomenon controlling the tissue-specific expression of this 
gene. In fact, we demonstrated a correlation between PDHA2 transcription and the 
demethylation of its coding region. We found that somatic cells, which do not normally 
express PDHA2, display the coding region fully methylated. On the other hand, 
spermatogenic cells, which do express PDHA2, show a complete demethylation of this 
region. Interestingly, the CpG island that comprises the promoter region remains highly 
methylated in all cell types, which seems to suggest that PDHA2 transcription is 
independent from promoter methylation status.  
However, and in line with the recent discover of 5hmC being enriched in 
promoter regions, it would be interesting to revisit the methylation status of PDHA2 
promoter. Effectively, the bisulfite sequencing technique used during this work does not 
allow to distinguish between 5mC and 5hmC (Huang et al., 2010). Accordingly, it is 
possible that the CpG dinucleotides in the PDHA2 promoter are not methylated, but 
instead hydroxymethylated, what would agree with the reported enrichment of 5hmC in 
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promoter regions and its correlation with transcriptional activity (Ficz et al., 2011; Wu 
et al., 2011). 
Moreover, we presented a direct evidence of the role of DNA methylation in 
PDHA2 gene regulation, as we showed that DAC (an hypomethylating drug) induced 
the exclusive demethylation of the coding region and also the PDHA2 derepression in a 
somatic cell line. Furthermore, the methylation analysis of PDHA2 genomic sequence in 
the family members showed similar patterns to the ones observed in cultured SH-SY5Y 
cells after DAC treatment, especially concerning the impairment in the methylation 
status of the coding sequence, while the promoter region remained fully methylated. 
The fact that we have shown that PDHA2 is normally silenced in somatic cells 
and exclusively expressed in testis tissue also comprised a clue to the involvement of 
DNA methylation upon this gene regulation. Indeed, the general rule-of-thumb for 
testis-specific genes is that higher levels of DNA methylation are associated with 
silencing in somatic cells, while the loss of methylation is associated with expression in 
reproductive tissues (De Smet et al., 1999; DeJong, 2006). An additional important 
outcome of our work, is the novel description of the PDHA genes expression profile 
during human spermatogenesis, which further improves our knowledge of gene 
regulation in the complex process of male germ cell differentiation. Furthermore, this 
study unveiled the possibility of PDHA2 protein performing other functions beyond 
energy production, for instance in sperm capacitation (Kumar et al., 2006).  
Taken together, our results resumed substantial proves that DNA methylation of 
the PDHA2 coding region is underlying the tissue-specific expression of this gene and, 
more importantly, we disclosed the possibility to activate PDHA2 expression in somatic 
cell lines with the epigenetic drug DAC. Nevertheless, despite we were able to provide 
answers for all the questions outlined for this work, many others were raised and further 
studies need to be designed. 
For instance, we state that the demethylation of the coding region causes 
PDHA2 derepression and that transcription initiation seems independent from promoter 
methylation status. Accordingly, it would be important to further fundament these 
hypotheses. Future experiments should attempt, for example, to identify possible 
transcription factors that bind the coding region of PDHA2 gene and that should be 
sensitive to DNA methylation. Moreover, and as previously referred, it would be 
important to employ new sequencing techniques, which allow to discriminate between 
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cytosine, methylcytosine and hydroxymethylcytosine; this would clarify if indeed 
promoter methylation status is irrelevant.  
Another important issue that should be addressed concerns the production of the 
PDHA protein, because it remains to be elucidated if the PDHA2 transcript induced by 
treatment with hypomethylating agents is effectively translated into a functional protein. 
Accordingly, we should investigate if the observed levels of demethylation, in DAC 
treated cells, induce the synthesis of a normal and functional PDHA2 protein.  
If indeed hypomethylation leads to the expression of PDHA2 protein, as we 
could observe in the family under study, the subsequent step should be to investigate if 
this protein is fully functional after assembly of the PDC complex. Actually, 
Korotchkina and collaborators (2006) already demonstrated, using recombinant 
proteins, that PDHA2 presents kinetic and regulatory characteristics largely similar to 
those of PDHA1 (Korotchkina, Sidhu et al. 2006). However, PDC only presents full 
activity when E1 tetramer is composed by only one type of α subunit (i.e. either two 
PDHA2 or two PDHA1 subunits) (Robinson et al., 1996). Accordingly, resorting to 
PDHA2 gene expression for the treatment of PDCD that result from a defective PDHA1 
gene might only be feasible if the mutant allele originated no protein. However, as the 
majority of the described mutations lead to non-functional proteins, but normal or 
impaired protein levels, this therapeutic approach to be effective should rely on 
silencing of the mutant PDHA1 gene prior to PDHA2 activation.  
Another interesting task would be to perform DAC treatment in cell lines from 
PDCD patients (with PDHA1 mutations), and check for PDHA2 expression at 
transcriptional and translational levels, and subsequently to measure PDC activity. 
Additionally, this task should be performed with and without silencing the PDHA1 
gene. 
Traditionally, after studies in cell lines, the next step should be the search for an 
animal model. However, and as previously referred and confirmed in this study, the 
regulatory mechanisms underlying PDHA2 gene expression in human and mouse are 
substantially different, what hampers the finding of an easy and adequate animal model.  
The ultimate and obvious question was raised after disclosing the possibility to 
activate PDHA2 expression in somatic cells with DAC treatment. Indeed, we must 
discuss if DAC could be used in clinical practice as a potential therapy for PDCD 
caused by PDHA1 mutations. Since 2006 that DAC (commonly named decitabine) is an 
approved drug for myelodysplastic syndromes by the U.S. Food and Drug 
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Administration (Gore, Jones et al. 2006). Multiple clinical trials have shown the 
promising activity of low-dose DCA in acute myeloid leukemia, chronic myelogenous 
leukemia and hemoglobinopathies, whereas its efficacy in solid tumors is rather limited 
(Daskalakis et al., 2010).  
However, it is unclear if the administration of DAC to PDCD patients will be a 
successful therapeutic approach, particularly because current treatments are unable to 
modulate specific genomic regions, which may increase the risk of off-target responses. 
Nevertheless, although it is not certain at what extended DAC may alter the epigenome, 
it is known that DAC-induced demethylation patterns are highly specific, nonrandom 
and reproducible (Hagemann et al., 2011). Moreover, only specific subset of genes 
display altered expression profiles after DAC treatment (Karpf et al., 2004) and testis-
specific genes are known to be very sensitive to hypomethylating conditions (De Smet 
et al., 1999; Xie et al., 2002). In the perspective of our work, it would be interesting to 
investigate if cancer patients, subject to DAC treatment, present PDHA2 derepression in 
somatic cells. 
Furthermore, it would be interesting to investigate the effect upon PDHA2 
expression of a physiological hypomethylating agent, S-adenosyl-homocysteine. This 
metabolite is formed, either as the product of all transmethylation reactions that use S-
adenosylmethionine as methyl group donor, or by condensation of homocysteine with 
adenosine, a thermodynamically favored reaction.  
High levels of S-adenosyl-homocysteine may be achieved by diets deficient in 
methyldonors, such as choline and methionine (Dizik et al., 1991; Tsujiuchi et al., 
1999; Ghoshal et al., 2006; Pogribny et al., 2009) and also by deficiency of vitamins 
(folate, B6 and B12) involved in methyl group transfer  (Duthie et al., 2000; Piyathilake 
et al., 2000; Kim et al., 2001; Liu et al., 2007; Schernhammer et al., 2010). 
Additionally, there are several genetic diseases characterized by elevated levels of 
homocysteine, namely cystathionine β-synthase (CBS), methyleno-tetra-hydrofolate 
(MTHFR) and methionine synthase (MS) deficiencies. Moreover, various studies report 
the association between MTHFR polymorphisms, high homocysteine levels and DNA 
hypomethylation (Castro et al., 2004; Balassiano et al., 2011; Pizzolo et al., 2011). So, 
investigating PDHA2 expression in these pathologies would be interesting. 
In summary, several questions were briefly outlined along this discussion that 
remain to be clarified, and most probably many others were neglected. Nevertheless, the 
present thesis constitutes a contribution to the knowledge of PDHA2 gene regulation, 
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and an important step towards new therapeutic approaches for the majority of PDC 
deficiencies.  
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Appendix 1: Alignment between PDHA1 and PDHA2 cDNA sequences and primers’ 
localization 
 
PDHA1   -145   AGCGCATGACGTTATTACGACTCTGTCACGCCGCGGTGCGACTGAGGCGTGGCGTCTGCT  -86 
                   ||                           |||            ||||             
PDHA2     -63   AG---------------------------GCC------------AGGC------------  -55 
   
                          PDHA1-5’                                       PDS1       
PDHA1     -85   GGGGCACCTGAAGGAGACTTGGGGGCACCCGCGTCGTGCCTCCTGGGTTGTGAGGAGTCG  -26 
                                    |||       || |||             || || | | | || 
PDHA2    -54   -----------------CTT-------CCGGCG-------------GTCGTTACGGGACG  -32 
 
                                 PDSTr-F    +1  
PDHA1       -25   CCGCTGCCGCC-ACTGCCTGTGCTTCATGAGGAAGATGCTCGCCGCCGTC---TCCCGCG  31 
                   ||||||||  | || ||     || | ||| ||| ||||| |||||| ||   ||||||| 
PDHA2        -31   CCGCTGCCATCTACAGCA----CTCCGTGAAGAATATGCTGGCCGCCTTCATCTCCCGCG  25 
                             PDHA2-F                  +1     
                                                          PDHA1-F 
PDHA1      32   TGCTGTCTGGCGCTTCTCAGAAGCCGGCAAGCAGAGTGCTGGTAGCATCCCGTAATTTTG  91 
                   || ||    | | | | |||||  | ||  ||||||||||||| ||||||||||| |    
PDHA2         26   TGTTGAGGCGAGTTGCCCAGAAATCAGCTCGCAGAGTGCTGGTGGCATCCCGTAACTCCT  85 
 
             
PDHA1         92   CAAATGATGCTACATTTGAAATTAAGAAATGTGACCTTCACCGGCTGGAAGAAGGCCCTC  151 
                   ||||||| |||||||||||||||||||||||||| ||| | | | ||||||| || || | 
PDHA2         86   CAAATGACGCTACATTTGAAATTAAGAAATGTGATCTTTATCTGTTGGAAGAGGGTCCCC  145 
 
  
PDHA1        152   CTGTCACAACAGTGCTCACCAGGGAGGATGGGCTCAAATACTACAGGATGATGCAGACTG  211 
                   ||||||| ||||||||||| |||| ||| ||||| ||||||||||||||||||| ||||| 
PDHA2        146   CTGTCACTACAGTGCTCACTAGGGCGGAGGGGCTTAAATACTACAGGATGATGCTGACTG  205 
                                
                        PDSTr-R  
PDHA1        212   TACGCCGAATGGAGTTGAAAGCAGATCAGCTGTATAAACAGAAAATTATTCGTGGTTTCT  271 
                   | ||||| ||||| ||||| |||||||||||||| ||||||||| | ||||| ||||||| 
PDHA2        206   TTCGCCGCATGGAATTGAAGGCAGATCAGCTGTACAAACAGAAATTCATTCGCGGTTTCT  265 
 
  
PDHA1        272   GTCACTTGTGTGATGGTCAGGAAGCTTGCTGTGTGGGCCTGGAGGCCGGCATCAACCCCA  331 
                   ||||| |||| ||||||||||||||||| || |||||||| ||||||||||| ||||||  
PDHA2        266   GTCACCTGTGCGATGGTCAGGAAGCTTGTTGCGTGGGCCTTGAGGCCGGCATAAACCCCT  325 
 
  
PDHA1        332   CAGACCATCTCATCACAGCCTACCGGGCTCACGGCTT-TACTTTCACCCGGGGCCTTTCC  390 
                   | || ||  |||| ||| ||||  ||||||| ||  | | || | || ||||| |||||  
PDHA2        326   CGGATCACGTCATTACATCCTATAGGGCTCATGGTGTGTGCTAT-ACTCGGGGACTTTCT  384 
 
  
PDHA1        391   GTCCGAGAAATTCTCGCAGAGCTTACAGGACGAAAAGGAGGTTGTGCTAAAGGGAAAGGA  450 
                   ||||||   |||||||||||||| || ||| ||| |||||||||||||||||| |||||| 
PDHA2        385   GTCCGATCCATTCTCGCAGAGCTGACGGGAAGAAGAGGAGGTTGTGCTAAAGGAAAAGGA  444 
 
  
PDHA1        451   GGATCGATGCACATGTATGCCAAGAACTTCTACGGGGGCAATGGCATCGTGGGAGCGCAG  510 
                   ||||||||||| |||||| ||||||||||||| ||||||||||||||||| || || ||| 
PDHA2        445   GGATCGATGCATATGTATACCAAGAACTTCTATGGGGGCAATGGCATCGTCGGTGCACAG  504 
 
  
PDHA1        511   GTGCCCCTGGGCGCTGGGATTGCTCTAGCCTGTAAGTATAATGGAAAAGATGAGGTCTGC  570 
                   |  |||||||||||||| |||||||| |||||||| ||||| ||||| |||||| ||||  
PDHA2        505   GGCCCCCTGGGCGCTGGCATTGCTCTGGCCTGTAAATATAAAGGAAACGATGAGATCTGT  564 
 
  
PDHA1        571   CTGACTTTATATGGCGATGGTGCTGCTAACCAGGGCCAGATATTCGAAGCTTACAACATG  630 
                   ||||||||||||| ||||| ||||| || ||||| ||||||  |||||||| ||| ||| 
PDHA2        565   TTGACTTTATATGGGGATGGCGCTGCGAATCAGGGGCAGATAGCCGAAGCTTTCAATATG  624 
 
  
PDHA1        631   GCAGCTTTGTGGAAATTACCTTGTATTTTCATCTGTGAGAATAATCGCTATGGAATGGGA  690 
                   |||||||| ||||||||||||||| ||||||||||||||||||| |  |||||||||||| 
PDHA2        625   GCAGCTTTATGGAAATTACCTTGTGTTTTCATCTGTGAGAATAACCTATATGGAATGGGA  684 
 
  
PDHA1        691   ACGTCTGTTGAGAGAGCGGCAGCCAGCACTGATTACTACAAGAGAGGCGATTTCATTCCT  750 
                   || |||  ||||||||| ||||||||| |||||||||||||||| ||| |||| || ||| 
PDHA2        685   ACATCTACTGAGAGAGCAGCAGCCAGCCCTGATTACTACAAGAGGGGCAATTTTATCCCT  744 
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PDHA1        751   GGGCTGAGAGTGGATGGAATGGATATCCTGTGCGTCCGAGAGGCAACAAGGTTTGCTGCT  810 
                   ||||| |  || |||||||||||| | ||||| || || ||||||||||  ||||| ||| 
PDHA2        745   GGGCTAAAGGTCGATGGAATGGATGTTCTGTGTGTTCGTGAGGCAACAAAATTTGCAGCT  804 
 
  
PDHA1        811   GCCTATTGTAGATCTGGGAAGGGGCCCATCCTGATGGAGCTGCAGACTTACCGTTACCAC  870 
                   ||| ||||||||||| ||||||||||| |||||||||||||| || |||||||| ||  
PDHA2        805   AACTACTGTAGATCTGGAAAGGGGCCCATACTGATGGAGCTGCAAACCTACCGTTATCAT  864 
 
  
PDHA1        871   GGACACAGTATGAGTGACCCTGGAGTCAGTTACCGTACACGAGAAGAAATTCAGGAAGTA  930 
                   ||||||||||||||||| |||||||||||||| ||||||||||||||||||||||||||| 
PDHA2        865   GGACACAGTATGAGTGATCCTGGAGTCAGTTATCGTACACGAGAAGAAATTCAGGAAGTA  924 
 
  
PDHA1        931   AGAAGTAAGAGTGACCCTATTATGCTTCTCAAGGACAGGATGGTGAACAGCAATCTTGCC  990 
                   ||||||||||| || ||||| ||  ||||| | || || ||||| |||||||| || ||| 
PDHA2        925   AGAAGTAAGAGGGATCCTATAATAATTCTCCAAGATAGAATGGTAAACAGCAAGCTCGCC  984 
                                
               PDHA1-R 
PDHA1        991   AGTGTGGAAGAACTAAAGGAAATTGATGTGGAAGTGAGGAAGGAGATTGAGGATGCTGCC  1050 
                   | |||||||||| ||||||||||||  |  || |||||||| || ||||| ||||||||| 
PDHA2        985   ACTGTGGAAGAATTAAAGGAAATTGGGGCTGAGGTGAGGAAAGAAATTGATGATGCTGCC  1044 
 
                        
PDHA1        1051  CAGTTTGCCACGGCCGATCCTGAGCCACCTTTGGAAGAGCTGGGCTACCACATCTACTCC  1110 
                   |||||||| ||  | ||||||||||||| |||||||||  | ||| | |||||||||  | 
PDHA2        1045  CAGTTTGCTACCACTGATCCTGAGCCACATTTGGAAGAATTAGGCCATCACATCTACAGC  1104 
 
  
PDHA1        1111  AGCGACCCACCTTTTGAAGTTCGTGGTGCCAATCAGTGGATCAAGTTTAAGTCAGTCAGT  1170 
                   || ||  || ||||||||||||||||||| ||||  ||||||||||||||||| |||||| 
PDHA2        1105  AGTGATTCATCTTTTGAAGTTCGTGGTGCAAATCCATGGATCAAGTTTAAGTCCGTCAGT  1164 
 
 
PDHA1        1171  TAAGGGGAGGAGAAGGAGAGGTTATACCTTCAGGGGGCTACCAGACAGTGTTCTCAACTT  1230 
                   ||| ||||||                           ||||                    
PDHA2        1165  TAAAGGGAGG---------------------------CTAC-------------------  1178 
 
 
PDHA1        1231  GGTTAAGGAGGAAGAAAACCCAGTCAATGAAATTCAATGAAATTCTTGGAAACTTCCATT  1290 
                                                                                         
PDHA2              ------------------------------------------------------------   
 
 
PDHA1        1291  AAGTGTGTAGATTGAGCAGGTAGTAATTGCATGCAGTTTGTACATTAGTGCATTAAAAGA  1350 
                     |||||                 ||||                                 
PDHA2        1179  --GTGTG-----------------AATT--------------------------------  1187 
 
 
PDHA1        1351  TGAATTATTGAGTGCTTAAAGATTATTTTTGACTTAAAATAGTATACTTTGAACAAATAC  1410 
                        |||                                                     
PDHA2        1188  -----TAT----------------------------------------------------  1190 
 
 
PDHA1        1411  TCTAATTATGAAAAGGAAGAACAATTCCTTGTATGCCTGTTTCCCCTGCCCCCAGCCACC  1470 
                                                                                         
PDHA2              ------------------------------------------------------------   
 
 
PDHA1        1471  TTTTTGGGAGGAGACCATTATGGCGGGGCCCCTCACAGCATTCTACCAACCATAGCACCC  1530 
                                  |||                 |||                       
PDHA2        1191  ---------------CAT-----------------CAG----------------------  1196 
 
 
PDHA1        1531  ACCCCGAGCAGCGCTGGTGCTGCAGCCTGTTCGCGCTGACCATTTCTCTACAAGATACAA  1590 
                                                               |||||        ||| 
PDHA2        1197  --------------------------------------------TCTCT--------CAA  1244 
 
 
 
PDHA1        1591  TATTTATTATCAGGCAAGAGGACAGTTCCATTTTAAAATAAGACTTTTGTAATCATTCCA  1650 
                   |                  |||                                       
PDHA2        1205  T------------------GGA--------------------------------------  1208 
 
 
PDHA1        1651  ATTTTGTAATCATTTCAAAGGCCACATAACTTAGTTTTCTCTACTTACACATTCAGTATA  1710 
                                                                                         
PDHA2               ------------------------------------------------------------   
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PDHA1        1711  AATATGAAGCTATTTTCTGTTCATATCAAACATTAACTACAAGGCACATTCGTATCAGTT  1770 
                      |||             |||||                  ||                 
PDHA2        1209  ---ATG-------------TTCAT------------------GG----------------  1218 
 
 
PDHA1        1771  TTGTGTTTCTCAAATTGAAGTACCATACCAGTTCTGAGGCAGTGTCCCAGCTTCCATGTT  1830 
                            ||||||| |||                                         
PDHA2        1219  ---------TCAAATTTAAG----------------------------------------  1229 
 
 
PDHA1        1831  TGTTAAATACCCCTTGTTTGTTTCACCATTCCAGCAAGTGCTGAAGGGTGTACTTTTTTT  1890 
                       |||                                 |||                  
PDHA2        1230  ----AAA---------------------------------CTG-----------------  1235 
 
 
PDHA1        1891  GAGACAGGGTCGGGCTCTGTTGCCCAGGCTGGAGTGCAGTGGTGTGATCATGGCTCACTG  1950 
                                    ||||                                ||||    
PDHA2        1236  -----------------TGTT--------------------------------CTCA---  1243 
                         PDHA2-R 
   
PDHA1        1951  CAGCCTCCACACCTCCTGGGCTCAAGCAATCCTCCCACCTCAGCCTCCTGCATAGCTGGG  2010 
                           ||           |||||                                   
PDHA2        1244  --------AC-----------TCAAG----------------------------------  1250 
 
 
PDHA1        2011  ACTACAAGTGAATTTCCTAATATTCCGGGAGGTCAAAACCAAGGCTCACTGTTTTCACAA  2070 
                                               ||||                             
PDHA2        1251  ----------------------------GAGG----------------------------  1254 
 
 
PDHA1        2071  TACACACAGTTCTATGTTTATAAATAACAGGTTTCAAAAGAAACTCAGGACAGTATTTAA  2130 
                                         |||||              ||||||          ||| 
PDHA2        1255  ----------------------AATAA--------------AACTCA----------TAA  1268 
 
 
PDHA1        2131  AACAAGTTCTTAAACTATTAATTGAACAATGGCATTTTTAAATATGTAAACACAGCGGAA  2190 
                   |||||                                                        
PDHA2        1269  AACAA-------------------------------------------------------  1273 
 
 
PDHA1        2191  TTCGTGTATACACTAACAGAAGCTTTAACAAAACATGTAGCGTGGTGGGACACTCTGCCA  2250 
                                                                                         
PDHA2              ------------------------------------------------------------   
 
 
PDHA1        2251  CAGCTTAGCTGATTGGTATCAAGCCTTGTCTTTGGTTTCTGAGGCCTCCTGAGCCCTTCT  2310 
                                       |||||||||                                
PDHA2        1274  --------------------AAGCCTTGT-------------------------------  1282 
 
 
PDHA1        2311  GTACTGGGAGACCGCACTCCAGAGTCTGCAGAGGAGACCACCCCTGGGAAACAAACACAG  2370 
                                                                                         
PDHA2              ------------------------------------------------------------   
 
 
PDHA1        2371  CTGTCTTCAGAGTCAGTGCTTCAAGCCAACAGAGCTTAAAACTGCAGTCCCTAATTTAAA  2430 
                                         ||||                           |||||   
PDHA2        1283  ----------------------AAGC---------------------------ATTTA--  1291 
 
 
PDHA1        2431  AACCTAATGAAAATAAAAACATTCTCCTCACATATGGAGGTGACGCTCGTGTCCCAGCAG  2490 
                                                                                         
PDHA2              ------------------------------------------------------------   
 
 
PDHA1        2491  TAGTAGGACATGGCCTTAGAGGTACGTACCTGCAGAGAGCTGGCTATTTCAAATGACTCG  2550 
                                  |||                                           
PDHA2        1292  ---------------TTA------------------------------------------  1294 
 
 
PDHA1        2551  GGAACAAGAAGGCAGGCTGCAGTTTAAAGAAGGGGGTGGGTCCAGCGTGCAGGCACGCTT  2610 
                                            |||||                               
PDHA2        1295  -------------------------AAAGA------------------------------  1299 
 
 
PDHA1        2611  GCCATGTGCCTCCACCCACTCCCAGCCAGGCATTAATGGCAGGAGATTGGCCAGCTCTTC  2670 
                                                               ||||             
PDHA2        1300  --------------------------------------------GATT------------  1303 
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PDHA1        2671  TCTGTCACATTCCTATTTCTGACTTCTGCCTGGCTTTCAGTTTCTGCCCCACCTTGGCTT  2730 
                                                                                         
PDHA2              ------------------------------------------------------------   
 
 
PDHA1        2731  TTTCCCAGCTTGAACCTAATAGAACTCCAGAGTTTGGGGGGAGGCCCAGCCCTTTGTTTT  2790 
                                                                                         
PDHA2               ------------------------------------------------------------   
 
 
PDHA1        2791  CTGCTCTTGAAGCATATTCACACATAAAAAGTTGTATTCTCTTATACAAACTGTTTTGAG  2850 
                                                                                         
PDHA2               ------------------------------------------------------------   
 
 
PDHA1        2851  GCTCTTACCGTAGTCGAAGGTATCTTAGATCTTCCTTAGTGATCTCATTAAGAATATCCG  2910 
                                                                 |||||          
PDHA2        1304  ----------------------------------------------ATTAA---------  1308 
 
 
PDHA1        2911  AAAGTGTATAACCCTCTTCAACAATCTGAAACAAAGATCAGATCCTTAAGAGCTGAGCAG  2970 
                                                                  |||||         
PDHA2        1309  -----------------------------------------------AAGAG--------  1313 
 
 
PDHA1        2971  CTGTGTAACAACAGCATAAGAATTTCTTTGTTGTAAATTTACCTTTTCAATTGTCTTTGC  3030 
                                                                    ||||        
PDHA2        1314  -------------------------------------------------ATTG-------  1317 
 
 
PDHA1        3031  ATCAGCTCCTTGCAGCCGCAACCAGTCTATAAGCTCTTTATCTGTTCTCTGCCCGTAGGG  3090 
                                                                                         
PDHA2              ------------------------------------------------------------   
 
 
PDHA1      3091  GCCTGCTGGGTTCTCTGTAATACCTGTAACGATTGGCAATTTGTTATATATTAGTCTAAC  3150 
                                                                                         
PDHA2              ------------------------------------------------------------   
 
 
PDHA1  3151  CATAAAACTCTTCAAAAGTAACCAGTTGGATTAATAAATGATTCCAGAATGTAAATGTGA  3210 
                                                                                         
PDHA2              ------------------------------------------------------------   
 
 
PDHA1  3211  TGTGAAAAAGAGATGAAAAAAAAAAAAAAAAAAAA  3245 
                         ||||| |                       
PDHA2      1318  ------AAAGACA                        1324 
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Appendix 2: Alignment between PDHA1 and PDHA2 protein sequences  
 
PDHA1   4    MLAA-VSRVLSGASQKPASRVLVASRNFANDATFEIKKCDLHRLEEGPPVTTVLTREDGL  62 
              MLAA +SRVL   +QK A RVLVASRN +NDATFEIKKCDL+ LEEGPPVTTVLTR +GL 
PDHA2   1    MLAAFISRVLRRVAQKSARRVLVASRNSSNDATFEIKKCDLYLLEEGPPVTTVLTRAEGL  60 
 
 
PDHA1   63   KYYRMMQTVRRMELKADQLYKQKIIRGFCHLCDGQEACCVGLEAGINPTDHLITAYRAHG  122 
                 KYYRMM TVRRMELKADQLYKQK IRGFCHLCDGQEACCVGLEAGINP+DH+IT+YRAHG 
PDHA2   61   KYYRMMLTVRRMELKADQLYKQKFIRGFCHLCDGQEACCVGLEAGINPSDHVITSYRAHG  120 
 
 
PDHA1   123  FTFTRGLSVREILAELTGRKGGCAKGKGGSMHMYAKNFYGGNGIVGAQVPLGAGIALACK  182 
                 +TRGLSVR ILAELTGR+GGCAKGKGGSMHMY KNFYGGNGIVGAQ PLGAGIALACK 
PDHA2   121  VCYTRGLSVRSILAELTGRRGGCAKGKGGSMHMYTKNFYGGNGIVGAQGPLGAGIALACK  180 
 
 
PDHA1   183  YNGKDEVCLTLYGDGAANQGQIFEAYNMAALWKLPCIFICENNRYGMGTSVERAAASTDY  242 
                 Y G DE+CLTLYGDGAANQGQI EA+NMAALWKLPC+FICENN YGMGTS ERAAAS DY 
PDHA2   181  YKGNDEICLTLYGDGAANQGQIAEAFNMAALWKLPCVFICENNLYGMGTSTERAAASPDY  240 
 
 
PDHA1   243  YKRGDFIPGLRVDGMDILCVREATRFAAAYCRSGKGPILMELQTYRYHGHSMSDPGVSYR  302 
                 YKRG+FIPGL+VDGMD+LCVREAT+FAA YCRSGKGPILMELQTYRYHGHSMSDPGVSYR 
PDHA2   241  YKRGNFIPGLKVDGMDVLCVREATKFAANYCRSGKGPILMELQTYRYHGHSMSDPGVSYR  300 
 
 
PDHA1   303  TREEIQEVRSKSDPIMLLKDRMVNSNLASVEELKEIDVEVRKEIEDAAQFATADPEPPLE  362 
                 TREEIQEVRSK DPI++L+DRMVNS LA+VEELKEI  EVRKEI+DAAQFAT DPEP LE 
PDHA2   301  TREEIQEVRSKRDPIIILQDRMVNSKLATVEELKEIGAEVRKEIDDAAQFATTDPEPHLE  360 
 
 
PDHA1   363  ELGYHIYSSDPPFEVRGANQWIKFKSVS  390 
                 ELG+HIYSSD  FEVRGAN WIKFKSVS 
PDHA2   361  ELGHHIYSSDSSFEVRGANPWIKFKSVS  388 
 
 
